(54) Title: POLYNUCLEOTIDE VACCINES EXPRESSING CODON OPTIMIZED HIV-1 POL AND MODIFIED HIV-1 POL

(57) Abstract: Pharmaceutical compositions which comprise HIV Pol DNA vaccines are disclosed, along with the production and use of these DNA vaccines. The pol-based DNA vaccines of the invention are administered directly introduced into living vertebrate tissue, preferably humans, and preferably express inactivated versions of the HIV Pol protein devoid of protease, reverse transcriptase activity, RNase H activity and integrase activity, inducing a cellular immune response which specifically recognizes human immunodeficiency virus-1 (HIV-1). The DNA molecules which comprise the open reading frame of these DNA vaccines are synthetic DNA molecules encoding codon optimized HIV-1 Pol and codon optimized inactive derivatives of optimized HIV-1 Pol, including DNA molecules which encode inactive Pol proteins which comprise an amino terminal leader peptide.

TITLE OF THE INVENTION

POLYNUCLEOTIDE VACCINES EXPRESSING CODON OPTIMIZED HIV-1

5   POL AND MODIFIED HIV-1 POL

CROSS-REFERENCE TO RELATED APPLICATIONS

          This application claims the benefit, under 35 U.S.C. §119(e), of U.S.

          provisional application 60/171,542, filed December 22, 1999.

10

STATEMENT REGARDING FEDERALLY-SPONSORED R&D

          Not Applicable

15   REFERENCE TO MICROFICHE APPENDIX

          Not Applicable

FIELD OF THE INVENTION

          The present invention relates to HIV Pol polynucleotide pharmaceutical

20   products, as well as the production and use thereof which, when directly introduced

       into living vertebrate tissue, preferably a mammalian host such as a human or a

       non-human mammal of commercial or domestic veterinary importance, express the

       HIV Pol protein or biologically relevant portions thereof within the animal, inducing a

       cellular immune response which specifically recognizes human immunodeficiency

25   virus-1 (HIV-1). The polynucleotides of the present invention are synthetic DNA

       molecules encoding codon optimized HIV-1 Pol and derivatives of optimized HIV-1

       Pol, including constructs wherein protease, reverse transcriptase, RNAse H and

       integrase activity of HIV-1 Pol is inactivated. The polynucleotide vaccines of the

       present invention should offer a prophylactic advantage to previously uninfected

30   individuals and/or provide a therapeutic effect by reducing viral load levels within an

       infected individual, thus prolonging the asymptomatic phase of HIV-1 infection.

BACKGROUND OF THE INVENTION

Human Immunodeficiency Virus-1 (HIV-1) is the etiological agent of acquired human immune deficiency syndrome (AIDS) and related disorders. HIV-1 is an RNA virus of the Retroviridae family and exhibits the 5'LTR-*gag-pol-env*-
5   LTR 3' organization of all retroviruses. The integrated form of HIV-1, known as the provirus, is approximately 9.8 Kb in length. Each end of the viral genome contains flanking sequences known as long terminal repeats (LTRs). The HIV genes encode at least nine proteins and are divided into three classes; the major structural proteins (Gag, Pol, and Env), the regulatory proteins (Tat and Rev); and the accessory proteins
10   (Vpu, Vpr, Vif and Nef).

The *gag* gene encodes a 55-kilodalton (kDa) precursor protein (p55) which is expressed from the unspliced viral mRNA and is proteolytically processed by the HIV protease, a product of the *pol* gene. The mature p55 protein products are p17 (matrix), p24 (capsid), p9 (nucleocapsid) and p6.
15   The *pol* gene encodes proteins necessary for virus replication; a reverse transcriptase, a protease, integrase and RNAse H. These viral proteins are expressed as a Gag-Pol fusion protein, a 160 kDa precursor protein which is generated via a ribosomal frame shifting. The viral encoded protease proteolytically cleaves the Pol polypeptide away from the Gag-Pol fusion and further cleaves the Pol polypeptide to
20   the mature proteins which provide protease (Pro, P10), reverse transcriptase (RT, P50), integrase (IN, p31) and RNAse H (RNAse, p15) activities.

The *nef* gene encodes an early accessory HIV protein (Nef) which has been shown to possess several activities such as down regulating CD4 expression, disturbing T-cell activation and stimulating HIV infectivity.
25   The *env* gene encodes the viral envelope glycoprotein that is translated as a 160-kilodalton (kDa) precursor (gp160) and then cleaved by a cellular protease to yield the external 120-kDa envelope glycoprotein (gp120) and the transmembrane 41-kDa envelope glycoprotein (gp41). Gp120 and gp41 remain associated and are displayed on the viral particles and the surface of HIV-infected cells.
30   The *tat* gene encodes a long form and a short form of the Tat protein, a RNA binding protein which is a transcriptional transactivator essential for HIV-1 replication.

The *rev* gene encodes the 13 kDa Rev protein, a RNA binding protein. The Rev protein binds to a region of the viral RNA termed the Rev response element

(RRE). The Rev protein is promotes transfer of unspliced viral RNA from the nucleus to the cytoplasm. The Rev protein is required for HIV late gene expression and in turn, HIV replication.

Gp120 binds to the CD4/chemokine receptor present on the surface of helper
5   T-lymphocytes, macrophages and other target cells in addition to other co-receptor molecules. X4 (macrophage tropic) virus show tropism for CD4/CXCR4 complexes while a R5 (T-cell line tropic) virus interacts with a CD4/CCR5 receptor complex. After gp120 binds to CD4, gp41 mediates the fusion event responsible for virus entry. The virus fuses with and enters the target cell, followed by reverse transcription of its
10   single stranded RNA genome into the double-stranded DNA via a RNA dependent DNA polymerase. The viral DNA, known as provirus, enters the cell nucleus, where the viral DNA directs the production of new viral RNA within the nucleus, expression of early and late HIV viral proteins, and subsequently the production and cellular release of new virus particles. Recent advances in the ability to detect viral load
15   within the host shows that the primary infection results in an extremely high generation and tissue distribution of the virus, followed by a steady state level of virus (albeit through a continual viral production and turnover during this phase), leading ultimately to another burst of virus load which leads to the onset of clinical AIDS. Productively infected cells have a half life of several days, whereas chronically or
20   latently infected cells have a 3-week half life, followed by non-productively infected cells which have a long half life (over 100 days) but do not significantly contribute to day to day viral loads seen throughout the course of disease.

Destruction of CD4 helper T lymphocytes, which are critical to immune defense, is a major cause of the progressive immune dysfunction that is the hallmark
25   of HIV infection. The loss of CD4 T-cells seriously impairs the body's ability to fight most invaders, but it has a particularly severe impact on the defenses against viruses, fungi, parasites and certain bacteria, including mycobacteria.

Effective treatment regimens for HIV-1 infected individuals have become available recently. However, these drugs will not have a significant impact on the
30   disease in many parts of the world and they will have a minimal impact in halting the spread of infection within the human population. As is true of many other infectious diseases, a significant epidemiologic impact on the spread of HIV-1 infection will only occur subsequent to the development and introduction of an effective vaccine. There are a number of factors that have contributed to the lack of successful vaccine

development to date. As noted above, it is now apparent that in a chronically infected person there exists constant virus production in spite of the presence of anti-HIV-1 humoral and cellular immune responses and destruction of virally infected cells. As in the case of other infectious diseases, the outcome of disease is the result of a

5   balance between the kinetics and the magnitude of the immune response and the pathogen replicative rate and accessibility to the immune response. Pre-existing immunity may be more successful with an acute infection than an evolving immune response can be with an established infection. A second factor is the considerable genetic variability of the virus. Although anti-HIV-1 antibodies exist that can

10   neutralize HIV-1 infectivity in cell culture, these antibodies are generally virus isolate-specific in their activity. It has proven impossible to define serological groupings of HIV-1 using traditional methods. Rather, the virus seems to define a serological "continuum" so that individual neutralizing antibody responses, at best, are effective against only a handful of viral variants. Given this latter observation, it

15   would be useful to identify immunogens and related delivery technologies that are likely to elicit anti-HIV-1 cellular immune responses. It is known that in order to generate CTL responses antigen must be synthesized within or introduced into cells, subsequently processed into small peptides by the proteasome complex, and translocated into the endoplasmic reticulum/Golgi complex secretory pathway for

20   eventual association with major histocompatibility complex (MHC) class I proteins. $CD8^+$ T lymphocytes recognize antigen in association with class I MHC via the T cell receptor (TCR) and the CD8 cell surface protein. Activation of naive $CD8^+$ T cells into activated effector or memory cells generally requires both TCR engagement of antigen as described above as well as engagement of costimulatory proteins. Optimal

25   induction of CTL responses usually requires "help" in the form of cytokines from $CD4^+$ T lymphocytes which recognize antigen associated with MHC class II molecules via TCR and CD4 engagement.

        Larder, et al., (1987, *Nature* 327: 716-717) and Larder, et al., (1989, *Proc. Natl. Acad. Sci.* 86: 4803-4807) disclose site specific mutagenesis of HIV-1 RT and

30   the effect such changes have on *in vitro* activity and infectivity related to interaction with known inhibitors of RT.

        Davies, et al. (1991, *Science* 252:, 88-95) disclose the crystal structure of the RNase H domain of HIV-1 Pol.

Schatz, et al. (1989, *FEBS Lett.* 257: 311-314) disclose that mutations Glu478Gln and His539Phe in a complete HIV-1 RT/RNase H DNA fragment results in defective RNase activity without effecting RT activity.

5   Mizrahi, et al. (1990, *Nucl. Acids. Res.* 18: pp. 5359-5353) disclose additional mutations Asp443Asn and Asp498Asn in the RNase region of the *pol* gene which also results in defective RNase activity. The authors note that the Asp498Asn mutant was difficult to characterize due to instability of this mutant protein.

Leavitt, et al. (1993, *J. Biol. Chem.* 268: 2113-2119) disclose several mutations, including a Asp64Val mutation, which show differing effect on HIV-1
10   integrase (IN) activity.

Wiskerchen, et al. (1995, *J. Virol.* 69: 376-386) disclose singe and double mutants, including mutation of aspartic acid residues which effect HIV-1 IN and viral replication functions.

It would be of great import in the battle against AIDS to produce a
15   prophylactic- and/or therapeutic-based HIV vaccine which generates a strong cellular immune response against an HIV infection. The present invention addresses and meets this needs by disclosing a class of DNA vaccines based on host delivery and expression of modified versions of the HIV-1 gene, *pol*.

20   SUMMARY OF THE INVENTION

The present invention relates to synthetic DNA molecules (also referred to herein as "polynucleotides") and associated DNA vaccines (also referred to herein as "polynucleotide vaccines") which elicit cellular immune and humoral responses upon administration to the host, including primates and especially humans, and also
25   including a non-human mammal of commercial or domestic veterinary importance. An effect of the cellular immune-directed vaccines of the present invention should be the lower transmission rate to previously uninfected individuals and/or reduction in the levels of the viral loads within an infected individual, so as to prolong the asymptomatic phase of HIV-1 infection. In particular, the present invention relates to
30   DNA vaccines which encode various forms of HIV-1 Pol, wherein administration, intracellular delivery and expression of the HIV-1 Pol gene of interest elicits a host CTL and Th response. The preferred synthetic DNA molecules of the present invention encode codon optimized versions of wild type HIV-1 Pol, codon optimized versions of HIV-1 Pol fusion proteins, and codon optimized versions of HIV-1 Pol

proteins and fusion protein, including but not limited to *pol* modifications involving residues within the catalytic regions responsible for RT, RNase and IN activity within the host cell.

A particular embodiment of the present invention relates to codon optimized

5   wt-pol DNA constructs wherein DNA sequences encoding the protease (PR) activity are deleted, leaving codon optimized "wild type" sequences which encode RT (reverse transcriptase and RNase H activity) and IN integrase activity. The nucleotide sequence of a DNA molecule which encodes this protein is disclosed herein as SEQ ID NO:1 and the corresponding amino acid sequence of the expressed protein is

10   disclosed herein as SEQ ID NO:2.

The present invention preferably relates to a HIV-1 DNA pol construct which is devoid of DNA sequences encoding any PR activity, as well as containing a mutation(s) which at least partially, and preferably substantially, abolishes RT, RNase and/or IN activity. One type of HIV-1 pol mutant may include but is not limited to a

15   mutated DNA molecule comprising at least one nucleotide substitution which results in a point mutation which effectively alters an active site within the RT, RNase and/or IN regions of the expressed protein, resulting in at least substantially decreased enzymatic activity for the RT, RNase H and/or IN functions of HIV-1 Pol. In a preferred embodiment of this portion of the invention, a HIV-1 DNA pol construct

20   contains a mutation or mutations within the Pol coding region which effectively abolishes RT, RNase H and IN activity. An especially preferable HIV-1 DNA pol construct in a DNA molecule which contains at least one point mutation which alters the active site of the RT, RNase H and IN domains of Pol, such that each activity is at least substantially abolished. Such a HIV-1 Pol mutant will most likely comprise at

25   least one point mutation in or around each catalytic domain responsible for RT, RNase H and IN activity, respectfully. To this end, an especially preferred HIV-1 DNA pol construct is exemplified herein and contains nine codon substitution mutations which results in an inactivated Pol protein (IA Pol: SEQ ID NO:4, Figure 2A-C) which has no PR, RT, RNase or IN activity, wherein three such point

30   mutations reside within each of the RT, RNase and IN catalytic domains. Any combination of the mutations disclosed herein may suitable and therefore may be utilized as an IA-Pol-based vaccine of the present invention. While addition and deletion mutations are contemplated and within the scope of the invention, the

preferred mutation is a point mutation resulting in a substitution of the wild type amino acid with an alternative amino acid residue.

 Another aspect of the present invention is to generate HIV-1 Pol-based vaccine constructions which comprise a eukaryotic trafficking signal peptide such as

5 the leader peptide from human tPA. To this end, the present invention relates to a DNA molecule which encodes a codon optimized wt-pol DNA construct wherein the protease (PR) activity is deleted and a human tPA leader sequence is fused to the 5' end of the coding region. A DNA molecule which encodes this protein is disclosed herein as SEQ ID NO:5, the open reading frame disclosed herein as SEQ ID NO:6.

10 The present invention especially relates to a HIV-1 Pol mutant such as IA-Pol (SEQ ID NO:4) which comprises a leader peptide, such as the human tPA leader, at the amino terminal portion of the protein, which may effect cellular trafficking and hence, immunogenicity of the expressed protein within the host cell. Any such HIV-1 DNA pol mutant disclosed in the above paragraphs is suitable for fusion downstream of a leader

15 peptide, including but by no means limited to the human tPA leader sequence. Therefore, any such leader peptide-based HIV-1 pol mutant construct may include but is not limited to a mutated DNA molecule which effectively alters the catalytic activity of the RT, RNase and/or IN region of the expressed protein, resulting in at least substantially decreased enzymatic activity one or more of the RT, RNase H and/or IN functions of

20 HIV-1 Pol. In a preferred embodiment of this portion of the invention, a leader peptide/HIV-1 DNA pol construct contains a mutation or mutations within the Pol coding region which effectively abolishes RT, RNase H and IN activity. An especially preferable HIV-1 DNA pol construct is a DNA molecule which contains at least one point mutation which alters the active site and catalytic activity within the RT, RNase H and IN

25 domains of Pol, such that each activity is at least substantially abolished, and preferably totally abolished. Such a HIV-1 Pol mutant will most likely comprise at least one point mutation in or around each catalytic domain responsible for RT, RNase H and IN activity, respectfully. An especially preferred embodiment of this portion of the invention relates to a human tPA leader fused to the IA-Pol protein comprising the nine mutations shown

30 in Table 1. The DNA molecule is disclosed herein as SEQ ID NO:7 and the expressed tPA-IA Pol protein comprises a fusion junction as shown in Figure 3. The complete amino acid sequence of the expressed protein is set forth in SEQ ID NO:8.

 The present invention also relates to a substantially purified protein expressed from the DNA polynucleotide vaccines of the present invention, especially the purified

proteins set forth below as SEQ ID NOs: 2, 4, 6, and 8. These purified proteins may be useful as protein-based HIV vaccines.

The present invention also relates to non-codon optimized versions of DNA molecules and associated polynucleotides and associated DNA vaccines which
5   encode the various wild type and modified forms of the HIV Pol protein disclosed herein. Partial or fully codon optimized DNA vaccine expression vector constructs are preferred, but it is within the scope of the present invention to utilize "non-codon optimized" versions of the constructs disclosed herein, especially modified versions of HIV Pol which are shown to promote a substantial cellular immune and humoral
10   immune responses subsequent to host administration.

The DNA backbone of the DNA vaccines of the present invention are preferably DNA plasmid expression vectors. DNA plasmid expression vectors utilized in the present invention include but are not limited to constructs which comprise the cytomegalovirus promoter with the intron A sequence (CMV-intA) and
15   a bovine growth hormone transcription termination sequence. In addition, DNA plasmid vectors of the present invention preferably comprise an antibiotic resistance marker, including but not limited to an ampicillin resistance gene, a neomycin resistance gene or any other pharmaceutically acceptable antibiotic resistance marker. In addition, an appropriate polylinker cloning site and a prokaryotic origin of
20   replication sequence are also preferred. Specific DNA vectors exemplified herein include V1, V1J (SEQ ID NO:13), V1Jneo (SEQ ID NO:14), V1Jns (Figure 1A, SEQ ID NO:15), V1R (SEQ ID NO:26), and any of the aforementioned vectors wherein a nucleotide sequence encoding a leader peptide, preferably the human tPA leader, is fused directly downstream of the CMV-intA promoter, including but not limited to
25   V1Jns-tpa, as shown in Figure 1B and SEQ ID NO:28.

The present invention especially relates to a DNA vaccine and a pharmaceutically active vaccine composition which contains this DNA vaccine, and the use as prophylactic and/or therapeutic vaccine for host immunization, preferably human host immunization, against an HIV infection or to combat an existing HIV
30   condition. These DNA vaccines are represented by codon optimized DNA molecules encoding codon optimized HIV-1 Pol (e.g. SEQ ID NO:2), codon optimized HIV-1 Pol fused to an amino terminal localized leader sequence (e.g. SEQ ID NO:6), and especially preferable, and the essence of the present invention, biologically inactive Pol proteins (IA Pol; e.g., SEQ ID NO:4) devoid of significant PR, RT, RNase or IN

activity associated with wild type Pol and a concomitant construct which contains a leader peptide at the amino terminal region of the IA Pol protein. These constructs are ligated within an appropriate DNA plasmid vector, with or without a nucleotide sequence encoding a functional leader peptide. Preferred DNA vaccines of the

5   present invention comprise codon optimized DNA molecules encoding codon optimized HIV-1 Pol and inactivated version of Pol, ligated in DNA vectors disclosed herein, or any of the aforementioned vectors wherein a nucleotide sequence encoding a leader peptide, preferably the human tPA leader, is fused directly downstream of the CMV-intA promoter, including but not limited to V1Jns-tpa, as shown in Figure 1B

10   and SEQ ID NO:28.

Therefore, the present invention relates to DNA vaccines which include, but are in no way limited to V1Jns-WTPol (comprising the DNA molecule encoding WT Pol, as set forth in SEQ ID NO:2), V1Jns-tPA-WTPol, (comprising the DNA molecule encoding tPA Pol, as set forth in SEQ ID NO:6), V1Jns-IAPol (comprising

15   the DNA molecule encoding IA Pol, as set forth in SEQ ID NO:4), and V1Jns-tPA-IAPol, (comprising the DNA molecule encoding tPA-IA Pol, as set forth in SEQ ID NO:8). Especially preferred are V1Jns-IAPol and V1Jns-tPA-IAPol, as exemplified in Example Section 2.

The present invention also relates to HIV Pol polynucleotide

20   pharmaceutical products, as well as the production and use thereof, wherein the DNA vaccines are formulated with an adjuvant or adjuvants which may increase immunogenicity of the DNA polynucleotide vaccines of the present invention, namely by promoting an enhanced cellular and/or humoral response subsequent to inoculation. A preferred adjuvant is an aluminum phosphate-based adjuvant or a

25   calcium phosphate based adjuvant, with an aluminum phosphate adjuvant being especially preferred. Another preferred adjuvant is a non-ionic block copolymer, preferably comprising the blocks of polyoxyethylene (POE) and polyoxypropylene (POP) such as a POE-POP-POE block copolymer. These adjuvanted forms comprising the DNA vaccines disclosed herein are useful in

30   increasing cellular responses to DNA vaccination.

As used herein, a DNA vaccine or DNA polynucleotide vaccine is a DNA molecule (i.e., "nucleic acid", "polynucleotide") which contains essential regulatory elements such that upon introduction into a living, vertebrate cell, it is able to direct the cellular machinery to produce translation products encoded by the respective pol

genes of the present invention.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1A-B shows schematic representation of DNA vaccine expression
vectors V1Jns (A) and V1Jns-tPA (B) utilized for HIV-1 pol and HIV-1 modified pol
constructs.

Figure 2A-C shows the nucleotide (SEQ ID NO:3) and amino acid sequence
(SEQ ID NO:4) of IA-Pol. Underlined codons and amino acids denote mutations, as
listed in Table 1.

Figure 3 shows the codon optimized nucleotide and amino acid sequences
through the fusion junction of tPA-IA-Pol (contained within SEQ ID NOs: 7 and 8,
respectively). The underlined portion represents the NH_2-terminal region of IA-Pol.

Figure 4 shows generation of a humoral response (measured as the geometric
means of anti-RT endpoint titers) from mice immunized with one or two doses of
codon optimized V1Jns-IApol and V1Jns-tpa-IApol. A portion of mice that received
30 ug of each plasmid was boosted at T=8 wks; sera from all mice were collected at 4
wk post dose 2.

Figure 5 shows the number of IFN-gamma secreting cells per 10e6 cells
following stimulation with pools of either $CD4^+$ (aa641-660, aa731-750) or $CD8^+$
(aa201-220, aa311-330, aa571-590, aa781-800) specific peptides of splenocytes (pool
of 5 spleens/cohort) from control mice and those vaccinated with increasing single
dose of codon optimized V1Jns-IApol or 30 ug of codon optimized V1Jns-tpa-IApol
(13 wks post dose 1). Mice (n=5) vaccinated with a second dose of 30 ug of either
plasmid were analyzed in an Elispot assay at 6 wks post dose 2. Reported are the
sums of the number of spots stimulated by each individual $CD8^+$ peptides because the
spots in the wells to which the pool was added are too dense to acquire accurate
counts. The $CD4^+$ cell counts are taken from the responses to the peptide pool. Error
bars represent standard deviations for counts from triplicate wells per sample per
antigen.

Figure 6A-C shows ELIspot analysis of peripheral blood cells collected from
rhesus macaques immunized three times (T=0, 4, 8 wks) with 5 mgs of codon
optimized HIV-1 Pol expressing plasmids. Antigen-specific IFN-gamma secretion
was stimulated by adding one of two pools consisting of 20-mer peptides derived
from vaccine sequence (mpol-1, aa1-420; mpol-2, aa411-850). (A) Frequencies of

spot-forming cells (SFC) as a function of time for 3 monkeys (Tag No. 94R008, 94R013, 94R033) vaccinated with V1Jns-IApol. The reported values are corrected for background responses without peptide restimulation. (B) Frequencies of spot-forming cells (SFC) as a function of time for 3 monkeys (Tag No. 920078, 920073, 94R028) vaccinated with 5mgs of V1Jns-tpa-IApol. (C) ELIspot responses were also measured from a monkey (920072) that did not receive any immunization.

Figure 7A-B show bulk CTL killing from rhesus macaques immunized with codon optimized V1Jns-IApol (A)or codon optimized V1Jns-tpa-IApol (B) at 8 weeks following the third vaccination. Restimulation was performed using recombinant vaccinia virus expressing pol and target cells were prepared by pulsing with the peptide pools, mpol-1 and mpol-2.

Figure 8 shows detection of *in vitro* pol expression from cell lysates of 293 cells transfected with 10 ug of various pol constructs. Bands were detected using anti-serum from an HIV-1 seropositive human subject. Equal amounts of total protein were loaded for each lane. The lanes contain the lysates from cells transfected with the following: 1: mock; 2: V1Jns-wt-pol; 3: V1Jns-IApol (codon optimized); 4: V1Jns-tpa-IApol (codon optimized); 5: V1Jns-tpa-pol (codon optimized); 6: V1R-wt-pol (codon optimized); 7: blank; and 8: 80 ng RT.

Figure 9 shows the geometric mean anti-RT titers (GMT) plus the standard errors of the geometric means for cohorts of 5 mice that received one (open circles) or two doses (solid circles) of 1, 10, 100 µg of V1R-wt-pol (codon optimized) or V1Jns-wt-pol. Sera from all animals were collected at 2 weeks post dose 2 (or 7 wks post dose 1) and assayed simultaneously. Statistical analyses were performed to compare cohorts that received the same amount and number of immunization of either plasmids; p values (two-tail) less than 5% are above the bars the connect the correlated cohorts to reflect statistically significant differences.

Figure 10 shows cellular immune responses in BALB/c mice vaccinated i.m. with 1 (pd1) or 2 (pd2) doses of varying amounts of either wt-pol (virus derived) or wt-pol (codon optimized) plasmids. At 3 wks post dose 2, frequencies of IFN-γ-secreting splenocytes are determined from pools of 5 spleens per cohort against mixtures of either $CD4^+$ peptides (aa21-40, aa411-430, aa531-550, aa641-660, aa731-750, aa771-790) or $CD8^+$ peptides (aa201-220, aa311-330) at 4 µg/mL final concentration per peptide.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to synthetic DNA molecules and associated DNA vaccines which elicit CTL and Th cellular immune responses upon administration to the host, including primates and especially humans. An effect of the

5   cellular immune-directed vaccines of the present invention should be a lower transmission rate to previously uninfected individuals and/or reduction in the levels of the viral loads within an infected individual, so as to prolong the asymptomatic phase of HIV-1 infection. In particular, the present invention relates to DNA vaccines which encode various forms of HIV-1 Pol, wherein administration, intracellular

10   delivery and expression of the HIV-1 Pol gene of interest elicits a host CTL and Th response. The preferred synthetic DNA molecules of the present invention encode codon optimized wild type Pol (without Pro activity) and various codon optimized inactivated HIV-1 Pol proteins. The HIV-1 *pol* constructs disclosed herein are especially preferred for pharmaceutical uses, especially for human administration as a

15   DNA vaccine. The HIV-1 genome employs predominantly uncommon codons compared to highly expressed human genes. Therefore, the pol open reading frame has been synthetically manipulated using optimal codons for human expression. As noted above, a preferred embodiment of the present invention relates to DNA molecules which comprise a HIV-1 pol open reading frame, whether encoding full

20   length pol or a modification or fusion as described herein, wherein the codon usage has been optimized for expression in a mammal, especially a human.

The synthetic *pol* gene disclosed herein comprises the coding sequences for the reverse transcriptase (or RT which consists of a polymerase and RNase H activity) and integrase (IN). The protein sequence is based on that of Hxb2r, a clonal isolate of

25   IIIB; this sequence has been shown to be closest to the consensus clade B sequence with only 16 nonidentical residues out of 848 (Korber, et al., 1998, Human retroviruses and AIDS, Los Alamos National Laboratory, Los Alamos, New Mexico). The skilled artisan will understand after review of this specification that any available HIV-1 or HIV-2 strain provides a potential template for the generation of HIV pol

30   DNA vaccine constructs disclosed herein. It is further noted that the protease gene is excluded from the DNA vaccine constructs of the present invention to insure safety from any residual protease activity in spite of mutational inactivation. The design of the gene sequences for both wild-type (wt-pol) and inactivated pol (IA-pol) incorporates the use of human preferred ("humanized") codons for each amino acid

residue in the sequence in order to maximize *in vivo* mammalian expression (Lathe, 1985, J. Mol. Biol. 183:1-12). As can be discerned by inspecting the codon usage in SEQ ID NOs: 1, 3, 5 and 7, the following codon usage for mammalian optimization is preferred: Met (ATG), Gly (GGC), Lys (AAG), Trp (TGG), Ser (TCC), Arg (AGG),

5   Val (GTG), Pro (CCC), Thr (ACC), Glu (GAG); Leu (CTG), His (CAC), Ile (ATC), Asn (AAC), Cys (TGC), Ala (GCC), Gln (CAG), Phe (TTC) and Tyr (TAC). For an additional discussion relating to mammalian (human) codon optimization, see WO 97/31115 (PCT/US97/02294), which is hereby incorporated by reference. It is intended that the skilled artisan may use alternative versions of codon optimization or

10   may omit this step when generating HIV pol vaccine constructs within the scope of the present invention. Therefore, the present invention also relates to non-codon optimized versions of DNA molecules and associated DNA vaccines which encode the various wild type and modified forms of the HIV Pol protein disclosed herein. However, codon optimization of these constructs is a preferred embodiment of this

15   invention.

A particular embodiment of the present invention relates to codon optimized wt-pol DNA constructs (herein, "wt-pol" or "wt-pol (codon optimized))" wherein DNA sequences encoding the protease (PR) activity are deleted, leaving codon optimized "wild type" sequences which encode RT (reverse transcriptase and RNase

20   H activity) and IN integrase activity. A DNA molecule which encodes this protein is disclosed herein as SEQ ID NO:1, the open reading frame being contained from an initiating Met residue at nucleotides 10-12 to a termination codon from nucleotides 2560-2562. SEQ ID NO:1 is as follows:

```
       AGATCTACCA TGGCCCCCAT CTCCCCCATT GAGACTGTGC CTGTGAAGCT GAAGCCTGGC
25     ATGGATGGCC CCAAGGTGAA GCAGTGGCCC CTGACTGAGG AGAAGATCAA GGCCCTGGTG
       GAAATCTGCA CTGAGATGGA GAAGGAGGGC AAAATCTCCA AGATTGGCCC CGAGAACCCC
       TACAACACCC CTGTGTTTGC CATCAAGAAG AAGGACTCCA CCAAGTGGAG GAAGCTGGTG
       GACTTCAGGG AGCTGAACAA GAGGACCCAG GACTTCTGGG AGGTGCAGCT GGGCATCCCC
       CACCCCGCTG GCCTGAAGAA GAAGAAGTCT GTGACTGTGC TGGATGTGGG GGATGCCTAC
30     TTCTCTGTGC CCCTGGATGA GGACTTCAGG AAGTACACTG CCTTCACCAT CCCCTCCATC
       AACAATGAGA CCCCTGGCAT CAGGTACCAG TACAATGTGC TGCCCCAGGG CTGGAAGGGC
       TCCCCTGCCA TCTTCCAGTC CTCCATGACC AAGATCCTGG AGCCCTTCAG GAAGCAGAAC
       CCTGACATTG TGATCTACCA GTACATGGAT GACCTGTATG TGGGCTCTGA CCTGGAGATT
       GGGCAGCACA GGACCAAGAT TGAGGAGCTG AGGCAGCACC TGCTGAGGTG GGGCCTGACC
```

```
       ACCCCTGACA AGAAGCACCA GAAGGAGCCC CCCTTCCTGT GGATGGGCTA TGAGCTGCAC
       CCCGACAAGT GGACTGTGCA GCCCATTGTG CTGCCTGAGA AGGACTCCTG GACTGTGAAT
       GACATCCAGA AGCTGGTGGG CAAGCTGAAC TGGGCCTCCC AAATCTACCC TGGCATCAAG
       GTGAGGCAGC TGTGCAAGCT GCTGAGGGGC ACCAAGGCCC TGACTGAGGT GATCCCCCTG
  5    ACTGAGGAGG CTGAGCTGGA GCTGGCTGAG AACAGGGAGA TCCTGAAGGA GCCTGTGCAT
       GGGGTGTACT ATGACCCCTC CAAGGACCTG ATTGCTGAGA TCCAGAAGCA GGGCCAGGGC
       CAGTGGACCT ACCAAATCTA CCAGGAGCCC TTCAAGAACC TGAAGACTGG CAAGTATGCC
       AGGATGAGGG GGGCCCACAC CAATGATGTG AAGCAGCTGA CTGAGGCTGT GCAGAAGATC
       ACCACTGAGT CCATTGTGAT CTGGGGCAAG ACCCCCAAGT TCAAGCTGCC CATCCAGAAG
  10   GAGACCTGGG AGACCTGGTG GACTGAGTAC TGGCAGGCCA CCTGGATCCC TGAGTGGGAG
       TTTGTGAACA CCCCCCCCCT GGTGAAGCTG TGGTACCAGC TGGAGAAGGA GCCCATTGTG
       GGGGCTGAGA CCTTCTATGT GGATGGGGCT GCCAACAGGG AGACCAAGCT GGGCAAGGCT
       GGCTATGTGA CCAACAGGGG CAGGCAGAAG GTGGTGACCC TGACTGACAC CACCAACCAG
       AAGACTGAGC TCCAGGCCAT CTACCTGGCC CTCCAGGACT CTGGCCTGGA GGTGAACATT
  15   GTGACTGACT CCCAGTATGC CCTGGGCATC ATCCAGGCCC AGCCTGATCA GTCTGAGTCT
       GAGCTGGTGA ACCAGATCAT TGAGCAGCTG ATCAAGAAGG AGAAGGTGTA CCTGGCCTGG
       GTGCCTGCCC ACAAGGGCAT TGGGGGCAAT GAGCAGGTGG ACAAGCTGGT GTCTGCTGGC
       ATCAGGAAGG TGCTGTTCCT GGATGGCATT GACAAGGCCC AGGATGAGCA TGAGAAGTAC
       CACTCCAACT GGAGGGCTAT GGCCTCTGAC TTCAACCTGC CCCCTGTGGT GGCTAAGGAG
  20   ATTGTGGCCT CCTGTGACAA GTGCCAGCTG AAGGGGGAGG CCATGCATGG GCAGGTGGAC
       TGCTCCCCTG GCATCTGGCA GCTGGACTGC ACCCACCTGG AGGGCAAGGT GATCCTGGTG
       GCTGTGCATG TGGCCTCCGG CTACATTGAG GCTGAGGTGA TCCCTGCTGA GACAGGCCAG
       GAGACTGCCT ACTTCCTGCT GAAGCTGGCT GGCAGGTGGC CTGTGAAGAC CATCCACACT
       GACAATGGCT CCAACTTCAC TGGGGCCACA GTGAGGGCTG CCTGCTGGTG GGCTGGCATC
  25   AAGCAGGAGT TTGGCATCCC CTACAACCCC CAGTCCCAGG GGGTGGTGGA GTCCATGAAC
       AAGGAGCTGA AGAAGATCAT TGGGCAGGTG AGGGACCAGG CTGAGCACCT GAAGACAGCT
       GTGCAGATGG CTGTGTTCAT CCACAACTTC AAGAGGAAGG GGGGCATCGG GGGCTACTCC
       GCTGGGGAGA GGATTGTGGA CATCATTGCC ACAGACATCC AGACCAAGGA GCTCCAGAAG
       CAGATCACCA AGATCCAGAA CTTCAGGGTG TACTACAGGG ACTCCAGGAA CCCCCTGTGG
  30   AAGGGCCCTG CCAAGCTGCT GTGGAAGGGG GAGGGGGCTG TGGTGATCCA GGACAACTCT
       GACATCAAGG TGGTGCCCAG GAGGAAGGCC AAGATCATCA GGGACTATGG CAAGCAGATG
       GCTGGGGATG ACTGTGTGGC CTCCAGGCAG GATGAGGACT AAAGCCCGGG CAGATCT (SEQ
       ID NO:1).
```

The open reading frame of the wild type pol construct disclosed as SEQ ID
NO:1 contains 850 amino acids, disclosed herein as SEQ ID NO:2, as follows:

Met Ala Pro Ile Ser Pro Ile Glu Thr Val Pro Val Lys Leu Lys Pro

Gly Met Asp Gly Pro Lys Val Lys Gln Trp Pro Leu Thr Glu Glu Lys

5   Ile Lys Ala Leu Val Glu Ile Cys Thr Glu Met Glu Lys Glu Gly Lys

Ile Ser Lys Ile Gly Pro Glu Asn Pro Tyr Asn Thr Pro Val Phe Ala

Ile Lys Lys Lys Asp Ser Thr Lys Trp Arg Lys Leu Val Asp Phe Arg

Glu Leu Asn Lys Arg Thr Gln Asp Phe Trp Glu Val Gln Leu Gly Ile

Pro His Pro Ala Gly Leu Lys Lys Lys Lys Ser Val Thr Val Leu Asp

10 Val Gly Asp Ala Tyr Phe Ser Val Pro Leu Asp Glu Asp Phe Arg Lys

Tyr Thr Ala Phe Thr Ile Pro Ser Ile Asn Asn Glu Thr Pro Gly Ile

Arg Tyr Gln Tyr Asn Val Leu Pro Gln Gly Trp Lys Gly Ser Pro Ala

Ile Phe Gln Ser Ser Met Thr Lys Ile Leu Glu Pro Phe Arg Lys Gln

Asn Pro Asp Ile Val Ile Tyr Gln Tyr Met Asp Asp Leu Tyr Val Gly

15 Ser Asp Leu Glu Ile Gly Gln His Arg Thr Lys Ile Glu Glu Leu Arg

Gln His Leu Leu Arg Trp Gly Leu Thr Thr Pro Asp Lys Lys His Gln

Lys Glu Pro Pro Phe Leu Trp Met Gly Tyr Glu Leu His Pro Asp Lys

Trp Thr Val Gln Pro Ile Val Leu Pro Glu Lys Asp Ser Trp Thr Val

Asn Asp Ile Gln Lys Leu Val Gly Lys Leu Asn Trp Ala Ser Gln Ile

20 Tyr Pro Gly Ile Lys Val Arg Gln Leu Cys Lys Leu Leu Arg Gly Thr

Lys Ala Leu Thr Glu Val Ile Pro Leu Thr Glu Glu Ala Glu Leu Glu

Leu Ala Glu Asn Arg Glu Ile Leu Lys Glu Pro Val His Gly Val Tyr

Tyr Asp Pro Ser Lys Asp Leu Ile Ala Glu Ile Gln Lys Gln Gly Gln

Gly Gln Trp Thr Tyr Gln Ile Tyr Gln Glu Pro Phe Lys Asn Leu Lys

25 Thr Gly Lys Tyr Ala Arg Met Arg Gly Ala His Thr Asn Asp Val Lys

Gln Leu Thr Glu Ala Val Gln Lys Ile Thr Thr Glu Ser Ile Val Ile

Trp Gly Lys Thr Pro Lys Phe Lys Leu Pro Ile Gln Lys Glu Thr Trp

Glu Thr Trp Trp Thr Glu Tyr Trp Gln Ala Thr Trp Ile Pro Glu Trp

Glu Phe Val Asn Thr Pro Pro Leu Val Lys Leu Trp Tyr Gln Leu Glu

30 Lys Glu Pro Ile Val Gly Ala Glu Thr Phe Tyr Val Asp Gly Ala Ala

Asn Arg Glu Thr Lys Leu Gly Lys Ala Gly Tyr Val Thr Asn Arg Gly

Arg Gln Lys Val Val Thr Leu Thr Asp Thr Thr Asn Gln Lys Thr Glu

Leu Gln Ala Ile Tyr Leu Ala Leu Gln Asp Ser Gly Leu Glu Val Asn

Ile Val Thr Asp Ser Gln Tyr Ala Leu Gly Ile Ile Gln Ala Gln Pro

```
        Asp Gln Ser Glu Ser Glu Leu Val Asn Gln Ile Ile Glu Gln Leu Ile

        Lys Lys Glu Lys Val Tyr Leu Ala Trp Val Pro Ala His Lys Gly Ile

        Gly Gly Asn Glu Gln Val Asp Lys Leu Val Ser Ala Gly Ile Arg Lys

        Val Leu Phe Leu Asp Gly Ile Asp Lys Ala Gln Asp Glu His Glu Lys

    5   Tyr His Ser Asn Trp Arg Ala Met Ala Ser Asp Phe Asn Leu Pro Pro

        Val Val Ala Lys Glu Ile Val Ala Ser Cys Asp Lys Cys Gln Leu Lys

        Gly Glu Ala Met His Gly Gln Val Asp Cys Ser Pro Gly Ile Trp Gln

        Leu Asp Cys Thr His Leu Glu Gly Lys Val Ile Leu Val Ala Val His

        Val Ala Ser Gly Tyr Ile Glu Ala Glu Val Ile Pro Ala Glu Thr Gly

   10   Gln Glu Thr Ala Tyr Phe Leu Leu Lys Leu Ala Gly Arg Trp Pro Val

        Lys Thr Ile His Thr Asp Asn Gly Ser Asn Phe Thr Gly Ala Thr Val

        Arg Ala Ala Cys Trp Trp Ala Gly Ile Lys Gln Glu Phe Gly Ile Pro

        Tyr Asn Pro Gln Ser Gln Gly Val Val Glu Ser Met Asn Lys Glu Leu

        Lys Lys Ile Ile Gly Gln Val Arg Asp Gln Ala Glu His Leu Lys Thr

   15   Ala Val Gln Met Ala Val Phe Ile His Asn Phe Lys Arg Lys Gly Gly

        Ile Gly Gly Tyr Ser Ala Gly Glu Arg Ile Val Asp Ile Ile Ala Thr

        Asp Ile Gln Thr Lys Glu Leu Gln Lys Gln Ile Thr Lys Ile Gln Asn

        Phe Arg Val Tyr Tyr Arg Asp Ser Arg Asn Pro Leu Trp Lys Gly Pro

        Ala Lys Leu Leu Trp Lys Gly Glu Gly Ala Val Val Ile Gln Asp Asn

   20   Ser Asp Ile Lys Val Val Pro Arg Arg Lys Ala Lys Ile Ile Arg Asp

        Tyr Gly Lys Gln Met Ala Gly Asp Asp Cys Val Ala Ser Arg Gln Asp

        Glu Asp (SEQ ID NO:2).
```

The present invention especially relates to a codon optimized HIV-1 DNA pol construct wherein, in addition to deletion of the portion of the wild type sequence encoding the protease activity, a combination of active site residue mutations are introduced which are deleterious to HIV-1 pol (RT-RH-IN) activity of the expressed protein. Therefore, the present invention preferably relates to a HIV-1 DNA pol construct which is devoid of DNA sequences encoding any PR activity, as well as containing a mutation(s) which at least partially, and preferably substantially, abolishes RT, RNase and/or IN activity. One type of HIV-1 pol mutant may include but is not limited to a mutated DNA molecule comprising at least one nucleotide substitution which results in a point mutation which effectively alters an active site within the RT, RNase and/or IN regions of the expressed protein, resulting in at least substantially decreased enzymatic activity for the RT, RNase H and/or IN functions of

HIV-1 Pol. In a preferred embodiment of this portion of the invention, a HIV-1 DNA pol construct contains a mutation or mutations within the Pol coding region which effectively abolishes RT, RNase H and IN activity. An especially preferable HIV-1 DNA pol construct in a DNA molecule which contains at least one point mutation which alters the active site of the RT, RNase H and IN domains of Pol, such that each activity is at least substantially abolished. Such a HIV-1 Pol mutant will most likely comprise at least one point mutation in or around each catalytic domain responsible for RT, RNase H and IN activity, respectfully. To this end, an especially preferred HIV-1 DNA pol construct is exemplified herein and contains nine codon substitution mutations which results in an inactivated Pol protein (IA Pol: SEQ ID NO:4, Figure 2A-C) which has no PR, RT, RNase or IN activity, wherein three such point mutations reside within each of the RT, RNase and IN catalytic domains. Therefore, an especially preferred exemplification is a DNA molecule which encodes IA-pol, which contains all nine mutations as shown below in Table 1. An additional preferred amino acid residue for substitution is Asp551, localized within the RNase domain of Pol. Any combination of the mutations disclosed herein may suitable and therefore may be utilized as an IA-Pol-based vaccine of the present invention. While addition and deletion mutations are contemplated and within the scope of the invention, the preferred mutation is a point mutation resulting in a substitution of the wild type amino acid with an alternative amino acid residue.

Table 1

wt aa	aa residue	mutant aa	enzyme function
Asp	112	Ala	RT
Asp	187	Ala	RT
Asp	188	Ala	RT
Asp	445	Ala	RNase H
Glu	480	Ala	RNase H
Asp	500	Ala	RNase H
Asp	626	Ala	IN
Asp	678	Ala	IN
Glu	714	Ala	IN

It is preferred that point mutations be incorporated into the IApol mutant vaccines of
the present invention so as to lessen the possibility of altering epitopes in and around
the active site(s) of HIV-1 Pol.

5   To this end, SEQ ID NO:3 discloses the nucleotide sequence which codes for
a codon optimized pol in addition to the nine mutations shown in Table 1, disclosed as
follows, and referred to herein as "IApol":

```
AGATCTACCA  TGGCCCCCAT  CTCCCCCATT  GAGACTGTGC  CTGTGAAGCT  GAAGCCTGGC
ATGGATGGCC  CCAAGGTGAA  GCAGTGGCCC  CTGACTGAGG  AGAAGATCAA  GGCCCTGGTG
GAAATCTGCA  CTGAGATGGA  GAAGGAGGGC  AAAATCTCCA  AGATTGGCCC  CGAGAACCCC
10     TACAACACCC  CTGTGTTTGC  CATCAAGAAG  AAGGACTCCA  CCAAGTGGAG  GAAGCTGGTG
GACTTCAGGG  AGCTGAACAA  GAGGACCCAG  GACTTCTGGG  AGGTGCAGCT  GGGCATCCCC
CACCCCGCTG  GCCTGAAGAA  GAAGAAGTCT  GTGACTGTGC  TGGCTGTGGG  GGATGCCTAC
TTCTCTGTGC  CCCTGGATGA  GGACTTCAGG  AAGTACACTG  CCTTCACCAT  CCCCTCCATC
AACAATGAGA  CCCCTGGCAT  CAGGTACCAG  TACAATGTGC  TGCCCCAGGG  CTGGAAGGGC
15     TCCCCTGCCA  TCTTCCAGTC  CTCCATGACC  AAGATCCTGG  AGCCCTTCAG  GAAGCAGAAC
CCTGACATTG  TGATCTACCA  GTACATGGCT  GCCCTGTATG  TGGGCTCTGA  CCTGGAGATT
GGGCAGCACA  GGACCAAGAT  TGAGGAGCTG  AGGCAGCACC  TGCTGAGGTG  GGGCCTGACC
ACCCCTGACA  AGAAGCACCA  GAAGGAGCCC  CCCTTCCTGT  GGATGGGCTA  TGAGCTGCAC
CCCGACAAGT  GGACTGTGCA  GCCCATTGTG  CTGCCTGAGA  AGGACTCCTG  GACTGTGAAT
20     GACATCCAGA  AGCTGGTGGG  CAAGCTGAAC  TGGGCCTCCC  AAATCTACCC  TGGCATCAAG
GTGAGGCAGC  TGTGCAAGCT  GCTGAGGGGC  ACCAAGGCCC  TGACTGAGGT  GATCCCCCTG
ACTGAGGAGG  CTGAGCTGGA  GCTGGCTGAG  AACAGGGAGA  TCCTGAAGGA  GCCTGTGCAT
GGGGTGTACT  ATGACCCCTC  CAAGGACCTG  ATTGCTGAGA  TCCAGAAGCA  GGGCCAGGGC
CAGTGGACCT  ACCAAATCTA  CCAGGAGCCC  TTCAAGAACC  TGAAGACTGG  CAAGTATGCC
25     AGGATGAGGG  GGGCCCACAC  CAATGATGTG  AAGCAGCTGA  CTGAGGCTGT  GCAGAAGATC
ACCACTGAGT  CCATTGTGAT  CTGGGGCAAG  ACCCCCAAGT  TCAAGCTGCC  CATCCAGAAG
GAGACCTGGG  AGACCTGGTG  GACTGAGTAC  TGGCAGGCCA  CCTGGATCCC  TGAGTGGGAG
TTTGTGAACA  CCCCCCCCCT  GGTGAAGCTG  TGGTACCAGC  TGGAGAAGGA  GCCCATTGTG
GGGGCTGAGA  CCTTCTATGT  GGCTGGGGCT  GCCAACAGGG  AGACCAAGCT  GGGCAAGGCT
30     GGCTATGTGA  CCAACAGGGG  CAGGCAGAAG  GTGGTGACCC  TGACTGACAC  CACCAACCAG
AAGACTGCCC  TCCAGGCCAT  CTACCTGGCC  CTCCAGGACT  CTGGCCTGGA  GGTGAACATT
GTGACTGCCT  CCCAGTATGC  CCTGGGCATC  ATCCAGGCCC  AGCCTGATCA  GTCTGAGTCT
GAGCTGGTGA  ACCAGATCAT  TGAGCAGCTG  ATCAAGAAGG  AGAAGGTGTA  CCTGGCCTGG
GTGCCTGCCC  ACAAGGGCAT  TGGGGGCAAT  GAGCAGGTGG  ACAAGCTGGT  GTCTGCTGGC
```

```
         ATCAGGAAGG TGCTGTTCCT GGATGGCATT GACAAGGCCC AGGATGAGCA TGAGAAGTAC

         CACTCCAACT GGAGGGCTAT GGCCTCTGAC TTCAACCTGC CCCCTGTGGT GGCTAAGGAG

         ATTGTGGCCT CCTGTGACAA GTGCCAGCTG AAGGGGGAGG CCATGCATGG GCAGGTGGAC

         TGCTCCCCTG GCATCTGGCA GCTGGCCTGC ACCCACCTGG AGGGCAAGGT GATCCTGGTG

    5    GCTGTGCATG TGGCCTCCGG CTACATTGAG GCTGAGGTGA TCCCTGCTGA GACAGGCCAG

         GAGACTGCCT ACTTCCTGCT GAAGCTGGCT GGCAGGTGGC CTGTGAAGAC CATCCACACT

         GCCAATGGCT CCAACTTCAC TGGGGCCACA GTGAGGGCTG CCTGCTGGTG GGCTGGCATC

         AAGCAGGAGT TTGGCATCCC CTACAACCCC CAGTCCCAGG GGGTGGTGGC CTCCATGAAC

         AAGGAGCTGA AGAAGATCAT TGGGCAGGTG AGGGACCAGG CTGAGCACCT GAAGACAGCT

    10   GTGCAGATGG CTGTGTTCAT CCACAACTTC AAGAGGAAGG GGGGCATCGG GGGCTACTCC

         GCTGGGGAGA GGATTGTGGA CATCATTGCC ACAGACATCC AGACCAAGGA GCTCCAGAAG

         CAGATCACCA AGATCCAGAA CTTCAGGGTG TACTACAGGG ACTCCAGGAA CCCCCTGTGG

         AAGGGCCCTG CCAAGCTGCT GTGGAAGGGG GAGGGGGCTG TGGTGATCCA GGACAACTCT

         GACATCAAGG TGGTGCCCAG GAGGAAGGCC AAGATCATCA GGGACTATGG CAAGCAGATG

    15   GCTGGGGATG ACTGTGTGGC CTCCAGGCAG GATGAGGACT AAAGCCCGGG CAGATCT (SEQ ID
         NO:3).
```

In order to produce the IA-pol DNA vaccine construction, inactivation of the
enzymatic functions was achieved by replacing a total of nine active-site residues
from the enzyme subunits with alanine side-chains. As shown in Table 1, all residues

20 that comprise the catalytic triad of the polymerase, namely Asp112, Asp187, and
Asp188, were substituted with alanine (Ala) residues (Larder, et al., *Nature* 1987,
327: 716-717; Larder, et al., 1989, *Proc. Natl. Acad. Sci.* 1989, 86: 4803-4807).
Three additional mutations were introduced at Asp445, Glu480 and Asp500 to abolish
RNase H activity (Asp551 was left unchanged in this IA Pol construct), with each

25 residue being substituted for an Ala residue, respectively (Davies, et al., 1991,
Science 252:, 88-95; Schatz, et al., 1989, *FEBS Lett.* 257: 311-314; Mizrahi, et al.,
1990, Nucl. Acids. Res. 18: pp. 5359-5353). HIV pol integrase function was
abolished through three mutations at Asp626, Asp678 and Glu714. Again, each of
these residues has been substituted with an Ala residue (Wiskerchen, et al., 1995, J.

30 Virol. 69: 376-386; Leavitt, et al., 1993, J. Biol. Chem. 268: 2113-2119). Amino
acid residue Pro3 of SEQ ID NO:4 marks the start of the RT gene. The complete
amino acid sequence of IA-Pol is disclosed herein as SEQ ID NO:4, as follows:

```
         Met Ala Pro Ile Ser Pro Ile Glu Thr Val Pro Val Lys Leu Lys Pro

         Gly Met Asp Gly Pro Lys Val Lys Gln Trp Pro Leu Thr Glu Glu Lys
```

Ile Lys Ala Leu Val Glu Ile Cys Thr Glu Met Glu Lys Glu Gly Lys

Ile Ser Lys Ile Gly Pro Glu Asn Pro Tyr Asn Thr Pro Val Phe Ala

Ile Lys Lys Lys Asp Ser Thr Lys Trp Arg Lys Leu Val Asp Phe Arg

Glu Leu Asn Lys Arg Thr Gln Asp Phe Trp Glu Val Gln Leu Gly Ile

5 Pro His Pro Ala Gly Leu Lys Lys Lys Ser Val Thr Val Leu Ala

Val Gly Asp Ala Tyr Phe Ser Val Pro Leu Asp Glu Asp Phe Arg Lys

Tyr Thr Ala Phe Thr Ile Pro Ser Ile Asn Asn Glu Thr Pro Gly Ile

Arg Tyr Gln Tyr Asn Val Leu Pro Gln Gly Trp Lys Gly Ser Pro Ala

Ile Phe Gln Ser Ser Met Thr Lys Ile Leu Glu Pro Phe Arg Lys Gln

10 Asn Pro Asp Ile Val Ile Tyr Gln Tyr Met Ala Ala Leu Tyr Val Gly

Ser Asp Leu Glu Ile Gly Gln His Arg Thr Lys Ile Glu Glu Leu Arg

Gln His Leu Leu Arg Trp Gly Leu Thr Thr Pro Asp Lys Lys His Gln

Lys Glu Pro Pro Phe Leu Trp Met Gly Tyr Glu Leu His Pro Asp Lys

Trp Thr Val Gln Pro Ile Val Leu Pro Glu Lys Asp Ser Trp Thr Val

15 Asn Asp Ile Gln Lys Leu Val Gly Lys Leu Asn Trp Ala Ser Gln Ile

Tyr Pro Gly Ile Lys Val Arg Gln Leu Cys Lys Leu Leu Arg Gly Thr

Lys Ala Leu Thr Glu Val Ile Pro Leu Thr Glu Glu Ala Glu Leu Glu

Leu Ala Glu Asn Arg Glu Ile Leu Lys Glu Pro Val His Gly Val Tyr

Tyr Asp Pro Ser Lys Asp Leu Ile Ala Glu Ile Gln Lys Gln Gly Gln

20 Gly Gln Trp Thr Tyr Gln Ile Tyr Gln Glu Pro Phe Lys Asn Leu Lys

Thr Gly Lys Tyr Ala Arg Met Arg Gly Ala His Thr Asn Asp Val Lys

Gln Leu Thr Glu Ala Val Gln Lys Ile Thr Thr Glu Ser Ile Val Ile

Trp Gly Lys Thr Pro Lys Phe Lys Leu Pro Ile Gln Lys Glu Thr Trp

Glu Thr Trp Trp Thr Glu Tyr Trp Gln Ala Thr Trp Ile Pro Glu Trp

25 Glu Phe Val Asn Thr Pro Pro Leu Val Lys Leu Trp Tyr Gln Leu Glu

Lys Glu Pro Ile Val Gly Ala Glu Thr Phe Tyr Val Ala Gly Ala Ala

Asn Arg Glu Thr Lys Leu Gly Lys Ala Gly Tyr Val Thr Asn Arg Gly

Arg Gln Lys Val Val Thr Leu Thr Asp Thr Thr Asn Gln Lys Thr Ala

Leu Gln Ala Ile Tyr Leu Ala Leu Gln Asp Ser Gly Leu Glu Val Asn

30 Ile Val Thr Ala Ser Gln Tyr Ala Leu Gly Ile Ile Gln Ala Gln Pro

Asp Gln Ser Glu Ser Glu Leu Val Asn Gln Ile Ile Glu Gln Leu Ile

Lys Lys Glu Lys Val Tyr Leu Ala Trp Val Pro Ala His Lys Gly Ile

Gly Gly Asn Glu Gln Val Asp Lys Leu Val Ser Ala Gly Ile Arg Lys

Val Leu Phe Leu Asp Gly Ile Asp Lys Ala Gln Asp Glu His Glu Lys

```
      Tyr His Ser Asn Trp Arg Ala Met Ala Ser Asp Phe Asn Leu Pro Pro
      Val Val Ala Lys Glu Ile Val Ala Ser Cys Asp Lys Cys Gln Leu Lys
      Gly Glu Ala Met His Gly Gln Val Asp Cys Ser Pro Gly Ile Trp Gln
      Leu Ala Cys Thr His Leu Glu Gly Lys Val Ile Leu Val Ala Val His
5     Val Ala Ser Gly Tyr Ile Glu Ala Glu Val Ile Pro Ala Glu Thr Gly
      Gln Glu Thr Ala Tyr Phe Leu Leu Lys Leu Ala Gly Arg Trp Pro Val
      Lys Thr Ile His Thr Ala Asn Gly Ser Asn Phe Thr Gly Ala Thr Val
      Arg Ala Ala Cys Trp Trp Ala Gly Ile Lys Gln Glu Phe Gly Ile Pro
      Tyr Asn Pro Gln Ser Gln Gly Val Val Ala Ser Met Asn Lys Glu Leu
10    Lys Lys Ile Ile Gly Gln Val Arg Asp Gln Ala Glu His Leu Lys Thr
      Ala Val Gln Met Ala Val Phe Ile His Asn Phe Lys Arg Lys Gly Gly
      Ile Gly Gly Tyr Ser Ala Gly Glu Arg Ile Val Asp Ile Ile Ala Thr
      Asp Ile Gln Thr Lys Glu Leu Gln Lys Gln Ile Thr Lys Ile Gln Asn
      Phe Arg Val Tyr Tyr Arg Asp Ser Arg Asn Pro Leu Trp Lys Gly Pro
15    Ala Lys Leu Leu Trp Lys Gly Glu Gly Ala Val Val Ile Gln Asp Asn
      Ser Asp Ile Lys Val Val Pro Arg Arg Lys Ala Lys Ile Ile Arg Asp
      Tyr Gly Lys Gln Met Ala Gly Asp Asp Cys Val Ala Ser Arg Gln Asp
      Glu Asp (SEQ ID NO:4).
```

As noted above, it will be understood that any combination of the mutations
disclosed above may be suitable and therefore be utilized as an IA-pol-based vaccine
of the present invention. For example, it may be possible to mutate only 2 of the 3
residues within the respective reverse transcriptase, RNase H, and integrase coding
regions while still abolishing these enzymatic activities. However, the IA-pol
construct described above and disclosed as SEQ ID NO:3, as well as the expressed
protein (SEQ ID NO:4) is preferred. It is also preferred that at least one mutation be
present in each of the three catalytic domains.

Another aspect of the present invention is to generate codon optimized HIV-1
Pol-based vaccine constructions which comprise a eukaryotic trafficking signal
peptide such as from tPA (tissue-type plasminogen activator) or by a leader peptide
such as is found in highly expressed mammalian proteins such as immunoglobulin
leader peptides. Any functional leader peptide may be tested for efficacy. However,
a preferred embodiment of the present invention is to provide for HIV-1 Pol mutant
vaccine constructions as disclosed herein which also comprise a leader peptide,
preferably a leader peptide from human tPA. In other words, a codon optimized

HIV-1 Pol mutant such as IA-Pol (SEQ ID NO:4) may also comprise a leader peptide at the amino terminal portion of the protein, which may effect cellular trafficking and hence, immunogenicity of the expressed protein within the host cell. As shown in Figure 1A-B for the DNA vector V1Jns, a DNA vector which may be utilized to

5 practice the present invention may be modified by known recombinant DNA methodology to contain a leader signal peptide of interest, such that downstream cloning of the modified HIV-1 protein of interest results in a nucleotide sequence which encodes a modified HIV-1 tPA/Pol protein. In the alternative, as noted above, insertion of a nucleotide sequence which encodes a leader peptide may be inserted

10 into a DNA vector housing the open reading frame for the Pol protein of interest. Regardless of the cloning strategy, the end result is a polynucleotide vaccine which comprises vector components for effective gene expression in conjunction with nucleotide sequences which encode a modified HIV-1 Pol protein of interest, including but not limited to a HIV-1 Pol protein which contains a leader peptide. The

15 amino acid sequence of the human tPA leader utilized herein is as follows: MDAMKRGLCCVLLLCGAVFVSPSEISS (SEQ ID NO:28). Therefore, another aspect of the present invention is to generate HIV-1 Pol-based vaccine constructions which comprise a eukaryotic trafficking signal peptide such as from tPA. To this end, the present invention relates to a DNA molecule which encodes a codon optimized

20 wt-pol DNA construct wherein the protease (PR) activity is deleted and a human tPA leader sequence is fused to the 5' end of the coding region. A DNA molecule which encodes this protein is disclosed herein as SEQ ID NO:5, the open reading frame disclosed herein as SEQ ID NO:6.

To this end, the present invention relates to a DNA molecule which encodes a

25 codon optimized wt-pol DNA construct wherein the protease (PR) activity is deleted and a human tPA leader sequence is fused to the 5' end of the coding region (herein, "tPA-wt-pol"). A DNA molecule which encodes this protein is disclosed herein as SEQ ID NO:5, the open reading frame being contained from an initiating Met residue at nucleotides 8-10 to a termination codon from nucleotides 2633-2635. SEQ ID

30 NO:5 is as follows:

```
GATCACCATG GATGCAATGA AGAGAGGGCT CTGCTGTGTG CTGCTGCTGT GTGGAGCAGT
CTTCGTTTCG CCCAGCGAGA TCTCCGCCCC CATCTCCCCC ATTGAGACTG TGCCTGTGAA
GCTGAAGCCT GGCATGGATG GCCCCAAGGT GAAGCAGTGG CCCCTGACTG AGGAGAAGAT
CAAGGCCCTG GTGGAAATCT GCACTGAGAT GGAGAAGGAG GGCAAAATCT CCAAGATTGG
```

CCCCGAGAAC CCCTACAACA CCCCTGTGTT TGCCATCAAG AAGAAGGACT CCACCAAGTG

GAGGAAGCTG GTGGACTTCA GGGAGCTGAA CAAGAGGACC CAGGACTTCT GGGAGGTGCA

GCTGGGCATC CCCCACCCCG CTGGCCTGAA GAAGAAGAAG TCTGTGACTG TGCTGGATGT

GGGGGATGCC TACTTCTCTG TGCCCCTGGA TGAGGACTTC AGGAAGTACA CTGCCTTCAC

5   CATCCCCTCC ATCAACAATG AGACCCCTGG CATCAGGTAC CAGTACAATG TGCTGCCCCA

GGGCTGGAAG GGCTCCCCTG CCATCTTCCA GTCCTCCATG ACCAAGATCC TGGAGCCCTT

CAGGAAGCAG AACCCTGACA TTGTGATCTA CCAGTACATG GATGACCTGT ATGTGGGCTC

TGACCTGGAG ATTGGGCAGC ACAGGACCAA GATTGAGGAG CTGAGGCAGC ACCTGCTGAG

GTGGGGCCTG ACCACCCCTG ACAAGAAGCA CCAGAAGGAG CCCCCCTTCC TGTGGATGGG

10 CTATGAGCTG CACCCCGACA AGTGGACTGT GCAGCCCATT GTGCTGCCTG AGAAGGACTC

CTGGACTGTG AATGACATCC AGAAGCTGGT GGGCAAGCTG AACTGGGCCT CCCAAATCTA

CCCTGGCATC AAGGTGAGGC AGCTGTGCAA GCTGCTGAGG GGCACCAAGG CCCTGACTGA

GGTGATCCCC CTGACTGAGG AGGCTGAGCT GGAGCTGGCT GAGAACAGGG AGATCCTGAA

GGAGCCTGTG CATGGGGTGT ACTATGACCC CTCCAAGGAC CTGATTGCTG AGATCCAGAA

15 GCAGGGCCAG GGCCAGTGGA CCTACCAAAT CTACCAGGAG CCCTTCAAGA ACCTGAAGAC

TGGCAAGTAT GCCAGGATGA GGGGGGCCCA CACCAATGAT GTGAAGCAGC TGACTGAGGC

TGTGCAGAAG ATCACCACTG AGTCCATTGT GATCTGGGGC AAGACCCCCA AGTTCAAGCT

GCCCATCCAG AAGGAGACCT GGGAGACCTG GTGGACTGAG TACTGGCAGG CCACCTGGAT

CCCTGAGTGG GAGTTTGTGA ACACCCCCCC CCTGGTGAAG CTGTGGTACC AGCTGGAGAA

20 GGAGCCCATT GTGGGGGCTG AGACCTTCTA TGTGGATGGG GCTGCCAACA GGGAGACCAA

GCTGGGCAAG GCTGGCTATG TGACCAACAG GGGCAGGCAG AAGGTGGTGA CCCTGACTGA

CACCACCAAC CAGAAGACTG AGCTCCAGGC CATCTACCTG GCCCTCCAGG ACTCTGGCCT

GGAGGTGAAC ATTGTGACTG ACTCCCAGTA TGCCCTGGGC ATCATCCAGG CCCAGCCTGA

TCAGTCTGAG TCTGAGCTGG TGAACCAGAT CATTGAGCAG CTGATCAAGA AGGAGAAGGT

25 GTACCTGGCC TGGGTGCCTG CCCACAAGGG CATTGGGGGC AATGAGCAGG TGGACAAGCT

GGTGTCTGCT GGCATCAGGA AGGTGCTGTT CCTGGATGGC ATTGACAAGG CCCAGGATGA

GCATGAGAAG TACCACTCCA ACTGGAGGGC TATGGCCTCT GACTTCAACC TGCCCCCTGT

GGTGGCTAAG GAGATTGTGG CCTCCTGTGA CAAGTGCCAG CTGAAGGGGG AGGCCATGCA

TGGGCAGGTG GACTGCTCCC CTGGCATCTG GCAGCTGGAC TGCACCCACC TGGAGGGCAA

30 GGTGATCCTG GTGGCTGTGC ATGTGGCCTC CGGCTACATT GAGGCTGAGG TGATCCCTGC

TGAGACAGGC CAGGAGACTG CCTACTTCCT GCTGAAGCTG GCTGGCAGGT GGCCTGTGAA

GACCATCCAC ACTGACAATG GCTCCAACTT CACTGGGGCC ACAGTGAGGG CTGCCTGCTG

GTGGGCTGGC ATCAAGCAGG AGTTTGGCAT CCCCTACAAC CCCCAGTCCC AGGGGGTGGT

GGAGTCCATG AACAAGGAGC TGAAGAAGAT CATTGGGCAG GTGAGGGACC AGGCTGAGCA

CCTGAAGACA GCTGTGCAGA TGGCTGTGTT CATCCACAAC TTCAAGAGGA AGGGGGGCAT

CGGGGGCTAC TCCGCTGGGG AGAGGATTGT GGACATCATT GCCACAGACA TCCAGACCAA

GGAGCTCCAG AAGCAGATCA CCAAGATCCA GAACTTCAGG GTGTACTACA GGGACTCCAG

GAACCCCCTG TGGAAGGGCC CTGCCAAGCT GCTGTGGAAG GGGGAGGGGG CTGTGGTGAT

5   CCAGGACAAC TCTGACATCA AGGTGGTGCC CAGGAGGAAG GCCAAGATCA TCAGGGACTA

TGGCAAGCAG ATGGCTGGGG ATGACTGTGT GGCCTCCAGG CAGGATGAGG ACTAAAGCCC

GGGCAGATCT (SEQ ID NO:5).

The open reading frame of the wild type tPA-pol construct disclosed as SEQ
ID NO:5 contains 875 amino acids, disclosed herein as SEQ ID NO:6, as follows:

10   Met Asp Ala Met Lys Arg Gly Leu Cys Cys Val Leu Leu Leu Cys Gly

Ala Val Phe Val Ser Pro Ser Glu Ile Ser Ala Pro Ile Ser Pro Ile

Glu Thr Val Pro Val Lys Leu Lys Pro Gly Met Asp Gly Pro Lys Val

Lys Gln Trp Pro Leu Thr Glu Glu Lys Ile Lys Ala Leu Val Glu Ile

Cys Thr Glu Met Glu Lys Glu Gly Lys Ile Ser Lys Ile Gly Pro Glu

15   Asn Pro Tyr Asn Thr Pro Val Phe Ala Ile Lys Lys Lys Asp Ser Thr

Lys Trp Arg Lys Leu Val Asp Phe Arg Glu Leu Asn Lys Arg Thr Gln

Asp Phe Trp Glu Val Gln Leu Gly Ile Pro His Pro Ala Gly Leu Lys

Lys Lys Lys Ser Val Thr Val Leu Asp Val Gly Asp Ala Tyr Phe Ser

Val Pro Leu Asp Glu Asp Phe Arg Lys Tyr Thr Ala Phe Thr Ile Pro

20   Ser Ile Asn Asn Glu Thr Pro Gly Ile Arg Tyr Gln Tyr Asn Val Leu

Pro Gln Gly Trp Lys Gly Ser Pro Ala Ile Phe Gln Ser Ser Met Thr

Lys Ile Leu Glu Pro Phe Arg Lys Gln Asn Pro Asp Ile Val Ile Tyr

Gln Tyr Met Asp Asp Leu Tyr Val Gly Ser Asp Leu Glu Ile Gly Gln

His Arg Thr Lys Ile Glu Glu Leu Arg Gln His Leu Leu Arg Trp Gly

25   Leu Thr Thr Pro Asp Lys Lys His Gln Lys Glu Pro Pro Phe Leu Trp

Met Gly Tyr Glu Leu His Pro Asp Lys Trp Thr Val Gln Pro Ile Val

Leu Pro Glu Lys Asp Ser Trp Thr Val Asn Asp Ile Gln Lys Leu Val

Gly Lys Leu Asn Trp Ala Ser Gln Ile Tyr Pro Gly Ile Lys Val Arg

Gln Leu Cys Lys Leu Leu Arg Gly Thr Lys Ala Leu Thr Glu Val Ile

30   Pro Leu Thr Glu Glu Ala Glu Leu Glu Leu Ala Glu Asn Arg Glu Ile

Leu Lys Glu Pro Val His Gly Val Tyr Tyr Asp Pro Ser Lys Asp Leu

Ile Ala Glu Ile Gln Lys Gln Gly Gln Gly Gln Trp Thr Tyr Gln Ile

Tyr Gln Glu Pro Phe Lys Asn Leu Lys Thr Gly Lys Tyr Ala Arg Met

Arg Gly Ala His Thr Asn Asp Val Lys Gln Leu Thr Glu Ala Val Gln

Lys Ile Thr Thr Glu Ser Ile Val Ile Trp Gly Lys Thr Pro Lys Phe

Lys Leu Pro Ile Gln Lys Glu Thr Trp Glu Thr Trp Trp Thr Glu Tyr

Trp Gln Ala Thr Trp Ile Pro Glu Trp Glu Phe Val Asn Thr Pro Pro

Leu Val Lys Leu Trp Tyr Gln Leu Glu Lys Glu Pro Ile Val Gly Ala

5   Glu Thr Phe Tyr Val Asp Gly Ala Ala Asn Arg Glu Thr Lys Leu Gly

Lys Ala Gly Tyr Val Thr Asn Arg Gly Arg Gln Lys Val Val Thr Leu

Thr Asp Thr Thr Asn Gln Lys Thr Glu Leu Gln Ala Ile Tyr Leu Ala

Leu Gln Asp Ser Gly Leu Glu Val Asn Ile Val Thr Asp Ser Gln Tyr

Ala Leu Gly Ile Ile Gln Ala Gln Pro Asp Gln Ser Glu Ser Glu Leu

10 Val Asn Gln Ile Ile Glu Gln Leu Ile Lys Lys Glu Lys Val Tyr Leu

Ala Trp Val Pro Ala His Lys Gly Ile Gly Gly Asn Glu Gln Val Asp

Lys Leu Val Ser Ala Gly Ile Arg Lys Val Leu Phe Leu Asp Gly Ile

Asp Lys Ala Gln Asp Glu His Glu Lys Tyr His Ser Asn Trp Arg Ala

Met Ala Ser Asp Phe Asn Leu Pro Pro Val Val Ala Lys Glu Ile Val

15 Ala Ser Cys Asp Lys Cys Gln Leu Lys Gly Glu Ala Met His Gly Gln

Val Asp Cys Ser Pro Gly Ile Trp Gln Leu Asp Cys Thr His Leu Glu

Gly Lys Val Ile Leu Val Ala Val His Val Ala Ser Gly Tyr Ile Glu

Ala Glu Val Ile Pro Ala Glu Thr Gly Gln Glu Thr Ala Tyr Phe Leu

Leu Lys Leu Ala Gly Arg Trp Pro Val Lys Thr Ile His Thr Asp Asn

20 Gly Ser Asn Phe Thr Gly Ala Thr Val Arg Ala Ala Cys Trp Trp Ala

Gly Ile Lys Gln Glu Phe Gly Ile Pro Tyr Asn Pro Gln Ser Gln Gly

Val Val Glu Ser Met Asn Lys Glu Leu Lys Lys Ile Ile Gly Gln Val

Arg Asp Gln Ala Glu His Leu Lys Thr Ala Val Gln Met Ala Val Phe

Ile His Asn Phe Lys Arg Lys Gly Gly Ile Gly Gly Tyr Ser Ala Gly

25 Glu Arg Ile Val Asp Ile Ile Ala Thr Asp Ile Gln Thr Lys Glu Leu

Gln Lys Gln Ile Thr Lys Ile Gln Asn Phe Arg Val Tyr Tyr Arg Asp

Ser Arg Asn Pro Leu Trp Lys Gly Pro Ala Lys Leu Leu Trp Lys Gly

Glu Gly Ala Val Val Ile Gln Asp Asn Ser Asp Ile Lys Val Val Pro

Arg Arg Lys Ala Lys Ile Ile Arg Asp Tyr Gly Lys Gln Met Ala Gly

30 Asp Asp Cys Val Ala Ser Arg Gln Asp Glu Asp (SEQ ID NO:6).

    The present invention also relates to a codon optimized HIV-1 Pol mutant such as IA-Pol (SEQ ID NO:4) which comprises a leader peptide at the amino terminal portion of the protein, which may effect cellular trafficking and hence, immunogenicity of the expressed protein within the host cell. Any such HIV-1 DNA

pol mutant disclosed in the above paragraphs is suitable for fusion downstream of a
leader peptide, such as a leader peptide including but not limited to the human tPA
leader sequence. Therefore, any such leader peptide-based HIV-1 pol mutant
construct may include but is not limited to a mutated DNA molecule which effectively

5   alters the catalytic activity of the RT, RNase and/or IN region of the expressed protein,
resulting in at least substantially decreased enzymatic activity one or more of the RT,
RNase H and/or IN functions of HIV-1 Pol. In a preferred embodiment of this portion
of the invention, a leader peptide/HIV-1 DNA pol construct contains a mutation or
mutations within the Pol coding region which effectively abolishes RT, RNase H and

10   IN activity. An especially preferable HIV-1 DNA pol construct is a DNA molecule
which contains at least one point mutation which alters the active site and catalytic
activity within the RT, RNase H and IN domains of Pol, such that each activity is at
least substantially abolished, and preferably totally abolished. Such a HIV-1 Pol
mutant will most likely comprise at least one point mutation in or around each·

15 · catalytic domain responsible for RT, RNase H and IN activity, respectfully. An ·
especially preferred embodiment of this portion of the invention relates to a human
tPA leader fused to the IA-Pol protein comprising the nine mutations shown in Table
1. The DNA molecule is disclosed herein as SEQ ID NO:7 and the expressed tPA-IA
Pol protein comprises a fusion junction as shown in Figure 3. The complete amino

20   acid sequence of the expressed protein is set forth in SEQ ID NO:8. To this end, SEQ
ID NO:7 discloses the nucleotide sequence which codes for a human tPA leader fused
to the IA Pol protein comprising the nine mutations shown in Table 1 (herein, "tPA-
opt-IApol"). The open reading frame begins with the initiating Met (nucleotides 8-10)
and terminates with a "TAA" codon at nucleotides 2633-2635. The nucleotide

25   sequence encoding tPA-IAPol is also disclosed as follows:

```
GATCACCATG GATGCAATGA AGAGAGGGCT CTGCTGTGTG CTGCTGCTGT GTGGAGCAGT
CTTCGTTTCG CCCAGCGAGA TCTCCGCCCC CATCTCCCCC ATTGAGACTG TGCCTGTGAA
GCTGAAGCCT GGCATGGATG GCCCCAAGGT GAAGCAGTGG CCCCTGACTG AGGAGAAGAT
CAAGGCCCTG GTGGAAATCT GCACTGAGAT GGAGAAGGAG GGCAAAATCT CCAAGATTGG
CCCCGAGAAC CCCTACAACA CCCCTGTGTT TGCCATCAAG AAGAAGGACT CCACCAAGTG
GAGGAAGCTG GTGGACTTCA GGGAGCTGAA CAAGAGGACC CAGGACTTCT GGGAGGTGCA
GCTGGGCATC CCCCACCCCG CTGGCCTGAA GAAGAAGAAG TCTGTGACTG TGCTGGCTGT
GGGGGATGCC TACTTCTCTG TGCCCCTGGA TGAGGACTTC AGGAAGTACA CTGCCTTCAC
CATCCCCTCC ATCAACAATG AGACCCCTGG CATCAGGTAC CAGTACAATG TGCTGCCCCA
```

GGGCTGGAAG GGCTCCCCTG CCATCTTCCA GTCCTCCATG ACCAAGATCC TGGAGCCCTT

CAGGAAGCAG AACCCTGACA TTGTGATCTA CCAGTACATG GCTGCCCTGT ATGTGGGCTC

TGACCTGGAG ATTGGGCAGC ACAGGACCAA GATTGAGGAG CTGAGGCAGC ACCTGCTGAG

GTGGGGCCTG ACCACCCCTG ACAAGAAGCA CCAGAAGGAG CCCCCCTTCC TGTGGATGGG

5   CTATGAGCTG CACCCCGACA AGTGGACTGT GCAGCCCATT GTGCTGCCTG AGAAGGACTC

CTGGACTGTG AATGACATCC AGAAGCTGGT GGGCAAGCTG AACTGGGCCT CCCAAATCTA

CCCTGGCATC AAGGTGAGGC AGCTGTGCAA GCTGCTGAGG GGCACCAAGG CCCTGACTGA

GGTGATCCCC CTGACTGAGG AGGCTGAGCT GGAGCTGGCT GAGAACAGGG AGATCCTGAA

GGAGCCTGTG CATGGGGTGT ACTATGACCC CTCCAAGGAC CTGATTGCTG AGATCCAGAA

10 GCAGGGCCAG GGCCAGTGGA CCTACCAAAT CTACCAGGAG CCCTTCAAGA ACCTGAAGAC

TGGCAAGTAT GCCAGGATGA GGGGGGCCCA CACCAATGAT GTGAAGCAGC TGACTGAGGC

TGTGCAGAAG ATCACCACTG AGTCCATTGT GATCTGGGGC AAGACCCCCA AGTTCAAGCT

GCCCATCCAG AAGGAGACCT GGGAGACCTG GTGGACTGAG TACTGGCAGG CCACCTGGAT

CCCTGAGTGG GAGTTTGTGA ACACCCCCCC CCTGGTGAAG CTGTGGTACC AGCTGGAGAA

15 GGAGCCCATT GTGGGGGCTG AGACCTTCTA TGTGGCTGGG GCTGCCAACA GGGAGACCAA

GCTGGGCAAG GCTGGCTATG TGACCAACAG GGGCAGGCAG AAGGTGGTGA CCCTGACTGA

CACCACCAAC CAGAAGACTG CCCTCCAGGC CATCTACCTG GCCCTCCAGG ACTCTGGCCT

GGAGGTGAAC ATTGTGACTG CCTCCCAGTA TGCCCTGGGC ATCATCCAGG CCCAGCCTGA

TCAGTCTGAG TCTGAGCTGG TGAACCAGAT CATTGAGCAG CTGATCAAGA AGGAGAAGGT

20 GTACCTGGCC TGGGTGCCTG CCCACAAGGG CATTGGGGGC AATGAGCAGG TGGACAAGCT

GGTGTCTGCT GGCATCAGGA AGGTGCTGTT CCTGGATGGC ATTGACAAGG CCCAGGATGA

GCATGAGAAG TACCACTCCA ACTGGAGGGC TATGGCCTCT GACTTCAACC TGCCCCCTGT

GGTGGCTAAG GAGATTGTGG CCTCCTGTGA CAAGTGCCAG CTGAAGGGGG AGGCCATGCA

TGGGCAGGTG GACTGCTCCC CTGGCATCTG GCAGCTGGCC TGCACCCACC TGGAGGGCAA

25 GGTGATCCTG GTGGCTGTGC ATGTGGCCTC CGGCTACATT GAGGCTGAGG TGATCCCTGC

TGAGACAGGC CAGGAGACTG CCTACTTCCT GCTGAAGCTG GCTGGCAGGT GGCCTGTGAA

GACCATCCAC ACTGCCAATG GCTCCAACTT CACTGGGGCC ACAGTGAGGG CTGCCTGCTG

GTGGGCTGGC ATCAAGCAGG AGTTTGGCAT CCCCTACAAC CCCCAGTCCC AGGGGGTGGT

GGCCTCCATG AACAAGGAGC TGAAGAAGAT CATTGGGCAG GTGAGGGACC AGGCTGAGCA

30 CCTGAAGACA GCTGTGCAGA TGGCTGTGTT CATCCACAAC TTCAAGAGGA AGGGGGGCAT

CGGGGGCTAC TCCGCTGGGG AGAGGATTGT GGACATCATT GCCACAGACA TCCAGACCAA

GGAGCTCCAG AAGCAGATCA CCAAGATCCA GAACTTCAGG GTGTACTACA GGGACTCCAG

GAACCCCCTG TGGAAGGGCC CTGCCAAGCT GCTGTGGAAG GGGGAGGGGG CTGTGGTGAT

CCAGGACAAC TCTGACATCA AGGTGGTGCC CAGGAGGAAG GCCAAGATCA TCAGGGACTA

TGGCAAGCAG ATGGCTGGGG ATGACTGTGT GGCCTCCAGG CAGGATGAGG ACTAAAGCCC

GGGCAGATCT (SEQ ID NO:7).

The open reading frame of the tPA-IA-pol construct disclosed as SEQ ID

NO:7 contains 875 amino acids, disclosed herein as tPA-IA-Pol and SEQ ID NO:8, as

5   follows:

Met Asp Ala Met Lys Arg Gly Leu Cys Cys Val Leu Leu Leu Cys Gly

Ala Val Phe Val Ser Pro Ser Glu Ile Ser Ala Pro Ile Ser Pro Ile

Glu Thr Val Pro Val Lys Leu Lys Pro Gly Met Asp Gly Pro Lys Val

Lys Gln Trp Pro Leu Thr Glu Glu Lys Ile Lys Ala Leu Val Glu Ile

10   Cys Thr Glu Met Glu Lys Glu Gly Lys Ile Ser Lys Ile Gly Pro Glu

Asn Pro Tyr Asn Thr Pro Val Phe Ala Ile Lys Lys Lys Asp Ser Thr

Lys Trp Arg Lys Leu Val Asp Phe Arg Glu Leu Asn Lys Arg Thr Gln

Asp Phe Trp Glu Val Gln Leu Gly Ile Pro His Pro Ala Gly Leu Lys

Lys Lys Lys Ser Val Thr Val Leu Ala Val Gly Asp Ala Tyr Phe Ser

15   Val Pro Leu Asp Glu Asp Phe Arg Lys Tyr Thr Ala Phe Thr Ile Pro

Ser Ile Asn Asn Glu Thr Pro Gly Ile Arg Tyr Gln Tyr Asn Val Leu

Pro Gln Gly Trp Lys Gly Ser Pro Ala Ile Phe Gln Ser Ser Met Thr

Lys Ile Leu Glu Pro Phe Arg Lys Gln Asn Pro Asp Ile Val Ile Tyr

Gln Tyr Met Ala Ala Leu Tyr Val Gly Ser Asp Leu Glu Ile Gly Gln

20   His Arg Thr Lys Ile Glu Glu Leu Arg Gln His Leu Leu Arg Trp Gly

Leu Thr Thr Pro Asp Lys Lys His Gln Lys Glu Pro Pro Phe Leu Trp

Met Gly Tyr Glu Leu His Pro Asp Lys Trp Thr Val Gln Pro Ile Val

Leu Pro Glu Lys Asp Ser Trp Thr Val Asn Asp Ile Gln Lys Leu Val

Gly Lys Leu Asn Trp Ala Ser Gln Ile Tyr Pro Gly Ile Lys Val Arg

25   Gln Leu Cys Lys Leu Leu Arg Gly Thr Lys Ala Leu Thr Glu Val Ile

Pro Leu Thr Glu Glu Ala Glu Leu Glu Leu Ala Glu Asn Arg Glu Ile

Leu Lys Glu Pro Val His Gly Val Tyr Tyr Asp Pro Ser Lys Asp Leu

Ile Ala Glu Ile Gln Lys Gln Gly Gln Gly Gln Trp Thr Tyr Gln Ile

Tyr Gln Glu Pro Phe Lys Asn Leu Lys Thr Gly Lys Tyr Ala Arg Met

30   Arg Gly Ala His Thr Asn Asp Val Lys Gln Leu Thr Glu Ala Val Gln

Lys Ile Thr Thr Glu Ser Ile Val Ile Trp Gly Lys Thr Pro Lys Phe

Lys Leu Pro Ile Gln Lys Glu Thr Trp Glu Thr Trp Trp Thr Glu Tyr

Trp Gln Ala Thr Trp Ile Pro Glu Trp Glu Phe Val Asn Thr Pro Pro

Leu Val Lys Leu Trp Tyr Gln Leu Glu Lys Glu Pro Ile Val Gly Ala

Glu Thr Phe Tyr Val Ala Gly Ala Ala Asn Arg Glu Thr Lys Leu Gly

Lys Ala Gly Tyr Val Thr Asn Arg Gly Arg Gln Lys Val Val Thr Leu

Thr Asp Thr Thr Asn Gln Lys Thr Ala Leu Gln Ala Ile Tyr Leu Ala

Leu Gln Asp Ser Gly Leu Glu Val Asn Ile Val Thr Ala Ser Gln Tyr

5   Ala Leu Gly Ile Ile Gln Ala Gln Pro Asp Gln Ser Glu Ser Glu Leu

Val Asn Gln Ile Ile Glu Gln Leu Ile Lys Lys Glu Lys Val Tyr Leu

Ala Trp Val Pro Ala His Lys Gly Ile Gly Gly Asn Glu Gln Val Asp

Lys Leu Val Ser Ala Gly Ile Arg Lys Val Leu Phe Leu Asp Gly Ile

Asp Lys Ala Gln Asp Glu His Glu Lys Tyr His Ser Asn Trp Arg Ala

10   Met Ala Ser Asp Phe Asn Leu Pro Pro Val Val Ala Lys Glu Ile Val

Ala Ser Cys Asp Lys Cys Gln Leu Lys Gly Glu Ala Met His Gly Gln

Val Asp Cys Ser Pro Gly Ile Trp Gln Leu Ala Cys Thr His Leu Glu

Gly Lys Val Ile Leu Val Ala Val His Val Ala Ser Gly Tyr Ile Glu

Ala Glu Val Ile Pro Ala Glu Thr Gly Gln Glu Thr Ala Tyr Phe Leu

15   Leu Lys Leu Ala Gly Arg Trp Pro Val Lys Thr Ile His Thr Ala Asn

Gly Ser Asn Phe Thr Gly Ala Thr Val Arg Ala Ala Cys Trp Trp Ala

Gly Ile Lys Gln Glu Phe Gly Ile Pro Tyr Asn Pro Gln Ser Gln Gly

Val Val Ala Ser Met Asn Lys Glu Leu Lys Lys Ile Ile Gly Gln Val

Arg Asp Gln Ala Glu His Leu Lys Thr Ala Val Gln Met Ala Val Phe

20   Ile His Asn Phe Lys Arg Lys Gly Gly Ile Gly Gly Tyr Ser Ala Gly

Glu Arg Ile Val Asp Ile Ile Ala Thr Asp Ile Gln Thr Lys Glu Leu

Gln Lys Gln Ile Thr Lys Ile Gln Asn Phe Arg Val Tyr Tyr Arg Asp

Ser Arg Asn Pro Leu Trp Lys Gly Pro Ala Lys Leu Leu Trp Lys Gly

Glu Gly Ala Val Val Ile Gln Asp Asn Ser Asp Ile Lys Val Val Pro

25   Arg Arg Lys Ala Lys Ile Ile Arg Asp Tyr Gly Lys Gln Met Ala Gly

Asp Asp Cys Val Ala Ser Arg Gln Asp Glu Asp (SEQ ID NO:8).

The present invention also relates to a substantially purified protein expressed from the DNA polynucleotide vaccines of the present invention, especially the purified proteins set forth below as SEQ ID NOs: 2, 4, 6, and 8. These purified

30   proteins may be useful as protein-based HIV vaccines.

The DNA backbone of the DNA vaccines of the present invention are preferably DNA plasmid expression vectors. DNA plasmid expression vectors are well known in the art and the present DNA vector vaccines may be comprised of any such expression backbone which contains at least a promoter for RNA polymerase

transcription, and a transcriptional terminator 3' to the HIV pol coding sequence. In one preferred embodiment, the promoter is the Rous sarcoma virus (RSV) long terminal repeat (LTR) which is a strong transcriptional promoter. A more preferred promoter is the cytomegalovirus promoter with the intron A sequence (CMV-intA).

5   A preferred transcriptional terminator is the bovine growth hormone terminator. In addition, to assist in large scale preparation of an HIV pol DNA vector vaccine, an antibiotic resistance marker is also preferably included in the expression vector. Ampicillin resistance genes, neomycin resistance genes or any other pharmaceutically acceptable antibiotic resistance marker may be used. In a preferred embodiment of

10   this invention, the antibiotic resistance gene encodes a gene product for neomycin resistance. Further, to aid in the high level production of the pharmaceutical by fermentation in prokaryotic organisms, it is advantageous for the vector to contain an origin of replication and be of high copy number. Any of a number of commercially available prokaryotic cloning vectors provide these benefits. In a preferred

15   embodiment of this invention, these functionalities are provided by the commercially available vectors known as pUC. It is desirable to remove non-essential DNA sequences. Thus, the lacZ and lacI coding sequences of pUC are removed in one embodiment of the invention.

       DNA expression vectors which exemplify but in no way limit the present

20   invention are disclosed in PCT International Application No. PCT/US94/02751, International Publication No. WO 94/21797, hereby incorporated by reference. A first DNA expression vector is the expression vector pnRSV, wherein the rous sarcoma virus (RSV) long terminal repeat (LTR) is used as the promoter. A second embodiment relates to plasmid V1, a mutated pBR322 vector into which the CMV

25   promoter and the BGH transcriptional terminator is cloned. Another embodiment regarding DNA vector backbones relates to plasmid V1J. Plasmid V1J is derived from plasmid V1 and removes promoter and transcription termination elements in order to place them within a more defined context, create a more compact vector, and to improve plasmid purification yields. Therefore, V1J also contains the CMVintA

30   promoter and (BGH) transcription termination elements which control the expression of the HIV pol-based genes disclosed herein. The backbone of V1J is provided by pUC18. It is known to produce high yields of plasmid, is well-characterized by sequence and function, and is of minimum size. The entire *lac* operon was removed and the remaining plasmid was purified from an agarose electrophoresis gel,

blunt-ended with the T4 DNA polymerase, treated with calf intestinal alkaline phosphatase, and ligated to the CMVintA/BGH element. In a preferred DNA expression vector, the ampicillin resistance gene is removed from V1J and replaced with a neomycin resistance gene, to generate V1Jneo. An especially preferred DNA

5   expression vector is V1Jns, which is the same as V1J except that a unique Sfi1 restriction site has been engineered into the single Kpn1 site at position 2114 of V1J-neo. The incidence of Sfi1 sites in human genomic DNA is very low (approximately 1 site per 100,000 bases). Thus, this vector allows careful monitoring for expression vector integration into host DNA, simply by Sfi1 digestion of extracted genomic

10   DNA. Yet another preferred DNA expression vector used as the backbone to the HIV-1 pol-based DNA vaccines of the present invention is V1R. In this vector, as much non-essential DNA as possible is "trimmed" from the vector to produce a highly compact vector. This vector is a derivative of V1Jns. This vector allows larger inserts to be used, with less concern that undesirable sequences are encoded and

15   optimizes uptake by cells when the construct encoding specific influenza virus genes is introduced into surrounding tissue. The specific DNA vectors of the present invention include but are not limited to V1, V1J (SEQ ID NO:13), V1Jneo (SEQ ID NO:14), V1Jns (Figure 1A, SEQ ID NO:15), V1R (SEQ ID NO:26), and any of the aforementioned vectors wherein a nucleotide sequence encoding a leader peptide,

20   preferably the human tPA leader, is fused directly downstream of the CMV-intA promoter, including but not limited to V1Jns-tpa, as shown in Figure 1B and SEQ ID NO:28.

The present invention especially relates to a DNA vaccine and a pharmaceutically active vaccine composition which contains this DNA vaccine, and

25   the use as prophylactic and/or therapeutic vaccine for host immunization, preferably human host immunization, against an HIV infection or to combat an existing HIV condition. These DNA vaccines are represented by codon optimized DNA molecules encoding HIV-1 Pol or biologically active Pol modifications or Pol-containing fusion proteins which are ligated within an appropriate DNA plasmid vector, with or without

30   a nucleotide sequence encoding a functional leader peptide. DNA vaccines of the present invention may comprise codon optimized DNA molecules encoding HIV-1 Pol or biologically active Pol modifications or Pol-containing fusion proteins ligated in DNA vectors V1, V1J (SEQ ID NO:14), V1Jneo (SEQ ID NO:15), V1Jns (Figure 1A, SEQ ID NO:16), V1R (SEQ ID NO:26), or any of the aforementioned vectors

wherein a nucleotide sequence encoding a leader peptide, preferably the human tPA
leader, is fused directly downstream of the CMV-intA promoter, including but not
limited to V1Jns-tpa, as shown in Figure 1B and SEQ ID NO:28. To this end,
polynucleotide vaccine constructions include , V1Jns-wtpol and V1R-wtpol

5   (comprising the DNA molecule encoding WT Pol, as set forth in SEQ ID NO:2),
V1Jns-tPA-WTPol, (comprising the DNA molecule encoding tPA Pol, as set forth in
SEQ ID NO:6), V1Jns-IAPol (comprising the DNA molecule encoding IA Pol, as set
forth in SEQ ID NO:4), and V1Jns-tPA-IAPol, (comprising the DNA molecule
encoding tPA-IA Pol, as set forth in SEQ ID NO:8).   Polynucleotide vaccine

10   constructions V1R-wtpol, V1Jns-IAPol, and V1Jns-tPA-IAPol, are exemplified in
Example Sections 3-5.

It will be evident upon review of the teaching within this specification that
numerous vector/Pol antigen constructs may be generated. While the exemplified
constructs are preferred, any number of vector/Pol antigen combinations are within

15   the scope of the present invention, especially wild type or modified/inactivated Pol
proteins which comprise at least one, preferably 5 or more and especially all nine
mutations as shown in Table 1, with or without the inclusion of a leader sequence
such as human tPA.

The DNA vector vaccines of the present invention may be formulated in any

20   pharmaceutically effective formulation for host administration. Any such formulation
may be, for example, a saline solution such as phosphate buffered saline (PBS).
It will be useful to utilize pharmaceutically acceptable formulations which also
provide long-term stability of the DNA vector vaccines of the present invention.
During storage as a pharmaceutical entity, DNA plasmid vaccines undergo a

25   physiochemical change in which the supercoiled plasmid converts to the open circular
and linear form. A variety of storage conditions (low pH, high temperature, low ionic
strength) can accelerate this process. Therefore, the removal and/or chelation of trace
metal ions (with succinic or malic acid, or with chelators containing multiple
phosphate ligands) from the DNA plasmid solution, from the formulation buffers or

30   from the vials and closures, stabilizes the DNA plasmid from this degradation
pathway during storage. In addition, inclusion of non-reducing free radical
scavengers, such as ethanol or glycerol, are useful to prevent damage of the DNA
plasmid from free radical production that may still occur, even in apparently
demetalated solutions. Furthermore, the buffer type, pH, salt concentration, light

exposure, as well as the type of sterilization process used to prepare the vials, may be controlled in the formulation to optimize the stability of the DNA vaccine. Therefore, formulations that will provide the highest stability of the DNA vaccine will be one that includes a demetalated solution containing a buffer (phosphate or bicarbonate)

5   with a pH in the range of 7-8, a salt (NaCl, KCl or LiCl) in the range of 100-200 mM, a metal ion chelator (e.g., EDTA, diethylenetriaminepenta-acetic acid (DTPA), malate, inositol hexaphosphate, tripolyphosphate or polyphosphoric acid), a non-reducing free radical scavenger (e.g. ethanol, glycerol, methionine or dimethyl sulfoxide) and the highest appropriate DNA concentration in a sterile glass vial,

10   packaged to protect the highly purified, nuclease free DNA from light. A particularly preferred formulation which will enhance long term stability of the DNA vector vaccines of the present invention would comprise a Tris-HCl buffer at a pH from about 8.0 to about 9.0; ethanol or glycerol at about 3% w/v; EDTA or DTPA in a concentration range up to about 5 mM; and NaCl at a concentration from about 50

15   mM to about 500 mM. The use of such stabilized DNA vector vaccines and various alternatives to this preferred formulation range is described in detail in PCT International Application No. PCT/US97/06655 and PCT International Publication No. WO 97/40839, both of which are hereby incorporated by reference.

The DNA vector vaccines of the present invention may also be formulated

20   with an adjuvant or adjuvants which may increase immunogenicity of the DNA polynucleotide vaccines of the present invention. A number of these adjuvants are known in the art and are available for use in a DNA vaccine, including but not limited to particle bombardment using DNA-coated gold beads, co-administration of DNA vaccines with plasmid DNA expressing cytokines, chemokines, or

25   costimulatory molecules, formulation of DNA with cationic lipids or with experimental adjuvants such as saponin, monophosphoryl lipid A or other compounds which increase immunogenicity of the DNA vaccine. Another adjuvant for use in the DNA vector vaccines of the present invention are one or more forms of an aluminum phosphate-based adjuvant wherein the aluminum

30   phosphate-based adjuvant possesses a molar PO_4/Al ratio of approximately 0.9. An additional mineral-based adjuvant may be generated from one or more forms of a calcium phosphate. These mineral-based adjuvants are useful in increasing cellular and humoral responses to DNA vaccination. These mineral-based compounds for use as DNA vaccines adjuvants are disclosed in PCT International

Application No. PCT/US98/02414, PCT International Publication No.
WO 98/35562, which is hereby incorporated by reference. Another preferred
adjuvant is a non-ionic block copolymer which shows adjuvant activity with DNA
vaccines. The basic structure comprises blocks of polyoxyethylene (POE) and

5   polyoxypropylene (POP) such as a POE-POP-POE block copolymer. Newman et
al. (1998, *Critical Reviews in Therapeutic Drug Carrier Systems* 15(2): 89-142)
review a class of non-ionic block copolymers which show adjuvant activity. The
basic structure comprises blocks of polyoxyethylene (POE) and polyoxypropylene
(POP) such as a POE-POP-POE block copolymer. Newman et al. *id.,* disclose

10   that certain POE-POP-POE block copolymers may be useful as adjuvants to an
influenza protein-based vaccine, namely higher molecular weight POE-POP-POE
block copolymers containing a central POP block having a molecular weight of
over about 9000 daltons to about 20,000 daltons and flanking POE blocks which
comprise up to about 20% of the total molecular weight of the copolymer (see also

15   U.S. Reissue Patent No. 36,665, U.S. Patent No. 5,567,859, U.S. Patent No.
5,691,387, U.S. Patent No. 5,696,298 and U.S. Patent No. 5,990,241, all issued to
Emanuele, et al., regarding these POE-POP-POE block copolymers).
WO 96/04932 further discloses higher molecular weight POE/POP block
copolymers which have surfactant characteristics and show biological efficacy as

20   vaccine adjuvants. The above cited references within this paragraph are hereby
incorporated by reference in their entirety. It is therefore within the purview of
the skilled artisan to utilize available adjuvants which may increase the immune
response of the polynucleotide vaccines of the present invention in comparison to
administration of a non-adjuvanted polynucleotide vaccine.

25   The DNA vector vaccines of the present invention are administered to the host
by any means known in the art, such as enteral and parenteral routes. These routes of
delivery include but are not limited to intramusclar injection, intraperitoneal injection,
intravenous injection, inhalation or intranasal delivery, oral delivery, sublingual
administration, subcutaneous administration, transdermal administration,

30   transcutaneous administration, percutaneous administration or any form of particle
bombardment, such as a biolostic device such as a "gene gun" or by any available
needle-free injection device. The preferred methods of delivery of the HIV-1 Pol-
based DNA vaccines disclosed herein are intramuscular injection, subcutaneous
administration and needle-free injection. An especially preferred method is

intramuscular delivery.

The amount of expressible DNA to be introduced to a vaccine recipient will depend on the strength of the transcriptional and translational promoters used in the DNA construct, and on the immunogenicity of the expressed gene product. In

5   general, an immunologically or prophylactically effective dose of about 1 µg to greater than about 20 mg, and preferably in doses from about 1 mg to about 5 mg is administered directly into muscle tissue. As noted above, subcutaneous injection, intradermal introduction, impression through the skin, and other modes of administration such as intraperitoneal, intravenous, inhalation and oral delivery are

10   also contemplated. It is also contemplated that booster vaccinations are to be provided in a fashion which optimizes the overall immune response to the Pol-based DNA vector vaccines of the present invention.

The aforementioned polynucleotides, when directly introduced into a vertebrate *in vivo*, express the respective HIV-1 Pol protein within the animal and in

15   turn induce a cellular immune response within the host to the expressed Pol antigen. To this end, the present invention also relates to methods of using the HIV-1 Pol-based polynucleotide vaccines of the present invention to provide effective immunoprophylaxis, to prevent establishment of an HIV-1 infection following exposure to this virus, or as a post-HIV infection therapeutic vaccine to mitigate the

20   acute HIV-1 infection so as to result in the establishment of a lower virus load with beneficial long term consequences. As noted above, the present invention contemplates a method of administration or use of the DNA pol-based vaccines of the present invention using an any of the known routes of introducing polynucleotides into living tissue to induce expression of proteins.

25   Therefore, the present invention provides for methods of using a DNA pol-based vaccine utilizing the various parameters disclosed herein as well as any additional parameters known in the art, which, upon introduction into mammalian tissue induces intracellular expression of these DNA pol-based vaccines. This intracellular expression of the Pol-based immunogen induces a cellular immune

30   response which provides a substantial level of protection against an existing HIV-1 infection or provides a substantial level of protection against a future infection in a presently uninfected host.

The following examples are provided to illustrate the present invention without, however, limiting the same hereto.

EXAMPLE 1

Vaccine Vectors

V1 – Vaccine vector V1 was constructed from pCMVIE-AKI-DHFR (Whang

5   et al., 1987, *J. Virol.* 61: 1796). The AKI and DHFR genes were removed by cutting
the vector with EcoRI and self-ligating. This vector does not contain intron A in the
CMV promoter, so it was added as a PCR fragment that had a deleted internal SacI
site [at 1855 as numbered in Chapman, et al., 1991, *Nuc. Acids Res.* 19: 3979). The
template used for the PCR reactions was pCMVintA-Lux, made by ligating the

10   HindIII and NheI fragment from pCMV6a120 (see Chapman et al., *ibid.*), which
includes hCMV-IE1 enhancer/promoter and intron A, into the HindIII and XbaI sites
of pBL3 to generate pCMVIntBL. The 1881 base pair luciferase gene fragment
(HindIII-SmaI Klenow filled-in) from RSV-Lux (de Wet et al., 1987, *Mol. Cell Biol.*
7: 725) was ligated into the SalI site of pCMVIntBL, which was Klenow filled-in and

15   phosphatase treated. The primers that spanned intron A are: 5' primer: 5'-CTATAT
AAGCAGAGCTCGTTTAG-3' (SEQ ID NO:10); 3' primer: 5'-GTAGCAAA
GATCTAAGGACGGTGACTGCAG-3' (SEQ ID NO:11). The primers used to
remove the SacI site are: sense primer, 5'-GTATGTGTCTGAAAATGAGC<u>G</u>
<u>T</u>GGAGATTGGGCTCGCAC-3' (SEQ ID NO:12) and the antisense primer,

20   5'-GTGCGAGCCCAATCTCC<u>AC</u>GCTCATTTTCAGAC ACATAC-3' (SEQ ID
NO:13). The PCR fragment was cut with Sac I and Bgl II and inserted into the vector
which had been cut with the same enzymes.

V1J – Vaccine vector V1J was generated to remove the promoter and
transcription termination elements from vector V1 in order to place them within a

25   more defined context, create a more compact vector, and to improve plasmid
purification yields. V1J is derived from vectors V1 and pUC18, a commercially
available plasmid. V1 was digested with SspI and EcoRI restriction enzymes
producing two fragments of DNA. The smaller of these fragments, containing the
CMVintA promoter and Bovine Growth Hormone (BGH) transcription termination

30   elements which control the expression of heterologous genes, was purified from an
agarose electrophoresis gel. The ends of this DNA fragment were then "blunted"
using the T4 DNA polymerase enzyme in order to facilitate its ligation to another
"blunt-ended" DNA fragment. pUC18 was chosen to provide the "backbone" of the
expression vector. It is known to produce high yields of plasmid, is well-

characterized by sequence and function, and is of small size. The entire *lac* operon
was removed from this vector by partial digestion with the HaeII restriction enzyme.
The remaining plasmid was purified from an agarose electrophoresis gel, blunt-ended
with the T4 DNA polymerase treated with calf intestinal alkaline phosphatase, and

5   ligated to the CMVintA/BGH element described above. Plasmids exhibiting either of
two possible orientations of the promoter elements within the pUC backbone were
obtained. One of these plasmids gave much higher yields of DNA in *E. coli* and was
designated V1J. This vector's structure was verified by sequence analysis of the
junction regions and was subsequently demonstrated to give comparable or higher

10   expression of heterologous genes compared with V1. The nucleotide sequence of V1J
is as follows:

```
TCGCGCGTTT CGGTGATGAC GGTGAAAACC TCTGACACAT GCAGCTCCCG GAGACGGTCA

CAGCTTGTCT GTAAGCGGAT GCCGGGAGCA GACAAGCCCG TCAGGGCGCG TCAGCGGGTG

TTGGCGGGTG TCGGGGCTGG CTTAACTATG CGGCATCAGA GCAGATTGTA CTGAGAGTGC
```
15 ·
```
ACCATATGCG GTGTGAAATA CCGCACAGAT GCGTAAGGAG AAAATACCGC ATCAGATTGG

CTATTGGCCA TTGCATACGT TGTATCCATA TCATAATATG TACATTTATA TTGGCTCATG

TCCAACATTA CCGCCATGTT GACATTGATT ATTGACTAGT TATTAATAGT AATCAATTAC

GGGGTCATTA GTTCATAGCC CATATATGGA GTTCCGCGTT ACATAACTTA CGGTAAATGG

CCCGCCTGGC TGACCGCCCA ACGACCCCCG CCCATTGACG TCAATAATGA CGTATGTTCC
```
20
```
CATAGTAACG CCAATAGGGA CTTTCCATTG ACGTCAATGG GTGGAGTATT TACGGTAAAC

TGCCCACTTG GCAGTACATC AAGTGTATCA TATGCCAAGT ACGCCCCCTA TTGACGTCAA

TGACGGTAAA TGGCCCGCCT GGCATTATGC CCAGTACATG ACCTTATGGG ACTTTCCTAC

TTGGCAGTAC ATCTACGTAT TAGTCATCGC TATTACCATG GTGATGCGGT TTTGGCAGTA

CATCAATGGG CGTGGATAGC GGTTTGACTC ACGGGGATTT CCAAGTCTCC ACCCCATTGA
```
25
```
CGTCAATGGG AGTTTGTTTT GGCACCAAAA TCAACGGGAC TTTCCAAAAT GTCGTAACAA

CTCCGCCCCA TTGACGCAAA TGGGCGGTAG GCGTGTACGG TGGGAGGTCT ATATAAGCAG

AGCTCGTTTA GTGAACCGTC AGATCGCCTG GAGACGCCAT CCACGCTGTT TTGACCTCCA

TAGAAGACAC CGGGACCGAT CCAGCCTCCG CGGCCGGGAA CGGTGCATTG GAACGCGGAT

TCCCCGTGCC AAGAGTGACG TAAGTACCGC CTATAGAGTC TATAGGCCCA CCCCCTTGGC
```
30
```
TTCTTATGCA TGCTATACTG TTTTTGGCTT GGGGTCTATA CACCCCCGCT TCCTCATGTT

ATAGGTGATG GTATAGCTTA GCCTATAGGT GTGGGTTATT GACCATTATT GACCACTCCC

CTATTGGTGA CGATACTTTC CATTACTAAT CCATAACATG GCTCTTTGCC ACAACTCTCT

TTATTGGCTA TATGCCAATA CACTGTCCTT CAGAGACTGA CACGGACTCT GTATTTTTAC

AGGATGGGGT CTCATTTATT ATTTACAAAT TCACATATAC AACACCACCG TCCCCAGTGC
```

```
      CCGCAGTTTT TATTAAACAT AACGTGGGAT CTCCACGCGA ATCTCGGGTA CGTGTTCCGG
      ACATGGGCTC TTCTCCGGTA GCGGCGGAGC TTCTACATCC GAGCCCTGCT CCCATGCCTC
      CAGCGACTCA TGGTCGCTCG GCAGCTCCTT GCTCCTAACA GTGGAGGCCA GACTTAGGCA
      CAGCACGATG CCCACCACCA CCAGTGTGCC GCACAAGGCC GTGGCGGTAG GGTATGTGTC
    5 TGAAAATGAG CTCGGGGAGC GGGCTTGCAC CGCTGACGCA TTTGGAAGAC TTAAGGCAGC
      GGCAGAAGAA GATGCAGGCA GCTGAGTTGT TGTGTTCTGA TAAGAGTCAG AGGTAACTCC
      CGTTGCGGTG CTGTTAACGG TGGAGGGCAG TGTAGTCTGA GCAGTACTCG TTGCTGCCGC
      GCGCGCCACC AGACATAATA GCTGACAGAC TAACAGACTG TTCCTTTCCA TGGGTCTTTT
      CTGCAGTCAC CGTCCTTAGA TCTGCTGTGC CTTCTAGTTG CCAGCCATCT GTTGTTTGCC
   10 CCTCCCCCGT GCCTTCCTTG ACCCTGGAAG GTGCCACTCC CACTGTCCTT TCCTAATAAA
      ATGAGGAAAT TGCATCGCAT TGTCTGAGTA GGTGTCATTC TATTCTGGGG GGTGGGGTGG
      GGCAGCACAG CAAGGGGGAG GATTGGGAAG ACAATAGCAG GCATGCTGGG GATGCGGTGG
      GCTCTATGGG TACCCAGGTG CTGAAGAATT GACCCGGTTC CTCCTGGGCC AGAAAGAAGC
      AGGCACATCC CCTTCTCTGT GACACACCCT GTCCACGCCC CTGGTTCTTA GTTCCAGCCC
   15 CACTCATAGG ACACTCATAG CTCAGGAGGG CTCCGCCTTC AATCCCACCC GCTAAAGTAC
      TTGGAGCGGT CTCTCCCTCC CTCATCAGCC CACCAAACCA AACCTAGCCT CCAAGAGTGG
      GAAGAAATTA AAGCAAGATA GGCTATTAAG TGCAGAGGGA GAGAAAATGC CTCCAACATG
      TGAGGAAGTA ATGAGAGAAA TCATAGAATT TCTTCCGCTT CCTCGCTCAC TGACTCGCTG
      CGCTCGGTCG TTCGGCTGCG GCGAGCGGTA TCAGCTCACT CAAAGGCGGT AATACGGTTA
   20 TCCACAGAAT CAGGGGATAA CGCAGGAAAG AACATGTGAG CAAAAGGCCA GCAAAAGGCC
      AGGAACCGTA AAAAGGCCGC GTTGCTGGCG TTTTTCCATA GGCTCCGCCC CCCTGACGAG
      CATCACAAAA ATCGACGCTC AAGTCAGAGG TGGCGAAACC CGACAGGACT ATAAAGATAC
      CAGGCGTTTC CCCCTGGAAG CTCCCTCGTG CGCTCTCCTG TTCCGACCCT GCCGCTTACC
      GGATACCTGT CCGCCTTTCT CCCTTCGGGA AGCGTGGCGC TTTCTCAATG CTCACGCTGT
   25 AGGTATCTCA GTTCGGTGTA GGTCGTTCGC TCCAAGCTGG GCTGTGTGCA CGAACCCCCC
      GTTCAGCCCG ACCGCTGCGC CTTATCCGGT AACTATCGTC TTGAGTCCAA CCCGGTAAGA
      CACGACTTAT CGCCACTGGC AGCAGCCACT GGTAACAGGA TTAGCAGAGC GAGGTATGTA
      GGCGGTGCTA CAGAGTTCTT GAAGTGGTGG CCTAACTACG GCTACACTAG AAGGACAGTA
      TTTGGTATCT GCGCTCTGCT GAAGCCAGTT ACCTTCGGAA AAAGAGTTGG TAGCTCTTGA
   30 TCCGGCAAAC AAACCACCGC TGGTAGCGGT GGTTTTTTTG TTTGCAAGCA GCAGATTACG
      CGCAGAAAAA AAGGATCTCA AGAAGATCCT TTGATCTTTT CTACGGGGTC TGACGCTCAG
      TGGAACGAAA ACTCACGTTA AGGGATTTTG GTCATGAGAT TATCAAAAAG GATCTTCACC
      TAGATCCTTT TAAATTAAAA ATGAAGTTTT AAATCAATCT AAAGTATATA TGAGTAAACT
      TGGTCTGACA GTTACCAATG CTTAATCAGT GAGGCACCTA TCTCAGCGAT CTGTCTATTT
```

```
CGTTCATCCA TAGTTGCCTG ACTCCCCGTC GTGTAGATAA CTACGATACG GGAGGGCTTA
CCATCTGGCC CCAGTGCTGC AATGATACCG CGAGACCCAC GCTCACCGGC TCCAGATTTA
TCAGCAATAA ACCAGCCAGC CGGAAGGGCC GAGCGCAGAA GTGGTCCTGC AACTTTATCC
GCCTCCATCC AGTCTATTAA TTGTTGCCGG GAAGCTAGAG TAAGTAGTTC GCCAGTTAAT
```
5
```
AGTTTGCGCA ACGTTGTTGC CATTGCTACA GGCATCGTGG TGTCACGCTC GTCGTTTGGT
ATGGCTTCAT TCAGCTCCGG TTCCCAACGA TCAAGGCGAG TTACATGATC CCCCATGTTG
TGCAAAAAAG CGGTTAGCTC CTTCGGTCCT CCGATCGTTG TCAGAAGTAA GTTGGCCGCA
GTGTTATCAC TCATGGTTAT GGCAGCACTG CATAATTCTC TTACTGTCAT GCCATCCGTA
AGATGCTTTT CTGTGACTGG TGAGTACTCA ACCAAGTCAT TCTGAGAATA GTGTATGCGG
```
10
```
CGACCGAGTT GCTCTTGCCC GGCGTCAATA CGGGATAATA CCGCGCCACA TAGCAGAACT
TTAAAAGTGC TCATCATTGG AAAACGTTCT TCGGGGCGAA AACTCTCAAG GATCTTACCG
CTGTTGAGAT CCAGTTCGAT GTAACCCACT CGTGCACCCA ACTGATCTTC AGCATCTTTT
ACTTTCACCA GCGTTTCTGG GTGAGCAAAA ACAGGAAGGC AAAATGCCGC AAAAAAGGGA
ATAAGGGCGA CACGGAAATG TTGAATACTC ATACTCTTCC TTTTTCAATA TTATTGAAGC
```
15
```
ATTTATCAGG GTTATTGTCT CATGAGCGGA TACATATTTG AATGTATTTA GAAAAATAAA
CAAATAGGGG TTCCGCGCAC ATTTCCCCGA AAAGTGCCAC CTGACGTCTA AGAAACCATT
ATTATCATGA CATTAACCTA TAAAAATAGG CGTATCACGA GGCCCTTTCG TC (SEQ ID
NO:14).
```

V1Jneo – Construction of vaccine vector V1Jneo expression vector involved

20   removal of the amp^r gene and insertion of the kan^r gene (neomycin
phosphotransferase). The amp^r gene from the pUC backbone of V1J was removed by
digestion with SspI and Eam1105I restriction enzymes. The remaining plasmid was
purified by agarose gel electrophoresis, blunt-ended with T4 DNA polymerase, and
then treated with calf intestinal alkaline phosphatase. The commercially available

25   kan^r gene, derived from transposon 903 and contained within the pUC4K plasmid,
was excised using the PstI restriction enzyme, purified by agarose gel electrophoresis,
and blunt-ended with T4 DNA polymerase. This fragment was ligated with the V1J
backbone and plasmids with the kan^r gene in either orientation were derived which
were designated as V1Jneo #'s 1 and 3. Each of these plasmids was confirmed by

30   restriction enzyme digestion analysis, DNA sequencing of the junction regions, and
was shown to produce similar quantities of plasmid as V1J. Expression of
heterologous gene products was also comparable to V1J for these V1Jneo vectors.
V1Jneo#3, referred to as V1Jneo hereafter, was selected which contains the kan^r gene
in the same orientation as the amp^r gene in V1J as the expression construct and

provides resistance to neomycin, kanamycin and G418. The nucleotide sequence of V1Jneo is as follows:

```
    TCGCGCGTTT CGGTGATGAC GGTGAAAACC TCTGACACAT GCAGCTCCCG GAGACGGTCA
    CAGCTTGTCT GTAAGCGGAT GCCGGGAGCA GACAAGCCCG TCAGGGCGCG TCAGCGGGTG
 5  TTGGCGGGTG TCGGGGCTGG CTTAACTATG CGGCATCAGA GCAGATTGTA CTGAGAGTGC
    ACCATATGCG GTGTGAAATA CCGCACAGAT GCGTAAGGAG AAAATACCGC ATCAGATTGG
    CTATTGGCCA TTGCATACGT TGTATCCATA TCATAATATG TACATTTATA TTGGCTCATG
    TCCAACATTA CCGCCATGTT GACATTGATT ATTGACTAGT TATTAATAGT AATCAATTAC
    GGGGTCATTA GTTCATAGCC CATATATGGA GTTCCGCGTT ACATAACTTA CGGTAAATGG
10  CCCGCCTGGC TGACCGCCCA ACGACCCCCG CCCATTGACG TCAATAATGA CGTATGTTCC
    CATAGTAACG CCAATAGGGA CTTTCCATTG ACGTCAATGG GTGGAGTATT TACGGTAAAC
    TGCCCACTTG GCAGTACATC AAGTGTATCA TATGCCAAGT ACGCCCCCTA TTGACGTCAA
    TGACGGTAAA TGGCCCGCCT GGCATTATGC CCAGTACATG ACCTTATGGG ACTTTCCTAC
    TTGGCAGTAC ATCTACGTAT TAGTCATCGC TATTACCATG GTGATGCGGT TTTGGCAGTA
15  CATCAATGGG CGTGGATAGC GGTTTGACTC ACGGGGATTT CCAAGTCTCC ACCCCATTGA
    CGTCAATGGG AGTTTGTTTT GGCACCAAAA TCAACGGGAC TTTCCAAAAT GTCGTAACAA
    CTCCGCCCCA TTGACGCAAA TGGGCGGTAG GCGTGTACGG TGGGAGGTCT ATATAAGCAG
    AGCTCGTTTA GTGAACCGTC AGATCGCCTG GAGACGCCAT CCACGCTGTT TTGACCTCCA
    TAGAAGACAC CGGGACCGAT CCAGCCTCCG CGGCCGGGAA CGGTGCATTG GAACGCGGAT
20  TCCCCGTGCC AAGAGTGACG TAAGTACCGC CTATAGAGTC TATAGGCCCA CCCCCTTGGC
    TTCTTATGCA TGCTATACTG TTTTTGGCTT GGGGTCTATA CACCCCCGCT TCCTCATGTT
    ATAGGTGATG GTATAGCTTA GCCTATAGGT GTGGGTTATT GACCATTATT GACCACTCCC
    CTATTGGTGA CGATACTTTC CATTACTAAT CCATAACATG GCTCTTTGCC ACAACTCTCT
    TTATTGGCTA TATGCCAATA CACTGTCCTT CAGAGACTGA CACGGACTCT GTATTTTTAC
25  AGGATGGGGT CTCATTTATT ATTTACAAAT TCACATATAC AACACCACCG TCCCCAGTGC
    CCGCAGTTTT TATTAAACAT AACGTGGGAT CTCCACGCGA ATCTCGGGTA CGTGTTCCGG
    ACATGGGCTC TTCTCCGGTA GCGGCGGAGC TTCTACATCC GAGCCCTGCT CCCATGCCTC
    CAGCGACTCA TGGTCGCTCG GCAGCTCCTT GCTCCTAACA GTGGAGGCCA GACTTAGGCA
    CAGCACGATG CCCACCACCA CCAGTGTGCC GCACAAGGCC GTGGCGGTAG GGTATGTGTC
30  TGAAAATGAG CTCGGGGAGC GGGCTTGCAC CGCTGACGCA TTTGGAAGAC TTAAGGCAGC
    GGCAGAAGAA GATGCAGGCA GCTGAGTTGT TGTGTTCTGA TAAGAGTCAG AGGTAACTCC
    CGTTGCGGTG CTGTTAACGG TGGAGGGCAG TGTAGTCTGA GCAGTACTCG TTGCTGCCGC
    GCGCGCCACC AGACATAATA GCTGACAGAC TAACAGACTG TTCCTTTCCA TGGGTCTTTT
    CTGCAGTCAC CGTCCTTAGA TCTGCTGTGC CTTCTAGTTG CCAGCCATCT GTTGTTTGCC
```

```
     CCTCCCCCGT GCCTTCCTTG ACCCTGGAAG GTGCCACTCC CACTGTCCTT TCCTAATAAA
     ATGAGGAAAT TGCATCGCAT TGTCTGAGTA GGTGTCATTC TATTCTGGGG GGTGGGGTGG
     GGCAGCACAG CAAGGGGGAG GATTGGGAAG ACAATAGCAG GCATGCTGGG GATGCGGTGG
     GCTCTATGGG TACCCAGGTG CTGAAGAATT GACCCGGTTC CTCCTGGGCC AGAAAGAAGC
  5  AGGCACATCC CCTTCTCTGT GACACACCCT GTCCACGCCC CTGGTTCTTA GTTCCAGCCC
     CACTCATAGG ACACTCATAG CTCAGGAGGG CTCCGCCTTC AATCCCACCC GCTAAAGTAC
     TTGGAGCGGT CTCTCCCTCC CTCATCAGCC CACCAAACCA AACCTAGCCT CCAAGAGTGG
     GAAGAAATTA AAGCAAGATA GGCTATTAAG TGCAGAGGGA GAGAAAATGC CTCCAACATG
     TGAGGAAGTA ATGAGAGAAA TCATAGAATT TCTTCCGCTT CCTCGCTCAC TGACTCGCTG
 10  CGCTCGGTCG TTCGGCTGCG GCGAGCGGTA TCAGCTCACT CAAAGGCGGT AATACGGTTA
     TCCACAGAAT CAGGGGATAA CGCAGGAAAG AACATGTGAG CAAAAGGCCA GCAAAAGGCC
     AGGAACCGTA AAAAGGCCGC GTTGCTGGCG TTTTTCCATA GGCTCCGCCC CCCTGACGAG
     CATCACAAAA ATCGACGCTC AAGTCAGAGG TGGCGAAACC CGACAGGACT ATAAAGATAC
     CAGGCGTTTC CCCCTGGAAG CTCCCTCGTG CGCTCTCCTG TTCCGACCCT GCCGCTTACC
 15  GGATACCTGT CCGCCTTTCT CCCTTCGGGA AGCGTGGCGC TTTCTCAATG CTCACGCTGT
     AGGTATCTCA GTTCGGTGTA GGTCGTTCGC TCCAAGCTGG GCTGTGTGCA CGAACCCCCC
     GTTCAGCCCG ACCGCTGCGC CTTATCCGGT AACTATCGTC TTGAGTCCAA CCCGGTAAGA
     CACGACTTAT CGCCACTGGC AGCAGCCACT GGTAACAGGA TTAGCAGAGC GAGGTATGTA
     GGCGGTGCTA CAGAGTTCTT GAAGTGGTGG CCTAACTACG GCTACACTAG AAGGACAGTA
 20  TTTGGTATCT GCGCTCTGCT GAAGCCAGTT ACCTTCGGAA AAAGAGTTGG TAGCTCTTGA
     TCCGGCAAAC AAACCACCGC TGGTAGCGGT GGTTTTTTTG TTTGCAAGCA GCAGATTACG
     CGCAGAAAAA AAGGATCTCA AGAAGATCCT TTGATCTTTT CTACGGGGTC TGACGCTCAG
     TGGAACGAAA ACTCACGTTA AGGGATTTTG GTCATGAGAT TATCAAAAAG GATCTTCACC
     TAGATCCTTT TAAATTAAAA ATGAAGTTTT AAATCAATCT AAAGTATATA TGAGTAAACT
 25  TGGTCTGACA GTTACCAATG CTTAATCAGT GAGGCACCTA TCTCAGCGAT CTGTCTATTT
     CGTTCATCCA TAGTTGCCTG ACTCCGGGGG GGGGGGCGC TGAGGTCTGC CTCGTGAAGA
     AGGTGTTGCT GACTCATACC AGGCCTGAAT CGCCCCATCA TCCAGCCAGA AAGTGAGGGA
     GCCACGGTTG ATGAGAGCTT TGTTGTAGGT GGACCAGTTG GTGATTTTGA ACTTTTGCTT
     TGCCACGGAA CGGTCTGCGT TGTCGGGAAG ATGCGTGATC TGATCCTTCA ACTCAGCAAA
 30  AGTTCGATTT ATTCAACAAA GCCGCCGTCC CGTCAAGTCA GCGTAATGCT CTGCCAGTGT
     TACAACCAAT TAACCAATTC TGATTAGAAA AACTCATCGA GCATCAAATG AAACTGCAAT
     TTATTCATAT CAGGATTATC AATACCATAT TTTTGAAAAA GCCGTTTCTG TAATGAAGGA
     GAAAACTCAC CGAGGCAGTT CCATAGGATG GCAAGATCCT GGTATCGGTC TGCGATTCCG
     ACTCGTCCAA CATCAATACA ACCTATTAAT TTCCCCTCGT CAAAAATAAG GTTATCAAGT
```

```
     GAGAAATCAC CATGAGTGAC GACTGAATCC GGTGAGAATG GCAAAAGCTT ATGCATTTCT
     TTCCAGACTT GTTCAACAGG CCAGCCATTA CGCTCGTCAT CAAAATCACT CGCATCAACC
     AAACCGTTAT TCATTCGTGA TTGCGCCTGA GCGAGACGAA ATACGCGATC GCTGTTAAAA
     GGACAATTAC AAACAGGAAT CGAATGCAAC CGGCGCAGGA ACACTGCCAG CGCATCAACA
  5  ATATTTTCAC CTGAATCAGG ATATTCTTCT AATACCTGGA ATGCTGTTTT CCCGGGGATC
     GCAGTGGTGA GTAACCATGC ATCATCAGGA GTACGGATAA AATGCTTGAT GGTCGGAAGA
     GGCATAAATT CCGTCAGCCA GTTTAGTCTG ACCATCTCAT CTGTAACATC ATTGGCAACG
     CTACCTTTGC CATGTTTCAG AAACAACTCT GGCGCATCGG GCTTCCCATA CAATCGATAG
     ATTGTCGCAC CTGATTGCCC GACATTATCG CGAGCCCATT TATACCCATA TAAATCAGCA
 10  TCCATGTTGG AATTTAATCG CGGCCTCGAG CAAGACGTTT CCCGTTGAAT ATGGCTCATA
     ACACCCCTTG TATTACTGTT TATGTAAGCA GACAGTTTTA TTGTTCATGA TGATATATTT
     TTATCTTGTG CAATGTAACA TCAGAGATTT TGAGACACAA CGTGGCTTTC CCCCCCCCCC
     CATTATTGAA GCATTTATCA GGGTTATTGT CTCATGAGCG GATACATATT TGAATGTATT
     TAGAAAAATA AACAAATAGG GGTTCCGCGC ACATTTCCCC GAAAAGTGCC ACCTGACGTC
 15  TAAGAAACCA TTATTATCAT GACATTAACC TATAAAAATA GGCGTATCAC GAGGCCCTTT
     CGTC (SEQ ID NO:15).
```

V1Jns - The expression vector V1Jns was generated by adding an SfiI site to
V1Jneo to facilitate integration studies. A commercially available 13 base pair SfiI
linker (New England BioLabs) was added at the KpnI site within the BGH sequence
of the vector. V1Jneo was linearized with KpnI, gel purified, blunted by T4 DNA
polymerase, and ligated to the blunt SfiI linker. Clonal isolates were chosen by
restriction mapping and verified by sequencing through the linker. The new vector
was designated V1Jns. Expression of heterologous genes in V1Jns (with SfiI) was
comparable to expression of the same genes in V1Jneo (with KpnI).

The nucleotide sequence of V1Jns is as follows:

```
     TCGCGCGTTT CGGTGATGAC GGTGAAAACC TCTGACACAT GCAGCTCCCG GAGACGGTCA
     CAGCTTGTCT GTAAGCGGAT GCCGGGAGCA GACAAGCCCG TCAGGGCGCG TCAGCGGGTG
     TTGGCGGGTG TCGGGGCTGG CTTAACTATG CGGCATCAGA GCAGATTGTA CTGAGAGTGC
     ACCATATGCG GTGTGAAATA CCGCACAGAT GCGTAAGGAG AAAATACCGC ATCAGATTGG
  30 CTATTGGCCA TTGCATACGT TGTATCCATA TCATAATATG TACATTTATA TTGGCTCATG
     TCCAACATTA CCGCCATGTT GACATTGATT ATTGACTAGT TATTAATAGT AATCAATTAC
     GGGGTCATTA GTTCATAGCC CATATATGGA GTTCCGCGTT ACATAACTTA CGGTAAATGG
     CCCGCCTGGC TGACCGCCCA ACGACCCCCG CCCATTGACG TCAATAATGA CGTATGTTCC
     CATAGTAACG CCAATAGGGA CTTTCCATTG ACGTCAATGG GTGGAGTATT TACGGTAAAC
```

```
          TGCCCACTTG GCAGTACATC AAGTGTATCA TATGCCAAGT ACGCCCCCTA TTGACGTCAA
          TGACGGTAAA TGGCCCGCCT GGCATTATGC CCAGTACATG ACCTTATGGG ACTTTCCTAC
          TTGGCAGTAC ATCTACGTAT TAGTCATCGC TATTACCATG GTGATGCGGT TTTGGCAGTA
          CATCAATGGG CGTGGATAGC GGTTTGACTC ACGGGGATTT CCAAGTCTCC ACCCCATTGA
     5    CGTCAATGGG AGTTTGTTTT GGCACCAAAA TCAACGGGAC TTTCCAAAAT GTCGTAACAA
          CTCCGCCCCA TTGACGCAAA TGGGCGGTAG GCGTGTACGG TGGGAGGTCT ATATAAGCAG
          AGCTCGTTTA GTGAACCGTC AGATCGCCTG GAGACGCCAT CCACGCTGTT TTGACCTCCA
          TAGAAGACAC CGGGACCGAT CCAGCCTCCG CGGCCGGGAA CGGTGCATTG GAACGCGGAT
          TCCCCGTGCC AAGAGTGACG TAAGTACCGC CTATAGACTC TATAGGCACA CCCCTTTGGC
     10   TCTTATGCAT GCTATACTGT TTTTGGCTTG GGGCCTATAC ACCCCCGCTT CCTTATGCTA
          TAGGTGATGG TATAGCTTAG CCTATAGGTG TGGGTTATTG ACCATTATTG ACCACTCCCC
          TATTGGTGAC GATACTTTCC ATTACTAATC CATAACATGG CTCTTTGCCA CAACTATCTC
          TATTGGCTAT ATGCCAATAC TCTGTCCTTC AGAGACTGAC ACGGACTCTG TATTTTTACA
          GGATGGGGTC CCATTATTA TTTACAAATT CACATATACA ACAACGCCGT CCCCCGTGCC
     15   CGCAGTTTTT ATTAAACATA GCGTGGGATC TCCACGCGAA TCTCGGGTAC GTGTTCCGGA
          CATGGGCTCT TCTCCGGTAG CGGCGGAGCT TCCACATCCG AGCCCTGGTC CCATGCCTCC
          AGCGGCTCAT GGTCGCTCGG CAGCTCCTTG CTCCTAACAG TGGAGGCCAG ACTTAGGCAC
          AGCACAATGC CCACCACCAC CAGTGTGCCG CACAAGGCCG TGGCGGTAGG GTATGTGTCT
          GAAAATGAGC GTGGAGATTG GGCTCGCACG GCTGACGCAG ATGGAAGACT TAAGGCAGCG
     20   GCAGAAGAAG ATGCAGGCAG CTGAGTTGTT GTATTCTGAT AAGAGTCAGA GGTAACTCCC
          GTTGCGGTGC TGTTAACGGT GGAGGGCAGT GTAGTCTGAG CAGTACTCGT TGCTGCCGCG
          CGCGCCACCA GACATAATAG CTGACAGACT AACAGACTGT TCCTTTCCAT GGGTCTTTTC
          TGCAGTCACC GTCCTTAGAT CTGCTGTGCC TTCTAGTTGC CAGCCATCTG TTGTTTGCCC
          CTCCCCCGTG CCTTCCTTGA CCCTGGAAGG TGCCACTCCC ACTGTCCTTT CCTAATAAAA
     25.  TGAGGAAATT GCATCGCATT GTCTGAGTAG GTGTCATTCT ATTCTGGGGG GTGGGGTGGG
          GCAGGACAGC AAGGGGGAGG ATTGGGAAGA CAATAGCAGG CATGCTGGGG ATGCGGTGGG
          CTCTATGGCC GCTGCGGCCA GGTGCTGAAG AATTGACCCG GTTCCTCCTG GGCCAGAAAG
          AAGCAGGCAC ATCCCCTTCT CTGTGACACA CCCTGTCCAC GCCCCTGGTT CTTAGTTCCA
          GCCCCACTCA TAGGACACTC ATAGCTCAGG AGGGCTCCGC CTTCAATCCC ACCCGCTAAA
     30   GTACTTGGAG CGGTCTCTCC CTCCCTCATC AGCCCACCAA ACCAAACCTA GCCTCCAAGA
          GTGGGAAGAA ATTAAAGCAA GATAGGCTAT TAAGTGCAGA GGGAGAGAAA ATGCCTCCAA
          CATGTGAGGA AGTAATGAGA GAAATCATAG AATTTCTTCC GCTTCCTCGC TCACTGACTC
          GCTGCGCTCG GTCGTTCGGC TGCGGCGAGC GGTATCAGCT CACTCAAAGG CGGTAATACG
          GTTATCCACA GAATCAGGGG ATAACGCAGG AAAGAACATG TGAGCAAAAG GCCAGCAAAA
```

```
     GGCCAGGAAC CGTAAAAAGG CCGCGTTGCT GGCGTTTTTC CATAGGCTCC GCCCCCCTGA
     CGAGCATCAC AAAAATCGAC GCTCAAGTCA GAGGTGGCGA AACCCGACAG GACTATAAAG
     ATACCAGGCG TTTCCCCCTG GAAGCTCCCT CGTGCGCTCT CCTGTTCCGA CCCTGCCGCT
     TACCGGATAC CTGTCCGCCT TTCTCCCTTC GGGAAGCGTG GCGCTTTCTC ATAGCTCACG
5    CTGTAGGTAT CTCAGTTCGG TGTAGGTCGT TCGCTCCAAG CTGGGCTGTG TGCACGAACC
     CCCCGTTCAG CCCGACCGCT GCGCCTTATC CGGTAACTAT CGTCTTGAGT CCAACCCGGT
     AAGACACGAC TTATCGCCAC TGGCAGCAGC CACTGGTAAC AGGATTAGCA GAGCGAGGTA
     TGTAGGCGGT GCTACAGAGT TCTTGAAGTG GTGGCCTAAC TACGGCTACA CTAGAAGAAC
     AGTATTTGGT ATCTGCGCTC TGCTGAAGCC AGTTACCTTC GGAAAAAGAG TTGGTAGCTC
10   TTGATCCGGC AAACAAACCA CCGCTGGTAG CGGTGGTTTT TTTGTTTGCA AGCAGCAGAT
     TACGCGCAGA AAAAAAGGAT CTCAAGAAGA TCCTTTGATC TTTTCTACGG GGTCTGACGC
     TCAGTGGAAC GAAAACTCAC GTTAAGGGAT TTTGGTCATG AGATTATCAA AAAGGATCTT
     CACCTAGATC CTTTTAAATT AAAAATGAAG TTTTAAATCA ATCTAAAGTA TATATGAGTA
     AACTTGGTCT GACAGTTACC AATGCTTAAT CAGTGAGGCA CCTATCTCAG CGATCTGTCT
15   ATTTCGTTCA TCCATAGTTG CCTGACTCGG GGGGGGGGGG CGCTGAGGTC TGCCTCGTGA
     AGAAGGTGTT GCTGACTCAT ACCAGGCCTG AATCGCCCCA TCATCCAGCC AGAAAGTGAG
     GGAGCCACGG TTGATGAGAG CTTTGTTGTA GGTGGACCAG TTGGTGATTT TGAACTTTTG
     CTTTGCCACG GAACGGTCTG CGTTGTCGGG AAGATGCGTG ATCTGATCCT TCAACTCAGC
     AAAAGTTCGA TTTATTCAAC AAAGCCGCCG TCCCGTCAAG TCAGCGTAAT GCTCTGCCAG
20   TGTTACAACC AATTAACCAA TTCTGATTAG AAAAACTCAT CGAGCATCAA ATGAAACTGC
     AATTTATTCA TATCAGGATT ATCAATACCA TATTTTTGAA AAAGCCGTTT CTGTAATGAA
     GGAGAAAACT CACCGAGGCA GTTCCATAGG ATGGCAAGAT CCTGGTATCG GTCTGCGATT
     CCGACTCGTC CAACATCAAT ACAACCTATT AATTTCCCCT CGTCAAAAAT AAGGTTATCA
     AGTGAGAAAT CACCATGAGT GACGACTGAA TCCGGTGAGA ATGGCAAAAG CTTATGCATT
25   TCTTTCCAGA CTTGTTCAAC AGGCCAGCCA TTACGCTCGT CATCAAAATC ACTCGCATCA
     ACCAAACCGT TATTCATTCG TGATTGCGCC TGAGCGAGAC GAAATACGCG ATCGCTGTTA
     AAAGGACAAT TACAAACAGG AATCGAATGC AACCGGCGCA GGAACACTGC CAGCGCATCA
     ACAATATTTT CACCTGAATC AGGATATTCT TCTAATACCT GGAATGCTGT TTTCCCGGGG
     ATCGCAGTGG TGAGTAACCA TGCATCATCA GGAGTACGGA TAAAATGCTT GATGGTCGGA
30   AGAGGCATAA ATTCCGTCAG CCAGTTTAGT CTGACCATCT CATCTGTAAC ATCATTGGCA
     ACGCTACCTT TGCCATGTTT CAGAAACAAC TCTGGCGCAT CGGGCTTCCC ATACAATCGA
     TAGATTGTCG CACCTGATTG CCCGACATTA TCGCGAGCCC ATTTATACCC ATATAAATCA
     GCATCCATGT TGGAATTTAA TCGCGGCCTC GAGCAAGACG TTTCCCGTTG AATATGGCTC
     ATAACACCCC TTGTATTACT GTTTATGTAA GCAGACAGTT TTATTGTTCA TGATGATATA
```

-44-

TTTTTATCTT GTGCAATGTA ACATCAGAGA TTTTGAGACA CAACGTGGCT TTCCCCCCCC
CCCCATTATT GAAGCATTTA TCAGGGTTAT TGTCTCATGA GCGGATACAT ATTTGAATGT
ATTTAGAAAA ATAAACAAAT AGGGGTTCCG CGCACATTTC CCCGAAAAGT GCCACCTGAC
GTCTAAGAAA CCATTATTAT CATGACATTA ACCTATAAAA ATAGGCGTAT CACGAGGCCC
5   TTTCGTC (SEQ ID NO:16) . .

The underlined nucleotides of SEQ ID NO:16 represent the SfiI site
introduced into the Kpn 1 site of V1Jneo.

V1Jns-tPA – The vaccine vector V1Jns-tPA was constructed in order to fuse
an heterologous leader peptide sequence to the pol DNA constructs of the present
10   invention. More specifically, the vaccine vector V1Jns was modified to include the
human tissue-specific plasminogen activator (tPA) leader. As an exemplification, but
by no means a limitation of generating a pol DNA construct comprising an amino-
terminal leader sequence, plasmid V1Jneo was modified to include the human tissue-
specific plasminogen activator (tPA) leader. Two synthetic complementary oligomers
15   were annealed and then ligated into V1Jneo which had been BglII digested. The
sense and antisense oligomers were 5'-GATCACCATGGATGCAATGAAGAG
AGGGCTCTGCTGTGTGCTGCTGCTGTGTGGAGCAGTCTTCGTTTCGCCCAG
CGA-3' (SEQ ID NO:17); and, 5'-GATCTCGCTGGGCGAAACGAAGACTGCTCC
ACACAGCAGCAGCACACAGCAGAGCCCTCTCTTCATTGCATCCATGGT-3'
20   (SEQ ID NO:18). The Kozak sequence is underlined in the sense oligomer. These
oligomers have overhanging bases compatible for ligation to BglII-cleaved sequences.
After ligation the upstream BglII site is destroyed while the downstream BglII is
retained for subsequent ligations. Both the junction sites as well as the entire tPA
leader sequence were verified by DNA sequencing. Additionally, in order to conform
25   with V1Jns (=V1Jneo with an SfiI site), an SfiI restriction site was placed at the KpnI
site within the BGH terminator region of V1Jneo-tPA by blunting the KpnI site with
T4 DNA polymerase followed by ligation with an SfiI linker (catalogue #1138, New
England Biolabs), resulting in V1Jns-tPA. This modification was verified by
restriction digestion and agarose gel electrophoresis.
30   The V1Jns-tpa vector nucleotide sequence is as follows:

TCGCGCGTTT CGGTGATGAC GGTGAAAACC TCTGACACAT GCAGCTCCCG GAGACGGTCA
CAGCTTGTCT GTAAGCGGAT GCCGGGAGCA GACAAGCCCG TCAGGGCGCG TCAGCGGGTG
TTGGCGGGTG TCGGGGCTGG CTTAACTATG CGGCATCAGA GCAGATTGTA CTGAGAGTGC
ACCATATGCG GTGTGAAATA CCGCACAGAT GCGTAAGGAG AAAATACCGC ATCAGATTGG

```
      CTATTGGCCA TTGCATACGT TGTATCCATA TCATAATATG TACATTTATA TTGGCTCATG

      TCCAACATTA CCGCCATGTT GACATTGATT ATTGACTAGT TATTAATAGT AATCAATTAC

      GGGGTCATTA GTTCATAGCC CATATATGGA GTTCCGCGTT ACATAACTTA CGGTAAATGG

      CCCGCCTGGC TGACCGCCCA ACGACCCCCG CCCATTGACG TCAATAATGA CGTATGTTCC

   5  CATAGTAACG CCAATAGGGA CTTTCCATTG ACGTCAATGG GTGGAGTATT TACGGTAAAC

      TGCCCACTTG GCAGTACATC AAGTGTATCA TATGCCAAGT ACGCCCCCTA TTGACGTCAA

      TGACGGTAAA TGGCCCGCCT GGCATTATGC CCAGTACATG ACCTTATGGG ACTTTCCTAC

      TTGGCAGTAC ATCTACGTAT TAGTCATCGC TATTACCATG GTGATGCGGT TTTGGCAGTA

      CATCAATGGG CGTGGATAGC GGTTTGACTC ACGGGGATTT CCAAGTCTCC ACCCCATTGA

  10  CGTCAATGGG AGTTTGTTTT GGCACCAAAA TCAACGGGAC TTTCCAAAAT GTCGTAACAA

      CTCCGCCCCA TTGACGCAAA TGGGCGGTAG GCGTGTACGG TGGGAGGTCT ATATAAGCAG

      AGCTCGTTTA GTGAACCGTC AGATCGCCTG GAGACGCCAT CCACGCTGTT TTGACCTCCA

      TAGAAGACAC CGGGACCGAT CCAGCCTCCG CGGCCGGGAA CGGTGCATTG GAACGCGGAT

      TCCCCGTGCC AAGAGTGACG TAAGTACCGC CTATAGACTC TATAGGCACA CCCCTTTGGC

  15  TCTTATGCAT GCTATACTGT TTTTGGCTTG GGGCCTATAC ACCCCCGCTT CCTTATGCTA

      TAGGTGATGG TATAGCTTAG CCTATAGGTG TGGGTTATTG ACCATTATTG ACCACTCCCC

      TATTGGTGAC GATACTTTCC ATTACTAATC CATAACATGG CTCTTTGCCA CAACTATCTC

      TATTGGCTAT ATGCCAATAC TCTGTCCTTC AGAGACTGAC ACGGACTCTG TATTTTTACA

      GGATGGGGTC CCATTTATTA TTTACAAATT CACATATACA ACAACGCCGT CCCCCGTGCC

  20  CGCAGTTTTT ATTAAACATA GCGTGGGATC TCCACGCGAA TCTCGGGTAC GTGTTCCGGA

      CATGGGCTCT TCTCCGGTAG CGGCGGAGCT TCCACATCCG AGCCCTGGTC CCATGCCTCC

      AGCGGCTCAT GGTCGCTCGG CAGCTCCTTG CTCCTAACAG TGGAGGCCAG ACTTAGGCAC

      AGCACAATGC CCACCACCAC CAGTGTGCCG CACAAGGCCG TGGCGGTAGG GTATGTGTCT

      GAAAATGAGC GTGGAGATTG GGCTCGCACG GCTGACGCAG ATGGAAGACT TAAGGCAGCG

  25  GCAGAAGAAG ATGCAGGCAG CTGAGTTGTT GTATTCTGAT AAGAGTCAGA GGTAACTCCC

      GTTGCGGTGC TGTTAACGGT GGAGGGCAGT GTAGTCTGAG CAGTACTCGT TGCTGCCGCG

      CGCGCCACCA GACATAATAG CTGACAGACT AACAGACTGT TCCTTTCCAT GGGTCTTTTC

      TGCAGTCACC GTCCTT*AGAT CACCATGGAT GCAATGAAGA GAGGGCTCTG CTGTGTGCTG*

      *CTGCTGTGTG GAGCAGTCTT CGTTTCGCCC AGCGAGATCT* GCTGTGCCTT CTAGTTGCCA

  30  GCCATCTGTT GTTTGCCCCT CCCCCGTGCC TTCCTTGACC CTGGAAGGTG CCACTCCCAC

      TGTCCTTTCC TAATAAAATG AGGAAATTGC ATCGCATTGT CTGAGTAGGT GTCATTCTAT

      TCTGGGGGGT GGGGTGGGGC AGGACAGCAA GGGGGAGGAT TGGGAAGACA ATAGCAGGCA

      TGCTGGGGAT GCGGTGGGCT CTATGGCCGC TGCGGCCAGG TGCTGAAGAA TTGACCCGGT

      TCCTCCTGGG CCAGAAAGAA GCAGGCACAT CCCCTTCTCT GTGACACACC CTGTCCACGC
```

CCCTGGTTCT TAGTTCCAGC CCCACTCATA GGACACTCAT AGCTCAGGAG GGCTCCGCCT

TCAATCCCAC CCGCTAAAGT ACTTGGAGCG GTCTCTCCCT CCCTCATCAG CCCACCAAAC

CAAACCTAGC CTCCAAGAGT GGGAAGAAAT TAAAGCAAGA TAGGCTATTA AGTGCAGAGG

GAGAGAAAAT GCCTCCAACA TGTGAGGAAG TAATGAGAGA AATCATAGAA TTTCTTCCGC

5   TTCCTCGCTC ACTGACTCGC TGCGCTCGGT CGTTCGGCTG CGGCGAGCGG TATCAGCTCA

CTCAAAGGCG GTAATACGGT TATCCACAGA ATCAGGGGAT AACGCAGGAA AGAACATGTG

AGCAAAAGGC CAGCAAAAGG CCAGGAACCG TAAAAAGGCC GCGTTGCTGG CGTTTTTCCA

TAGGCTCCGC CCCCCTGACG AGCATCACAA AAATCGACGC TCAAGTCAGA GGTGGCGAAA

CCCGACAGGA CTATAAAGAT ACCAGGCGTT CCCCCTGGA AGCTCCCTCG TGCGCTCTCC

10   TGTTCCGACC CTGCCGCTTA CCGGATACCT GTCCGCCTTT CTCCCTTCGG GAAGCGTGGC

GCTTTCTCAT AGCTCACGCT GTAGGTATCT CAGTTCGGTG TAGGTCGTTC GCTCCAAGCT

GGGCTGTGTG CACGAACCCC CCGTTCAGCC CGACCGCTGC GCCTTATCCG GTAACTATCG

TCTTGAGTCC AACCCGGTAA GACACGACTT ATCGCCACTG GCAGCAGCCA CTGGTAACAG

GATTAGCAGA GCGAGGTATG TAGGCGGTGC TACAGAGTTC TTGAAGTGGT GGCCTAACTA

15   CGGCTACACT AGAAGAACAG TATTTGGTAT CTGCGCTCTG CTGAAGCCAG TTACCTTCGG

AAAAAGAGTT GGTAGCTCTT GATCCGGCAA ACAAACCACC GCTGGTAGCG GTGGTTTTTT

TGTTTGCAAG CAGCAGATTA CGCGCAGAAA AAAAGGATCT CAAGAAGATC CTTTGATCTT

TTCTACGGGG TCTGACGCTC AGTGGAACGA AAACTCACGT TAAGGGATTT TGGTCATGAG

ATTATCAAAA AGGATCTTCA CCTAGATCCT TTTAAATTAA AAATGAAGTT TTAAATCAAT

20   CTAAAGTATA TATGAGTAAA CTTGGTCTGA CAGTTACCAA TGCTTAATCA GTGAGGCACC

TATCTCAGCG ATCTGTCTAT TTCGTTCATC CATAGTTGCC TGACTCGGGG GGGGGGGCG

CTGAGGTCTG CCTCGTGAAG AAGGTGTTGC TGACTCATAC CAGGCCTGAA TCGCCCCATC

ATCCAGCCAG AAAGTGAGGG AGCCACGGTT GATGAGAGCT TTGTTGTAGG TGGACCAGTT

GGTGATTTTG AACTTTTGCT TTGCCACGGA ACGGTCTGCG TTGTCGGGAA GATGCGTGAT

25   CTGATCCTTC AACTCAGCAA AGTTCGATT TATTCAACAA AGCCGCCGTC CCGTCAAGTC

AGCGTAATGC TCTGCCAGTG TTACAACCAA TTAACCAATT CTGATTAGAA AAACTCATCG

AGCATCAAAT GAAACTGCAA TTTATTCATA TCAGGATTAT CAATACCATA TTTTTGAAAA

AGCCGTTTCT GTAATGAAGG AGAAAACTCA CCGAGGCAGT TCCATAGGAT GGCAAGATCC

TGGTATCGGT CTGCGATTCC GACTCGTCCA ACATCAATAC AACCTATTAA TTTCCCCTCG

30   TCAAAAATAA GGTTATCAAG TGAGAAATCA CCATGAGTGA CGACTGAATC CGGTGAGAAT

GGCAAAGCT TATGCATTTC TTTCCAGACT TGTTCAACAG CCAGCCATT ACGCTCGTCA

TCAAAATCAC TCGCATCAAC CAAACCGTTA TTCATTCGTG ATTGCGCCTG AGCGAGACGA

AATACGCGAT CGCTGTTAAA AGGACAATTA CAAACAGGAA TCGAATGCAA CCGGCGCAGG

AACACTGCCA GCGCATCAAC AATATTTTCA CCTGAATCAG GATATTCTTC TAATACCTGG

-47-

```
            AATGCTGTTT  TCCCGGGGAT  CGCAGTGGTG  AGTAACCATG  CATCATCAGG  AGTACGGATA
            AAATGCTTGA  TGGTCGGAAG  AGGCATAAAT  TCCGTCAGCC  AGTTTAGTCT  GACCATCTCA
            TCTGTAACAT  CATTGGCAAC  GCTACCTTTG  CCATGTTTCA  GAAACAACTC  TGGCGCATCG
            GGCTTCCCAT  ACAATCGATA  GATTGTCGCA  CCTGATTGCC  CGACATTATC  GCGAGCCCAT
    5       TTATACCCAT  ATAAATCAGC  ATCCATGTTG  GAATTTAATC  GCGGCCTCGA  GCAAGACGTT
            TCCCGTTGAA  TATGGCTCAT  AACACCCCTT  GTATTACTGT  TTATGTAAGC  AGACAGTTTT
            ATTGTTCATG  ATGATATATT  TTTATCTTGT  GCAATGTAAC  ATCAGAGATT  TTGAGACACA
            ACGTGGCTTT  CCCCCCCCCC  CCATTATTGA  AGCATTTATC  AGGGTTATTG  TCTCATGAGC
            GGATACATAT  TTGAATGTAT  TTAGAAAAAT  AAACAAATAG  GGGTTCCGCG  CACATTTCCC
    10      CGAAAAGTGC  CACCTGACGT  CTAAGAAACC  ATTATTATCA  TGACATTAAC  CTATAAAAAT
            AGGCGTATCA  CGAGGCCCTT  TCGTC  (SEQ ID NO:9).
```

V1R – Vaccine vector V1R was constructed to obtain a minimum-sized vaccine vector without unneeded DNA sequences, which still retained the overall optimized heterologous gene expression characteristics and high plasmid yields that V1J and V1Jns afford. It was determined that (1) regions within the pUC backbone comprising the *E. coli* origin of replication could be removed without affecting plasmid yield from bacteria; (2) the 3'-region of the kan^r gene following the kanamycin open reading frame could be removed if a bacterial terminator was inserted in its place; and, (3) ~300 bp from the 3'- half of the BGH terminator could be removed without affecting its regulatory function (following the original KpnI restriction enzyme site within the BGH element). V1R was constructed by using PCR to synthesize three segments of DNA from V1Jns representing the CMVintA promoter/BGH terminator, origin of replication, and kanamycin resistance elements, respectively. Restriction enzymes unique for each segment were added to each segment end using the PCR oligomers: SspI and XhoI for CMVintA/BGH; EcoRV and BamHI for the kan^r gene; and, BclI and SalI for the ori^r. These enzyme sites were chosen because they allow directional ligation of each of the PCR-derived DNA segments with subsequent loss of each site: EcoRV and SspI leave blunt-ended DNAs which are compatible for ligation while BamHI and BclI leave complementary overhangs as do SalI and XhoI. After obtaining these segments by PCR each segment was digested with the appropriate restriction enzymes indicated above and then ligated together in a single reaction mixture containing all three DNA segments. The 5'-end of the ori^r was designed to include the T2 rho independent terminator sequence that is normally found in this region so that it could provide termination

information for the kanamycin resistance gene. The ligated product was confirmed by
restriction enzyme digestion (>8 enzymes) as well as by DNA sequencing of the
ligation junctions. DNA plasmid yields and heterologous expression using viral genes
within V1R appear similar to V1Jns. The net reduction in vector size achieved was

5   1346 bp (V1Jns = 4.86 kb; V1R = 3.52 kb). PCR oligomer sequences used to
synthesize V1R (restriction enzyme sites are underlined and identified in brackets
following sequence) are as follows: (1) 5'-GGTACAAATATTGGCTATTGG
CCATTGCATACG-3' (SEQ ID NO:19) [SspI]; (2) 5'-CCACATCTCGAGGAAC
CGGGTCAATTCTTCAGCACC-3' (SEQ ID NO:20) [XhoI] (for CMVintA/BGH

10   segment); (3) 5'-GGTACAGATATCGGAAAGCCACGTTGTG TCTCAAAATC-3'
(SEQ ID NO:21) [EcoRV]; (4) 5'-CACATGGATCCGTAAT GCTCTGCCAGTGTT
ACAACC-3' (SEQ ID NO:2) [BamHI], (for kanamycin resistance gene segment) (5)
5'-GGTACATG ATCACGTAGAAAAGATCA AAGGATCTTCTTG-3' (SEQ ID
NO:23) [BclI]; (6) 5'-CCACATGTCGACCCGTAAA AAGGCCGCGTTGCTGG-3'

15   (SEQ ID NO:24): [SalI], (for *E. coli* origin of replication).

The nucleotide sequence of vector V1R is as follows:

```
     TCGCGCGTTT CGGTGATGAC GGTGAAAACC TCTGACACAT GCAGCTCCCG GAGACGGTCA
     CAGCTTGTCT GTAAGCGGAT GCCGGGAGCA GACAAGCCCG TCAGGGCGCG TCAGCGGGTG
     TTGGCGGGTG TCGGGGCTGG CTTAACTATG CGGCATCAGA GCAGATTGTA CTGAGAGTGC
20   ACCATATGCG GTGTGAAATA CCGCACAGAT GCGTAAGGAG AAAATACCGC ATCAGATTGG
     CTATTGGCCA TTGCATACGT TGTATCCATA TCATAATATG TACATTTATA TTGGCTCATG
     TCCAACATTA CCGCCATGTT GACATTGATT ATTGACTAGT TATTAATAGT AATCAATTAC
     GGGGTCATTA GTTCATAGCC CATATATGGA GTTCCGCGTT ACATAACTTA CGGTAAATGG
     CCCGCCTGGC TGACCGCCCA ACGACCCCCG CCCATTGACG TCAATAATGA CGTATGTTCC
25   CATAGTAACG CCAATAGGGA CTTTCCATTG ACGTCAATGG GTGGAGTATT TACGGTAAAC
     TGCCCACTTG GCAGTACATC AAGTGTATCA TATGCCAAGT ACGCCCCCTA TTGACGTCAA
     TGACGGTAAA TGGCCCGCCT GGCATTATGC CCAGTACATG ACCTTATGGG ACTTTCCTAC
     TTGGCAGTAC ATCTACGTAT TAGTCATCGC TATTACCATG GTGATGCGGT TTTGGCAGTA
     CATCAATGGG CGTGGATAGC GGTTTGACTC ACGGGGATTT CCAAGTCTCC ACCCCATTGA
30   CGTCAATGGG AGTTTGTTTT GGCACCAAAA TCAACGGGAC TTTCCAAAAT GTCGTAACAA
     CTCCGCCCCA TTGACGCAAA TGGGCGGTAG GCGTGTACGG TGGGAGGTCT ATATAAGCAG
     AGCTCGTTTA GTGAACCGTC AGATCGCCTG GAGACGCCAT CCACGCTGTT TTGACCTCCA
     TAGAAGACAC CGGGACCGAT CCAGCCTCCG CGGCCGGGAA CGGTGCATTG GAACGCGGAT
     TCCCCGTGCC AAGAGTGACG TAAGTACCGC CTATAGAGTC TATAGGCCCA CCCCCTTGGC
```

```
       TTCTTATGCA TGCTATACTG TTTTTGGCTT GGGGTCTATA CACCCCCGCT TCCTCATGTT
       ATAGGTGATG GTATAGCTTA GCCTATAGGT GTGGGTTATT GACCATTATT GACCACTCCC
       CTATTGGTGA CGATACTTTC CATTACTAAT CCATAACATG GCTCTTTGCC ACAACTCTCT
       TTATTGGCTA TATGCCAATA CACTGTCCTT CAGAGACTGA CACGGACTCT GTATTTTTAC
   5   AGGATGGGGT CTCATTTATT ATTTACAAAT TCACATATAC AACACCACCG TCCCCAGTGC
       CCGCAGTTTT TATTAAACAT AACGTGGGAT CTCCACGCGA ATCTCGGGTA CGTGTTCCGG
       ACATGGGCTC TTCTCCGGTA GCGGCGGAGC TTCTACATCC GAGCCCTGCT CCCATGCCTC
       CAGCGACTCA TGGTCGCTCG GCAGCTCCTT GCTCCTAACA GTGGAGGCCA GACTTAGGCA
       CAGCACGATG CCCACCACCA CCAGTGTGCC GCACAAGGCC GTGGCGGTAG GGTATGTGTC
  10   TGAAAATGAG CTCGGGGAGC GGGCTTGCAC CGCTGACGCA TTTGGAAGAC TTAAGGCAGC
       GGCAGAAGAA GATGCAGGCA GCTGAGTTGT TGTGTTCTGA TAAGAGTCAG AGGTAACTCC
       CGTTGCGGTG CTGTTAACGG TGGAGGGCAG TGTAGTCTGA GCAGTACTCG TTGCTGCCGC
       GCGCGCCACC AGACATAATA GCTGACAGAC TAACAGACTG TTCCTTTCCA TGGGTCTTTT
       CTGCAGTCAC CGTCCTTAGA TCTGCTGTGC CTTCTAGTTG CCAGCCATCT GTTGTTTGCC
  15   CCTCCCCCGT GCCTTCCTTG ACCCTGGAAG GTGCCACTCC CACTGTCCTT TCCTAATAAA
       ATGAGGAAAT TGCATCGCAT TGTCTGAGTA GGTGTCATTC TATTCTGGGG GGTGGGGTGG
       GGCAGCACAG CAAGGGGGAG GATTGGGAAG ACAATAGCAG GCATGCTGGG GATGCGGTGG
       GCTCTATGGG TACCCAGGTG CTGAAGAATT GACCCGGTTC CTCCTGGGCC AGAAAGAAGC
       AGGCACATCC CCTTCTCTGT GACACACCCT GTCCACGCCC CTGGTTCTTA GTTCCAGCCC
  20   CACTCATAGG ACACTCATAG CTCAGGAGGG CTCCGCCTTC AATCCCACCC GCTAAAGTAC
       TTGGAGCGGT CTCTCCCTCC CTCATCAGCC CACCAAACCA AACCTAGCCT CCAAGAGTGG
       GAAGAAATTA AAGCAAGATA GGCTATTAAG TGCAGAGGGA GAGAAAATGC CTCCAACATG
       TGAGGAAGTA ATGAGAGAAA TCATAGAATT TCTTCCGCTT CCTCGCTCAC TGACTCGCTG
       CGCTCGGTCG TTCGGCTGCG GCGAGCGGTA TCAGCTCACT CAAAGGCGGT AATACGGTTA
  25   TCCACAGAAT CAGGGGATAA CGCAGGAAAG AACATGTGAG CAAAAGGCCA GCAAAAGGCC
       AGGAACCGTA AAAAGGCCGC GTTGCTGGCG TTTTTCCATA GGCTCCGCCC CCCTGACGAG
       CATCACAAAA ATCGACGCTC AAGTCAGAGG TGGCGAAACC CGACAGGACT ATAAAGATAC
       CAGGCGTTTC CCCCTGGAAG CTCCCTCGTG CGCTCTCCTG TTCCGACCCT GCCGCTTACC
       GGATACCTGT CCGCCTTTCT CCCTTCGGGA AGCGTGGCGC TTTCTCAATG CTCACGCTGT
  30   AGGTATCTCA GTTCGGTGTA GGTCGTTCGC TCCAAGCTGG GCTGTGTGCA CGAACCCCCC
       GTTCAGCCCG ACCGCTGCGC CTTATCCGGT AACTATCGTC TTGAGTCCAA CCCGGTAAGA
       CACGACTTAT CGCCACTGGC AGCAGCCACT GGTAACAGGA TTAGCAGAGC GAGGTATGTA
       GGCGGTGCTA CAGAGTTCTT GAAGTGGTGG CCTAACTACG GCTACACTAG AAGGACAGTA
       TTTGGTATCT GCGCTCTGCT GAAGCCAGTT ACCTTCGGAA AAAGAGTTGG TAGCTCTTGA
```

```
     TCCGGCAAAC AAACCACCGC TGGTAGCGGT GGTTTTTTTG TTTGCAAGCA GCAGATTACG
     CGCAGAAAAA AAGGATCTCA AGAAGATCCT TTGATCTTTT CTACGGGGTC TGACGCTCAG
     TGGAACGAAA ACTCACGTTA AGGGATTTTG GTCATGAGAT TATCAAAAAG GATCTTCACC
     TAGATCCTTT TAAATTAAAA ATGAAGTTTT AAATCAATCT AAAGTATATA TGAGTAAACT
  5  TGGTCTGACA GTTACCAATG CTTAATCAGT GAGGCACCTA TCTCAGCGAT CTGTCTATTT
     CGTTCATCCA TAGTTGCCTG ACTCCGGGGG GGGGGGGCGC TGAGGTCTGC CTCGTGAAGA
     AGGTGTTGCT GACTCATACC AGGCCTGAAT CGCCCCATCA TCCAGCCAGA AAGTGAGGGA
     GCCACGGTTG ATGAGAGCTT TGTTGTAGGT GGACCAGTTG GTGATTTTGA ACTTTTGCTT
     TGCCACGGAA CGGTCTGCGT TGTCGGGAAG ATGCGTGATC TGATCCTTCA ACTCAGCAAA.
 10  AGTTCGATTT ATTCAACAAA GCCGCCGTCC CGTCAAGTCA GCGTAATGCT CTGCCAGTGT
     TACAACCAAT TAACCAATTC TGATTAGAAA AACTCATCGA GCATCAAATG AAACTGCAAT
     TTATTCATAT CAGGATTATC AATACCATAT TTTTGAAAAA GCCGTTTCTG TAATGAAGGA
     GAAAACTCAC CGAGGCAGTT CCATAGGATG GCAAGATCCT GGTATCGGTC TGCGATTCCG
     ACTCGTCCAA CATCAATACA ACCTATTAAT TTCCCCTCGT CAAAAATAAG GTTATCAAGT
 15  GAGAAATCAC CATGAGTGAC GACTGAATCC GGTGAGAATG GCAAAAGCTT ATGCATTTCT
     TTCCAGACTT GTTCAACAGG CCAGCCATTA CGCTCGTCAT CAAAATCACT CGCATCAACC
     AAACCGTTAT TCATTCGTGA TTGCGCCTGA GCGAGACGAA ATACGCGATC GCTGTTAAAA
     GGACAATTAC AAACAGGAAT CGAATGCAAC CGGCGCAGGA ACACTGCCAG CGCATCAACA
     ATATTTTCAC CTGAATCAGG ATATTCTTCT AATACCTGGA ATGCTGTTTT CCCGGGGATC
 20  GCAGTGGTGA GTAACCATGC ATCATCAGGA GTACGGATAA AATGCTTGAT GGTCGGAAGA
     GGCATAAATT CCGTCAGCCA GTTTAGTCTG ACCATCTCAT CTGTAACATC ATTGGCAACG
     CTACCTTTGC CATGTTTCAG AAACAACTCT GGCGCATCGG GCTTCCCATA CAATCGATAG
     ATTGTCGCAC CTGATTGCCC GACATTATCG CGAGCCCATT TATACCCATA TAAATCAGCA
     TCCATGTTGG AATTTAATCG CGGCCTCGAG CAAGACGTTT CCCGTTGAAT ATGGCTCATA
 25  ACACCCCTTG TATTACTGTT TATGTAAGCA GACAGTTTTA TTGTTCATGA TGATATATTT
     TTATCTTGTG CAATGTAACA TCAGAGATTT TGAGACACAA CGTGGCTTTC CCCCCCCCCC
     CATTATTGAA GCATTTATCA GGGTTATTGT CTCATGAGCG GATACATATT TGAATGTATT
     TAGAAAAATA AACAAATAGG GGTTCCGCGC ACATTTCCCC GAAAAGTGCC ACCTGACGTC
     TAAGAAACCA TTATTATCAT GACATTAACC TATAAAAATA GGCGTATCAC GAGGCCCTTT
 30  CGTC (SEQ ID NO:25).
```

EXAMPLE 2

Codon Optimized HIV-1 Pol and HIV-1 IA Pol Derivatives as DNA Vector Vaccines

Synthesis of WT-optpol and IA-opt-pol Gene - Construction of both genes were

conducted by Midland Certified Reagent Company (Midland, TX) following

5   established strategies. Ten double stranded oligonucleotides, ranging from 159 to 340

bases long and encompassing the entire pol gene, were synthesized by solid state

methods and cloned separately into pUC18. For the wt-pol gene, the fragments are as

follows:

*Bgl*II#1-*Ecl*136II half site at 282	= pJS6A1-7
*Pml*I half site at #285 – *Ecl*136II half site at #597	= pJS6B2-5
*Ssp*I half site at #600 – *Ecl*136II half site at #866	= pJS6C1-4
*Sma*I half site at #869 – *Apa*I #1095	= pJS6D1-4
*Apa*I #1095 - *Kpn*I #1296	= pJS6E1-4
*Kpn*I #1296 – *Xcm*I #1636	= pJS6F1-5
*Xcm*I #1636 – *Nsi*I #1847	= pJS6G1-2
*Nsi*I #1847 – *Bcl*I half site at #2174	= pJS6H1-14
*Bcl*I half site at #2174 – *Sac*I #2333	= pJS6I1-2
*Sac*I #2333 - *Bgl*II #2577	= pJS6J1-1

*Eco*RI and *Hind*III sequences were added upstream of each 5' end and downstream of

20   each 3' end, respectively, to allow cloning into the *Eco*RI-*Hind*III sites of pUC18.

The next stage of the synthesis was to consolidate these cassettes into three

roughly equal fragments (alpha, beta, gamma) and was performed as follows:

Alpha: The *Ssp*I-*Hind*III small fragment of pJS6C1-4 was transferred into the

*Ecl*136II-*Hind*III sites of pJS6B2-5 to give pJS6BC1-1. Into the *Eco*RI-*Pml*I sites of

25   this plasmid was inserted the *Eco*RI-*Ecl*136II small fragment of pJS6A1-7 to give

pJS6α1-8.

Beta: The *Eco*RI-*Apa*I small fragment of pJS6D1-4 was inserted into the

corresponding sites of pJS6E1-2 to give pJS6DE1-2. Also, the *Eco*RI-*Xcm*I small

fragment of pJS6F1-5 was inserted into the corresponding sites of pJS6G1-2 to give

30   pJS6FG1-1. Then the *Eco*RI-*Kpn*I small fragment of pJS6DE1-2 was inserted into

the corresponding sites of pJS6FG1-1 to give pJS6β1-1.

Gamma: The *Sac*I-*Hind*III small fragment of pJS6J1-1 was inserted into the

corresponding sites of pJS6I1-2 to give pJS6IJ1-1. This plasmid was propagated

through *E. coli* SCS110 (*dam-/dcm-*) to permit subsequent cleavage at the *Bcl*I site.

The *BcI*I-*Hind*III small fragment of the unmethylated pJS6IJ1-1 was inserted into the *Bgl*II-*Hind*III sites of pJS6H1-14 to give pJS6χ1-1.

The wt-pol alpha, beta, gamma were ligated into the entire sequence as follows:

5   The *EcoRI*-*Ecl*136II small fragment of pJS6α1-8 was inserted into the *EcoRI*-*SmaI* sites of pJS6β1-1 to give pJS6αβ2-1.

Into the *NsiI*-*Hind*III sites of this plasmid was inserted the *NsiI*-*Hind*III small fragment of pJS6χ1-1 to give pUC18-wt-pol. This final plasmid was completely resequenced in both strands.

10   To construct the entire IA-pol gene, only 3 new small fragments were synthesized:

*PmI*I half site at #285 – *Ecl*136II half site at #597   = pJS7B1-1

KpnI #1296 – *XcmI* #1636   = pJS7F1-2

NsiI #1847 – *Bgl*II half site at #2174   = pJS7H1-5

15   These were then used in the same reconstruction strategy as described above to give pUC18-IA-pol.

Expression Vector Construction - pUC18-wt-pol and pUC18-IA-pol were digested with *Bgl*II in order to isolate fragments containing the entire pol genes. V1R, V1Jns, V1Jns-tpa (Shiver, et al., 1995, Immune responses to HIV gp120 elicited by

20 DNA vaccination. In *Vaccines 95* (eds. Chanock, R. M., Brown, F., Ginsberg, H.S., & Norrby, E.) @ pp. 95-98; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York; see also Example Section 1) were digested with *Bgl*II. The cut vectors were then treated with calf intestinal alkaline phosphatase. Both wt-pol and IA-pol genes were ligated into cut V1R using T4 DNA ligase (16 °C, overnight).

25 Competent DH5α cells were transformed with aliquots of the ligation mixtures. Colonies were screened by restriction digestion of amplified plasmid isolates. Following a similar strategy, the *Bgl*II fragment containing the IA-pol was subcloned into the *Bgl*II site of V1Jns. To ligate the IA-pol gene into V1Jns-tpa, the IA-pol gene was PCR-amplified from V1R-IA-pol using pfu polymerase and the following

30 pair of primers: 5'-GGTACAAGATCTCCGCCCCCATCTCCCCCATTGAGA-3' (SEQ ID NO:26), and 5'-CCACATAGATCTGCCCGGGCTTTAGTCCTCATC-3' (SEQ ID NO:27). The upstream primer was designed to remove the initiation met codon and place the pol gene in frame with the tpa leader coding sequence from V1Jns-tpa. The PCR product was purified from the agarose gel slab using Sigma

DNA Purification spin columns. The purified products were digested with *Bgl*II and subcloned into the *Bgl*II site of V1Jns-tpa.

     Results - The codon humanized wt- and IA-pol genes were constructed via stepwise ligation of 10 synthetic dsDNA fragments (Ferretti, et al., 1986, *Proc. Natl.*

5   *Acad. Sci. USA* 83: 599-603). For expression in mammalian systems, the IA-pol gene was subcloned into V1R, V1Jns, and V1Jns-tpa. All these vectors place the gene under the control of the human cytomegalovirus/intron A hybrid promoter (hCMVIA). The DNA sequence of the IA-pol gene and the expressed protein product are shown in Figure 2A-B. Subcloning into V1Jns-tpa attaches the leader sequence

10   from human tissue-specific plasminogen activator (tpa) to the N-terminus of the IA-pol (Pennica, et al., 1983, *Nature* 301: 214-221) to allow secretion of the protein. The sequences of the tpa leader and the fusion junction are shown in Figure 3.

EXAMPLE 3

15   HIV-1 POL Vaccine - Rodent Studies

    Materials - *E. coli* DH5α strain, penicillin, streptomycin, ACK lysis buffer, hepes, L-glutamine, RPMI1640, and ultrapure CsCl were obtained from Gibco/BRL (Grand Island, NY). Fetal bovine serum (FBS) was purchased from Hyclone. Kanamycin, Tween 20, bovine serum albumin, hydrogen peroxide (30%),

20   concentrated sulfuric acid, β-mercaptoethanol (β-ME), and concanavalin A were obtained from Sigma (St. Louis, MO). Female balb/c mice at 4-6 wks of age were obtained from Taconic Farms (Germantown, NY). 0.3-mL insulin syringes were purchased from Myoderm. 96-well flat bottomed Maxisorp plates were obtained form NUNC (Rochester, NY). HIV-1$_{IIIB}$ RT p66 recombinant protein was obtained from

25   Advanced Biotechnologies, Inc. (Columbia, MD). 20-mer peptides were synthesized by Research Genetics (Huntsville, AL). Horseradish peroxidase (HRP)-conjugated rabbit anti-mouse IgG1 was obtained from ZYMED (San Francisco, CA). 1,2-phenylenediamine dihydrochloride (OPD) tablets was obtained from DAKO (Norway). Purified rat anti-mouse IFN-gamma (IgG1, clone R4-6A2), biotin-

30   conjugated rat anti-mouse IFN-gamma (IgG1, clone XMG 1.2), and strepavidin-alkaline phosphatase conjugate were purchased from PharMingen (San Diego, CA). 1-STEP NBT/BCIP dye was obtained from Pierce Chemicals (Rockford, IL). 96-well Multiscreen membrane plate was purchased from Millipore (France). Cell strainer was obtained from Becton-Dickinson (Franklin Lakes, NJ).

Plasmid Preparation - *E. coli* DH5α cells expressing the pol plasmids were grown to saturation in LB broth supplemented with 100 ug/mL kanamycin. Plasmid were purified by standard CsCl method and solubilized in saline at concentrations greater than 5 mg/mL until further use.

Vaccination - The plasmids were prepared in phosphate-buffered saline and administered into balb/c by needle injection (28-1/2G insulin syringe) of 50 uL aliquot into each quad muscle. V1Jns-IApol was administered at 0.3, 3, 30 ug dose and for comparison, V1Jns-tpa-IApol was given at 30 ug dose. Immunizations were conducted at T=0 and T=8 wks (for select animals from the 30-ug dose cohorts).

ELISA Assay - At T=12 wks, blood samples were collected by making an incision of a tail vein and the serum separated. Anti-RT titers were obtained following standard secondary antibody-based ELISA. Briefly, Maxisorp plates were coated by overnight incubation with 100 uL of 1 ug/mL HIV-1 RT protein (in PBS). The plates were washed with PBS/0.05% Tween 20 and incubated for approx. 2h with 200 uL/well of blocking solution (PBS/0.05% tween/1% BSA). The blocking solution was decanted; 100 uL aliquot of serially diluted serum samples were added per well and incubated for 2 h at room temperature. The plates were washed and 100 uL of 1/1000-diluted HRP-rabbit anti-mouse IgG were added with 1 h incubation. The plates were washed thoroughly and soaked with 100 uL OPD/H_2O_2 solution for 15 min. The reaction was quenched by adding 100 uL of 0.5M H_2SO_4 per well. OD_{492} readings were recorded.

ELIspot - Spleens were collected from 5 mice/cohort at T=13-14 wks and pooled into a tube of 8-mL R10 medium (RPMI1640, 10% FBS, 2mM L-glutamine, 100U/mL Penicillin, 100 u/mL streptomycin, 10 mM Hepes, 50 uM β-ME). Multiscreen opaque plates were coated with 100μl/well of capture mAb (purified R4-6A2 diluted in PBS to 5μg/ml) at 4°C overnight. The plates were washed with PBS/Pen/Strep in hood and blocked with 200μl/well of complete R10 medium for 37°C for at least 2 hrs. The mouse spleens were ground on steel mesh, collected into 15ml tubes and centrifuged at 1200rpm for 10min. The pellet was treated in ACK buffer (4ml of lysis buffer per spleen) for 5min at room temperature to lyse red blood cells. The cell pellet was centrifuged as before, resuspended in K-medium (5ml per mouse spleen), filtered through a cell strainer and counted using a hemacytometer. Block medium was decanted from the plates and 100μl/well of cell samples (5.0x10e5 cells per well) plus antigens were added. Pol-specific CD4$^+$ cells were stimulated

using a mixture of previously identified two epitope-containing peptides (aa641-660, aa731-750). Antigen-specific CD8+ cells were stimulated using a pool of four peptide epitope-containing peptides (aa201-220, aa311-330, aa571-590, aa781-800) or with individual peptides. A final concentration of 4 ug/mL per peptide was used.

5 Each splenocyte sample is tested for IFN-gamma secretion by adding the mitogen, concanavalin A. Plates were incubated at 37°C, 5% CO_2 for 20-24 h. The plates were washed with PBS/0.05% Tween 20 and soaked with 100 uL/well of 5 ug/mL biotin-conjugated rat anti-mouse IFN- mAb (clone XMG1.2) at 4°C overnight. The plates were washed and soaked with 100 uL/well 1/2500 dilution of strepavidin-AP

10 (in PBS/0.005% Tween/5%FCS) for 30 min at 37 °C. Following a wash, spots were developed by incubating with 100μl/well 1-step NBT/BCIP for 6-10 min. The plates were washed with water and allowed to air dry. The number of spots in each wells were determined using a dissecting microscope and normalized to 10e6 cells.

Results - Single vaccination of balb/c mice with V1Jns-IApol is able to induce

15 antigen-specific antibody (Figure 4) and T cell (Figure 5) responses in a dose response manner. IFN-gamma secretion from splenocytes can be detected from 3 and 30 ug cohort following stimulation with pools of peptides that contain CD4+ and CD8+ T cell epitopes. These epitopes were identified by (1) screening 20-mer peptides that encompass the entire pol sequence and overlap by 10 amino acid for

20 ability to stimulate IFN-gamma secretion from vaccinee splenocytes, and (2) determining the T cell type (CD4+ or CD8+) by depleting either population in an Elispot assay. Addition of tpa leader sequence to the pol gene is able to induce comparable, if not slightly higher, frequencies of pol-specific CD4+ and CD8+ cells. A second immunization with either V1Jns-IApol and V1Jns-tpa-IApol resulted in

25 effective boosting of the immune responses.

EXAMPLE 4
HIV-1 Pol Vaccine - Non Human Primate Studies
Materials - *E. coli* DH5α strain, penicillin, streptomycin, and ultrapure CsCl

30 were obtained from Gibco/BRL (Grand Island, NY). Kanamycin and phytohemagluttinin (PHA-M) were obtained from Sigma (St. Louis, MO). 20-mer peptides were synthesized by SynPep (Dublin, CA) and Research Genetics (Huntsville, AL). 96-well Multiscreen Immobilon-P membrane plates were obtained from Millipore (France). Strepavidin-alkaline phosphatase conjugate were purchased

-56-

form Pharmingen (San Diego, CA). 1-Step NBT/BCIP dye was obtained form Pierce Chemicals (Rockford, IL). Rat anti-human IFN-gamma mAb and biotin-conjugated anti-human IFN-gamma reagent were obtained from R&D Systems (Minneapolis, MN). Dynabeads M-450 anti-human CD4 were obtained from Dynal (Norway). HIVp24 antigen assay was purchased from Coulter Corporation (Miami, FL). HIV-1$_{IIIB}$ RT p66 recombinant protein was obtained from Advanced Biotechnologies, Inc. (Columbia, MD). Plastic 8 well strips/plates, flat bottom, Maxisorp, are obtained from NUNC (Rochester, NY). HIV+ human serum 9711234 was obtained from Biological Specialty Corp.

Plasmid Preparation - E. coli DH5α cells expressing the pol plasmids were grown to saturation in LB supplemented with 100 ug/mL kanamycin. Plasmid were purified by standard CsCl method and solubilized in saline at concentrations greater than 5 mg/mL until further use.

Vaccination - Cohorts of 3 rhesus macaques (approx. 5-10 kg) were vaccinated with 5 mg dose of either V1Jns-IApol or V1Jns-tpa-IApol. The vaccine was administered by needle injection of two 0.5 mL aliquots of 5 mg/mL plasmid solution (in phosphate-buffered saline, pH 7.2) into both deltoid muscles. Prior to vaccination, the monkeys were chemically restraint with i.m. injection of 10 mg/kg ketamine. The animals were immunized 3x at 4 week intervals (T=0, 4, 8 wks).

Sample Collection - Blood samples were collected at T = 0, 4, 8, 12, 16, 18 wks; sera and PBMCs were isolated using established protocols.

ELIspot Assay - Immobilon-IP plates were coated with 100 uL/well of rat anti-human IFN-gamma mAb at 15 ug/mL at 4 °C overnight. The plates are then washed with PBS and block by adding 200 uL/well of R10 medium. 4x10e5 peripheral blood cells were plated per well and to each well, either media or one of the pol peptide pools (final concentration of 4 ug/mL per peptide) or PHA, a known mitogen, is added to a final volume of 100 uL. Duplicate wells were set up per sample per antigen and stimulation was performed for 20-24 h at 37 °C. The plates are then washed; biotinylated anti-human IFN-gamma reagent is added (0.1 ug/mL, 100 uL per well) and allowed to incubate for overnight at 4 °C. The plates are again washed and 100 uL of 1:2500 dilution of the strepavidin-alkaline phosphatase reagent (in PBS/0.005% Tween/5% FCS) is added and allowed to incubate for 2 h at ambient room temperature. After another wash, spots are developed by incubating with 100 uL/well of 1-step NBT/BCIP for 6-10 min. CD4- T cell depletion was performed by

adding 1 bead particle/10 cell of Dynabeads M450 anti-human CD4, prewashed with PBS, and incubating on the shaker at 4 °C for 30 min. The beads are fractionated magnetically and the unbound cells collected and quantified before plating onto the ELISpot assay plates (at 4x10e5 cells per well).

5   *CTL Assay* - Procedures for establishing bulk CTL culture with fresh or cryopreserved peripheral blood mononuclear cells (PBMC) are as follows. Twenty percent total PBMC were infected in 0.5 ml volume with recombinant vaccinia virus, Vac-tpaPol, respectively, at multiplicity of infection (moi) of 5 for 1 hr at 37°C, and then combined with the remaining PBMC sample. The cells were washed once in 10

10   ml R-10 medium, and plated in a 12 well plate at approximately 5 to 10 x 10^6 cells/well in 4 ml R-10 medium. Recombinant human IL-7 was added to the culture at the concentration of 330 U/ml. Two or three days later, one milliliter of R-10 containing recombinant human IL-2 (100 U/ml) was added to each well. And twice weekly thereafter, two milliliters of cultured media were replaced with 2 ml fresh R-

15   10 medium with rhIL-2 (100 U/ml). The lymphocytes were cultured at 37°C in the presence of 5% CO_2 for approximately 2 weeks, and used in cytotoxicity assay as described below. The effector cells harvested from bulk CTL cultures were tested against autologous B lymphoid cell lines (BLCL) sensitized with peptide pools. To prepare for the peptide-sensitized targets, the BLCL cells were washed once with

20   R-10 medium, enumerated, and pulsed with peptide pool (about 4 to 8 $\mu g/ml$ concentration for each individual peptide) in 1 ml volume overnight. A mock target was prepared by pulsing cells with peptide-free DMSO diluent to match the DMSO concentration in the peptide-pulsed targets. The cells were enumerated the next morning, and 1 x 10^6 cells were resuspended in 0.5 ml R-10 medium. Five to ten

25   microliters of Na^{51}CrO$_4$ were added to the tubes at the same time, and the cells were incubated for 1 to 2 hr 37°C. The cells were then washed 3 times and resuspended at 5x10^4 cells/ml in R-10 medium to be used as target cells. The cultured lymphocytes were plated with target cells at designated effector to target (E:T) ratios in triplicates in 96-well plates, and incubated at 37°C for 4 hours in the presence of 5% CO_2. A

30   sample of 30 μl supernatant from each well of cell mixture was harvested onto a well of a Lumaplate-96 (Packard Instrument, Meriden, CT), and the plate was allowed to air dry overnight. The amount of ^{51}Cr in the well was determined through beta-particle emission, using a plate counter from Packard Instrument. The percentage of specific lysis was calculated using the formula as: % specific lysis = $(E\text{-}S) / (M\text{-}S)$.

The symbol E represents the average cpm released from target cells in the presence of effector cells, S is the spontaneous cpm released in the presence of medium only, and M is the maximum cpm released in the presence of 2% Triton X-100.

ELISA Assay - The pol-specific antibodies in the monkeys were measured in a competitive RT EIA assay, wherein sample activity is determined by the ability to block RT antigen from binding to coating antibody on the plate well. Briefly, Maxisorp plates were coated with saturating amounts of pol positive human serum (97111234). 250 uL of each sample is incubated with 15 uL of 266 ng/mL RT recombinant protein (in RCM 563, 1% BSA, 0.1% tween, 0.1% NaN_3) and 20 uL of lysis buffer (Coulter p24 antigen assay kit) for 15 min at room temperature. Similar mixtures are prepared using serially diluted samples of a standard and a negative control which defines maximum RT binding. 200 uL/well of each sample and standard were added to the washed plate and the plate incubated 16-24 h at room temperature. Bound RT is quantified following the procedures described in Coulter p24 assay kit and reported in milliMerck units per mL arbitrarily defined by the chosen standard.

Results - Repeated vaccinations with V1Jns-IApol induced in 1 of 3 monkeys (94R033) significant levels of antigen-specific T cell activation (Figure 6A-C and Table 2) and CTL killing of peptide-pulsed autologous cells (Figure 7A-B). A significant CD8+ component to the T cell responses in this animal was confirmed by peptide-stimulation of CD4-depleted PBMCs in an ELIspot assay (Table 2).

Immunization with V1Jns-tpa-IApol produced T cell responses from all 3 vaccinees (Figures 6A-C, Figure 7A-B; Table 2). Two (920078, 94R028) exhibited bulk CTL activity and detectable CD8+ components as measured by Elispot analyses of CD4-depleted PBMCs. For the third monkey (920073), the activated T cells were largely CD4+ (Table 2). Table 3 shows the time course data on the frequency of IFN-gamma secreting cells (SFC/million cells) upon antigen-specific stimulation for monkeys vaccinated 3x with either V1Jns-IApol or V1Jns-tpa-IApol (5 mg dose). At T=18 wks, CD4-cell depletion were performed; the reported values are the number of spots per million of fractionated cells and are not corrected for the resultant enrichment of CD8+ T cells. PBMCs were stimulated with peptide pools that represent either IA pol protein (mpol-1, mpol-2) or wt Pol (wtpol-1, wtpol-2).

TABLE 2

Vaccine	Animal No.	Antigen	T=0 wk	T=4 Wk	T=8 Wk	T=12 Wk	T=18 Wk	
			Dose 1	Dose 2	Dose 3			CD4-Depl
VlJns-lApd 5 mgs	94R008	medium	1	15	6	11	11	11
		mpd-1	3	69	28	61	20	15
		mpd-2	0	25	21	19	28	16
		wtpd-1		49	20	53	18	
		wtpd-2		34	24	24	19	
	94R013	medium	0	14	6	9	18	11
		mpd-1	0	9	63	25	34	9
		mpd-2	1	15	24	36	24	15
		wtpd-1		9	50	33	18	
		wtpd-2		6	21	29	25	
	94R033	medium	4	15	11	14	13	8
		mpd-1	3	29	86	51	41	24
		mpd-2	0	24	25	43	59	64
		wtpd-1		30	38	60	53	
		wtpd-2		48	46	86	61	
VlJns-tpolApd 5 mgs	920078	medium	0	24	13	11	14	11
		mpd-1	3	110	120	119	155	11
		mpd-2	1	221	130	561	289	145
		wtpd-1		115	53	70	116	
		wtpd-2		218	204	490	194	
	920073	medium	0	13	3	15	15	6
		mpd-1	0	36	51	113	90	14
		mpd-2	0	29	16	83	115	34
		wtpd-1		20	35	100	74	
		wtpd-2		25	16	79	61	
	94R028	medium	0	18	11	18	19	9
		mpd-1	1	30	24	29	30	28
		mpd-2	1	24	23	66	59	95
		wtpd-1		23	25	34	29	
		wtpd-2		26	28	71	40	
Naive	920072	medium	1	19	3	38	9	4
		mpd-1	0	24	11	25	4	6
		mpd-2	1	24	5	28	6	5
		wtpd-1		18	13	20	6	
		wtpd-2		23	14	33	14	

5

For the Elispot assay, antigen specific stimulation were performed by using pools of 20-mer peptide pools based on the vaccine sequence. The vaccine pol sequence differs from the wild-type HIV-1 sequence by 9 point mutations, thereby affecting 16 of the 20-mer peptides in the pool. Comparable responses were observed in the vaccinees when these peptides are replaced with those using the wild-type sequences.

Four of the vaccinees gave anti-RT titers above background after 3 dosages of the plasmids (Table 2).

TABLE 3
Anti-RT levels in Rhesus Macaques Vaccinated 3x (4 week intervals) with
5 mgs of V1Jns-IApol or V1Jns-tpa-IApol expressed in mMU/mL.

Vaccine/Monkey	T=0 Wk	T=4	T=8	T=12	T=16
	DOSE 1	DOSE 2	DOSE 3		
V1Jns-IApol, 5 mg					
94R008	ND	<10	<10	15	14
94R013	ND	<10	<10	<10	<10
94R033	ND	<10	<10	25	19
V1Jns-tpa-IApol, 5 mg					
920078	ND	<10	<10	35	17
920073	ND	<10	<10	<10	<10
94R028	ND	<10	<10	20	63

EXAMPLE 5

Effect of Codon Optimization on In Vivo Expression and
Cellular Immune Response of wt-pol

Materials and Methods - Extraction of virus-derived pol gene - The gene for RT-IN (wt-pol; a non-codon optimized wild type pol gene derived directly from the HIV IIIB genome) was extracted and amplified from the HIV IIIB genome using two primers, 5'-CAG GCG AGA TCT ACC ATG GCC CCC ATT AGC CCT ATT GAG ACT GTA-3' (SEQ ID NO:29) and 5'-CAG GCG AGA TCT GCC CGG GCT TTA ATC CTC ATC CTG TCT ACT TGC CAC-3' (SEQ ID NO:30), containing *Bgl*II sites. The reaction contained 200 nmol of each primer, 2.5 U of pfu Turbo DNA polymerase (Stratagene, La Jolla, CA), 0.2 mM of each dNTPs, and the template DNA in 10mM KCl, 10mM $(NH_4)_2SO_4$, 20mM Tris-HCl pH 8.75, 2mM $MgSO_4$, 0.1% TritonX-100, 0.1mg/ml bovine serum albumin (BSA). Thermocycling

conditions were as follows: 20 cycles of 1 min at 95 °C, 1 min at 56 °C, and 4 mins at
72 °C with 15-min capping at 72 °C. The digested PCR fragment was subcloned into
the *BglII* site of the expression plasmid V1Jns (Shiver, et al., 1995, Immune responses
to HIV gp120 elicited by DNA vaccination. In Chanock, R. M., Brown, F., Ginsberg,
5   H. S., and Norrby, E. (Eds.) *Vaccines 95.* Cold Spring Harbor Laboratory Press, Cold
Spring Harbor, New York, pp 95-98; see also Example section 1 herein) expression
plasmid following similar procedures as described above. The ligation mixtures were
then used to transform competent *E. coli* DH5 cells and screened by PCR
amplification of individual colonies. Sequence of the entire gene insert was
10   confirmed. All plasmid constructs for animal immunization were purified by CsCl
method (Sambrook, et al., 1989, Fritsch and Maniatis, T. (Eds) *Molecular cloning: a
laboratory manual.* Cold Spring Harbor Laboratory Press, Cold Spring Harbor).

         In vitro expression in mammalian cells - 1.5×10^6 293 cells were transfected
with 1 or 10 μg of V1R-wt-pol (codon optimized) and V1Jns-wt-pol (virus derived)
15   using the Cell Phect kit and incubated for 48 h at 37 °C, 5% CO_2, 90% humidity.
Supernatants and cell lysates were prepared and assayed for protein content using
Pierce Protein Assay reagent (Rockford, IL). Aliquots containing equal amounts of
total protein were loaded unto 10-20% Tris glycine gel (Novex, San Diego, CA) along
with the appropriate molecular weight markers. The pol product was detected using
20   anti-serum from a seropositive patient (Scripps Clinic, San Diego, CA) diluted 1:1000
and the bands developed using goat anti-human IgG-HRP (Bethyl, Montgomery, TX)
at 1:2000 dilution and standard ECL reagent kit (Pharmacia LKB Biotechnology,
Uppsala, Sweden).

         Ultrasensitive RT activity assay of pol constructs - RT activities from codon
25   optimized wt-pol and IA pol plasmids were analyzed by the Product-Enhanced
Reverse Transcriptase (PERT) assay using Perkin Elmer 7700, Taqman technology
(Arnold, et al., 1999, One-step fluorescent probe product-enhanced reverse
transcriptase assay. In McClelland, M., Pardee, A. (Eds.) *Expression genetics:
accelerated and high-throughput methods.* Biotechniques Books, Natick, MA, pp.
30   201-210). Background levels for this assay were determined using 1:100,000 dilution
of lysates from mock (chemical treatment only, no vector) transfected 293 cells. This
background range is set as RT/reaction tube of 0.00 to 56.28 which is taken from the
mean value of 13.80 +/- 3 standard deviations (sd=14.16). Any individual value
>56.28 would be considered positive for PERT assay. Cells lysates were prepared

similarly for the following samples: mock transfection with empty V1Jns vector; no vector control; transfection with V1Jns-tpa-pol (codon optimized); and transfection with V1Jns-IApol (codon optimized). Samples were serially diluted to 1:100,000 in PERT buffer and 24 replicates for each sample at this dilution were assayed for RT activity.

Rodent immunization with optimized and virus-derived pol plasmids - To compare the immunogenic properties of wt-pol (codon optimized) and virus-derived pol gene, cohorts of BALB/c mice (N=10) were vaccinated with 1 µg, 10 µg, and 100 µg doses of V1R-wt-pol (codon optimized) and V1Jns-wt-pol plasmid (virus derived). At 5 weeks post dose 1, 5 of 10 mice per cohort were boosted with the same dose of plasmid they initially received. In all cases, the vaccines were suspended or diluted in 6 mM sodium phosphate, 150 mM sodium chloride, pH 7.2, and the total dose was injected to both quadricep muscles in 50 µL aliquots using a 0.3-mL insulin syringe with 28-1/2G needles (Becton-Dickinson, Franklin Lakes, NJ).

Anti-RT ELISA - Anti-RT titers were obtained following standard secondary antibody-based ELISA. Maxisorp plates (NUNC, Rochester, NY) were coated by overnight incubation with 100 µL of 1 µg /mL HIV-1 RT protein (Advanced Biotechnologies, Columbia, MD) in PBS. The plates were washed with PBS/0.05% Tween 20 using Titertek MAP instrument (Hunstville, AL) and incubated for approximately 2h with 200 µL/well of blocking solution (PBS/0.05% tween/1% BSA). The blocking solution was decanted; 100 µL aliquot of serially diluted serum samples were added per well and incubated for 2 h at room temperature. An initial dilution of 100-fold is performed followed by 4-fold serial dilution. The plates were washed and 100 µL of 1/1000-diluted HRP-rabbit anti-mouse IgG (ZYMED, San Francisco, CA) were added with 1 h incubation. The plates were washed thoroughly and soaked with 100 µL 1,2-phenylenediamine dihydrochloride/hydrogen peroxide (DAKO, Norway) solution for 15 min. The reaction was quenched by adding 100 µL of 0.5M H_2SO_4 per well. OD_{492} readings were recorded using Titertek Multiskan MCC/340 with S20 stacker. Endpoint titers were defined as the highest serum dilution that resulted in an absorbance value of greater than or equal to 0.1 OD_{492} (2.5 times the background value).

ELIspot assay - Antigen-specific INFγ-secreting cells from mouse spleens were detected using the ELIspot assay (Miyahira, et al., 1995, Quantification of antigen specific CD8[+] T cells using an ELISPOT assay. *J. Immunol. Methods* 1995,

181, 45-54). Typically, spleens were collected from 3-5 mice/cohort and pooled into a tube of 8-mL complete RPMI media (RPMI1640, 10% FBS, 2mM L-glutamine, 100U/mL Penicillin, 100 u/mL streptomycin, 10 mM Hepes, 50 uM β-ME). Multiscreen opaque plates (Millipore, France) were coated with 100 μL/well of 5

5   μg/mL purified rat anti-mouse IFN-γ IgG1, clone R4-6A2 (Pharmingen, San Diego, CA), in PBS at 4°C overnight. The plates were washed with PBS/penicillin/streptomycin in hood and blocked with 200 μL/well of complete RPMI media for 37 °C for at least 2 h. The mouse spleens were ground on steel mesh, collected into 15ml tubes and centrifuged at 1200rpm for 10 min. The pellet

10   was treated with 4 mL ACK buffer (Gibco/BRL) for 5 min at room temperature to lyse red blood cells. The cell pellet was centrifuged as before, resuspended in complete RPMI media (5 ml per mouse spleen), filtered through a cell strainer and counted using a hemacytometer. Block media was decanted from the plates and to each well, 100 μL of cell samples (5x10^5 cells per well) and 100 μL of the antigen

15   solution were added. To the control well, 100 μL of the media were added; for specific responses, peptide pools containing either CD4$^+$ or CD8$^+$ epitopes were added. In all cases, a final concentration of 4 μg/mL per peptide was used. Each sample/antigen mixture were performed in triplicate wells. Plates were incubated at 37°C, 5% CO_2, 90% humidity for 20-24 h. The plates were washed with PBS/0.05%

20   Tween 20 and incubated with 100 μL/well of 1.25 μg/mL biotin-conjugated rat anti-mouse IFN-γ mAb, clone XMG1.2 (Pharmingen) at 4°C overnight. The plates were washed and incubated with 100 μL/well 1/2500 dilution of strepavidin-alkaline phosphatase conjugate (Pharmingen) in PBS/0.005% Tween/5% FBS for 30 min at 37 °C. Following a wash, spots were developed by incubating with 100 μl/well 1-step

25   NBT/BCIP (Pierce Chemicals) for 6-10 min. The plates were washed with water and allowed to air dry. The number of spots in each well was determined using a dissecting microscope and the data normalized to 10^6 cell input.

Results - In vitro expression of Pol in mammalian cells - Heterologous expression of the optimized wt or IA pol genes (V1R-wt-pol (codon optimized),

30   V1Jns-IApol (codon optimized), V1Jns-tpa-IApol (codon optimized)) in 293 cells (Figure 8) yielded a single polypeptide of correct approximate molecular size (90-kDa) for the RT-IN fusion product. In contrast, no expression could be detected by transfecting cells with 1 and 10 μg of the V1Jns-wt-pol, which bears the virus-derived *pol*.

-64-

Ultrasensitive RT assay of cells transfected with Pol constructs - Table 4
summarizes the levels of polymerase activity from mock (vector only) control, IApol
(codon optimized)and wt-pol plasmids (codon optimized). Results indicate that the
wild-type POL transfected cells contained RT activity approximately 4-5 logs higher
than the 293 cell only baseline values. Mock transfected cells contained activity no
higher than baseline values. The RT activity from opt-IApol-transfected cells was
also found to be no different than baseline values; no individual reaction tube resulted
in RT activity higher than the established cut-off value of 56.

Table 4

Sample	Avg. RT/tube	Standard deviation	Minimum	Maximum
Vector only	16.25	18.52	0.0	42.99
IApol (codon optimized)	2.99	8.01	0.0	35.20
Wt-pol (codon optimized)	126147	21338	68973	152007

Comparative immunogenicity of optimized and virus-derived pol plasmid - To
compare the *in vivo* potencies of both constructs, BALB/c mice (N=10 per group)
were vaccinated with escalating doses (1, 10, 100 µg) of either V1Jns-wt-pol (virus
derived) or V1R-wt-pol (codon optimized). At 5 wks post dose 1, 5 of 10 animals
were randomly boosted with the same vaccine and dose they received initially.
Figure 9 shows the geometric mean titers of the BALB/c cohorts determined at 2 wks
past boost. No significant anti-RT titers can be observed from animals immunized
with one or two doses of the wt-pol plasmid (virus derived). In contrast, animals
vaccinated with the humanized gene construct gave cohort anti-RT titers (>1000)
significantly above background levels at doses above 10 ug. The responses seen at 10
and 100 ug dose of V1R-wt-pol (codon optimized) were boosted approximately
10-fold with a second immunization, reaching titers as high as 10^6.
Spleens from all mice in each of the cohorts were collected to be analyzed for IFN-γ
secretion following stimulation with mixtures of either CD4+ peptide epitopes or
CD8+ peptide epitopes. The results are shown in Figure 10. All wt-pol vaccinees did

not show any significant cellular response above the background controls. In contrast, strong antigen-stimulated IFN-γ secretion were observed in a dose-responsive manner from animals vaccinated with one or two doses of 10 or more μg of the wt-pol (codon optimized) construct.

5   The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims.

10

WHAT IS CLAIMED IS:

1.   A pharmaceutically acceptable DNA vaccine composition, which comprises:

(a)   a DNA expression vector; and,

5   (b)   a DNA molecule containing a codon optimized open reading frame encoding a Pol protein or inactivated Pol derivative thereof, wherein upon administration of the DNA vaccine to a host the Pol protein or inactivated Pol derivative is expressed and generates a cellular immune response against HIV-1 infection.

10

2.   The DNA vaccine of claim 1 wherein the DNA molecule encodes wild type Pol.

3.   The DNA vaccine of claim 2 wherein the DNA molecule comprises
15   the nucleotide sequence as set forth in SEQ ID NO:1.

4.   The DNA vaccine of claim 3 which is V1Jns-wt-pol.

5.   The DNA vaccine of claim 1 wherein the DNA molecule encodes an
20   inactivated Pol derivative which contains a nucleotide sequence encoding a human tissue plasminogen activator leader peptide.

6..   The DNA vaccine of claim 5 wherein the DNA molecule comprises the nucleotide sequence as set forth in SEQ ID NO:5

25

7.   The DNA vaccine of claim 6 which is V1Jns-tPA-wt-pol.

8.   The DNA vaccine of claim 1 wherein the inactivated Pol protein contains at least one amino acid modification within each region of the Pol protein
30   responsible for reverse transcriptase activity, RNase H activity and integrase activity, such that the inactivated Pol protein shows no substantial reverse transcriptase activity, RNase H activity and integrase activity.

9.   The DNA vaccine of claim 8 wherein the DNA molecule comprises the nucleotide sequence as set forth in SEQ ID NO:3

10.   The DNA vaccine of claim 9 which is V1Jns-IAPol.

11.   The DNA vaccine of claim 8 wherein the DNA molecule encodes an inactivated Pol derivative which contains a nucleotide sequence encoding a human tissue plasminogen activator leader peptide.

12.   The DNA vaccine of claim 11 wherein the DNA molecule comprises the nucleotide sequence as set forth in SEQ ID NO:7.

13.   The DNA vaccine of claim 7 which is V1Jns-tPA-IAPol.

14.   A method for inducing an immune response against infection or disease caused by virulent strains of HIV which comprises administering into the tissue of a mammalian host a pharmaceutically acceptable DNA vaccine composition which comprises a DNA expression vector and a DNA molecule containing a codon optimized open reading frame encoding a Pol protein or inactivated Pol derivative thereof, wherein upon administration of the DNA vaccine to the vertebrate host the Pol protein or inactivated Pol derivative is expressed and generates the immune response.

15.   The method of claim 16 wherein the mammalian host is a human.

16.   The method of claim 17 wherein the DNA vaccine is selected from the group consisting of V1Jns-WTPol, V1Jns-tPA-WTPol, V1Jns-IAPol and V1Jns-tPA-IAPol.

17.   A substantially purified protein which comprises an amino acid sequence selected from the group consisting of SEQ ID NO:4, SEQ ID NO:6, and SEQ ID NO:8.

FIG.1A

FIG.1B

AGATCTACCATGGCCCCCATCTCCCCCATTGAGACTGTGCCTGTGAAGCTGAAGCCTGGCATGGATGGCCCCAAGGTGAA
BglII   MetAlaProIleSerProIleGluThrValProValLysLeuLysProGlyMetAspGlyProLysValLy
1   10   20

GCAGTGGCCCCTGACTGAGGAGAAGATCAAGGCCCTGGTGGAAATCTGCACTGAGATGGAGAAGGAGGGCAAAATCTCCA
sGlnTrpProLeuThrGluGluLysIleLysAlaLeuValGluIleCysThrGluMetGluLysGluGlyLysIleSerL
30   40   50

AGATTGGCCCCGAGAACCCCTACAACACCCCTGTGTTTGCCATCAAGAAGAAGGACTCCACCAAGTGGAGGAAGCTGGTG
ysIleGlyProGluAsnProTyrAsnThrProValPheAlaIleLysLysLysAspSerThrLysTrpArgLysLeuVal
60   70

GACTTCAGGGAGCTGAACAAGAGGACCCAGGACTTCTGGGAGGTGCAGCTGGGCATCCCCCACCCCGCTGGCCTGAAGAA
AspPheArgGluLeuAsnLysArgThrGlnAspPheTrpGluValGlnLeuGlyIleProHisProAlaGlyLeuLysLy
80   90   100

GAAGAAGTCTGTGACTGTGCTGGCTGTGGGGGGATGCCTACTTCTCTGTGCCCCTGGATGAGGACTTCAGGAAGTACACTG
sLysLysSerValThrValLeuAlaValGlyAspAlaTyrPheSerValProLeuAspGluAspPheArgLysTyrThrA
110   120   130

CCTTCACCATCCCCTCCATCAACAATGAGACCCCTGGCATCAGGTACCAGTACAATGTGCTGCCCCAGGGCTGGAAGGGC
laPheThrIleProSerIleAsnAsnGluThrProGlyIleArgTyrGlnTyrAsnValLeuProGlnGlyTrpLysGly
140   150

TCCCCTGCCATCTTCCAGTCCTCCATGACCAAGATCCTGGAGCCCTTCAGGAAGCAGAACCCTGACATTGTGATCTACCA
SerProAlaIlePheGlnSerSerMetThrLysIleLeuGluProPheArgLysGlnAsnProAspIleValIleTyrGl
160   170   180

GTACATGGCTGCCCTGTATGTGGGCTCTGACCTGGAGATTGGGCAGCACAGGACCAAGATTGAGGAGCTGAGGCAGCACC
nTyrMetAlaAlaLeuTyrValGlySerAspLeuGluIleGlyGlnHisArgThrLysIleGluGluLeuArgGlnHisL
190   200   210

TGCTGAGGTGGGGCCTGACCACCCCTGACAAGAAGCACCAGAAGGAGCCCCCCTTCCTGTGGATGGGCTATGAGCTGCAC
euLeuArgTrpGlyLeuThrThrProAspLysLysHisGlnLysGluProProPheLeuTrpMetGlyTyrGluLeuHis
220   230

CCCGACAAGTGGACTGTGCAGCCCATTGTGCTGCCTGAGAAGGACTCCTGGACTGTGAATGACATCCAGAAGCTGGTGGG
ProAspLysTrpThrValGlnProIleValLeuProGluLysAspSerTrpThrValAsnAspIleGlnLysLeuValGl
240   250   260

CAAGCTGAACTGGGCCTCCCAAATCTACCCTGGCATCAAGGTGAGGCAGCTGTGCAAGCTGCTGAGGGGCACCAAGGCCC
yLysLeuAsnTrpAlaSerGlnIleTyrProGlyIleLysValArgGlnLeuCysLysLeuLeuArgGlyThrLysAlaL
270   280   290

FIG.2A

TGACTGAGGTGATCCCCCTGACTGAGGAGGCTGAGCTGGAGCTGGCTGAGAACAGGGAGATCCTGAAGGAGCCTGTGCAT
EuThrGluValIleProLeuThrGluGluAlaGluLeuGluLeuAlaGluAsnArgGluIleLeuLysGluProValHis
                    300   310

GGGGTGTACTATGACCCCTCCAAGGACCTGATTGCTGAGATCCAGAAGCAGGGCCAGGGCCAGTGGACCTACCAAATCTA
GlyValTyrTyrAspProSerLysAspLeuIleAlaGluIleGlnLysGlnGlyGlnGlyGlnTrpThrTyrGlnIleTy
        320   330   340

CCAGGAGCCCTTCAAGAACCTGAAGACTGGCAAGTATGCCAGGATGAGGGGGGGCCCACACCAATGATGTGAAGCAGCTGA
rGlnGluProPheLysAsnLeuLysThrGlyLysTyrAlaArgMetArgGlyAlaHisThrAsnAspValLysGlnLeuT
            350   360   370

CTGAGGCTGTGCAGAAGATCACCACTGAGTCCATTGTGATCTGGGGCAAGACCCCCAAGTTCAAGCTGCCCATCCAGAAG
hrGluAlaValGlnLysIleThrThrGluSerIleValIleTrpGlyLysThrProLysPheLysLeuProIleGlnLys
                    380   390

GAGACCTGGGAGACCTGGTGGACTGAGTACTGGCAGGCCACCTGGATCCCTGAGTGGGAGTTTGTGAACACCCCCCCCCT
GluThrTrpGluThrTrpTrpThrGluTyrTrpGlnAlaThrTrpIleProGluTrpGluPheValAsnThrProProLe
        400   410   420

GGTGAAGCTGTGGTACCAGCTGGAGAAGGAGCCCATTGTGGGGGGCTGAGACCTTCTATGTGGCTGGGGGCTGCCAACAGGG
uValLysLeuTrpTyrGlnLeuGluLysGluProIleValGlyAlaGluThrPheTyrValAlaGlyAlaAlaAsnArgG
            430   440   450

AGACCAAGCTGGGCAAGGCTGGCTATGTGACCAACAGGGGCAGGCAGAAGGTGGTGACCCTGACTGACACCACCAACCAG
luThrLysLeuGlyLysAlaGlyTyrValThrAsnArgGlyArgGlnLysValValThrLeuThrAspThrThrAsnGln
                    460   470

AAGACTGCCCTCCAGGCCATCTACCTGGCCCTCCAGGACTCTGGCCTGGAGGTGAACATTGTGACTGCCTCCCAGTATGC
LysThrAlaLeuGlnAlaIleTyrLeuAlaLeuGlnAspSerGlyLeuGluValAsnIleValThrAlaSerGlnTyrAl
        480   490   500

CCTGGGCATCATCCAGGCCCAGCCTGATCAGTCTGAGTCTGAGCTGGTGAACCAGATCATTGAGCAGCTGATCAAGAAGG
aLeuGlyIleIleGlnAlaGlnProAspGlnSerGluSerGluLeuValAsnGlnIleIleGluGlnLeuIleLysLysG
            510   520   530

AGAAGGTGTACCTGGCCTGGGTGCCTGCCCACAAGGGCATTGGGGGCAATGAGCAGGTGGACAAGCTGGTGTCTGCTGGC
luLysValTyrLeuAlaTrpValProAlaHisLysGlyIleGlyGlyAsnGluGlnValAspLysLeuValSerAlaGly
                    540   550

ATCAGGAAGGTGCTGTTCCTGGATGGCATTGACAAGGCCCAGGATGAGCATGAGAAGTACCACTCCAACTGGAGGGCTAT
IleArgLysValLeuPheLeuAspGlyIleAspLysAlaGlnAspGluHisGluLysTyrHisSerAsnTrpArgAlaMe
        560   570   580

FIG.2B

GGCCTCTGACTTCAACCTGCCCCCTGTGGTGGCTAAGGAGATTGTGGCCTCCTGTGACAAGTGCCAGCTGAAGGGGGAGG
tAloSerAspPheAsnLeuProProValValAloLysGluIleValAloSerCysAspLysCysGlnLeuLysGlyGluA
   590   600   610

CCATGCATGGGCAGGTGGACTGCTCCCCTGGCATCTGGCAGCTGGCCTGCACCCACCTGGAGGGCAAGGTGATCCTGGTG
loMetHisGlyGlnValAspCysSerProGlyIleTrpGlnLeuAloCysThrHisLeuGluGlyLysValIleLeuVal
    620   630

GCTGTGCATGTGGCCTCCGGCTACATTGAGGCTGAGGTGATCCCTGCTGAGACAGGCCAGGAGACTGCCTACTTCCTGCT
AloValHisValAloSerGlyTyrIleGluAloGluValIleProAloGluThrGlyGlnGluThrAloTyrPheLeuLe
   640   650   660

GAAGCTGGCTGGCAGGTGGCCTGTGAAGACCATCCACACTGCCAATGGCTCCAACTTCACTGGGGCCACAGTGAGGGCTG
uLysLeuAloGlyArgTrpProValLysThrIleHisThrAloAsnGlySerAsnPheThrGlyAloThrValArgAloA
    670   680   690

CCTGCTGGTGGGCTGGCATCAAGCAGGAGTTTGGCATCCCCTACAACCCCCAGTCCCAGGGGGTGGTGGCCTCCATGAAC
loCysTrpTrpAloGlyIleLysGlnGluPheGlyIleProTyrAsnProGlnSerGlnGlyValValAloSerMetAsn
     700   710

AAGGAGCTGAAGAAGATCATTGGGCAGGTGAGGGACCAGGCTGAGCACCTGAAGACAGCTGTGCAGATGGCTGTGTTCAT
LysGluLeuLysLysIleIleGlyGlnValArgAspGlnAloGluHisLeuLysThrAloValGlnMetAloValPheIl
   720   730   740

CCACAACTTCAAGAGGAAGGGGGGCATCGGGGGGCTACTCCGCTGGGGAGAGGATTGTGGACATCATTGCCACAGACATCC
eHisAsnPheLysArgLysGlyGlyIleGlyGlyTyrSerAloGlyGluArgIleValAspIleIleAloThrAspIleG
   750   760   770

AGACCAAGGAGCTCCAGAAGCAGATCACCAAGATCCAGAACTTCAGGGTGTACTACAGGGACTCCAGGAACCCCCTGTGG
InThrLysGluLeuGlnLysGlnIleThrLysIleGlnAsnPheArgValTyrTyrArgAspSerArgAsnProLeuTrp
    780   790

AAGGGCCCTGCCAAGCTGCTGTGGAAGGGGGAGGGGGCTGTGGTGATCCAGGACAACTCTGACATCAAGGTGGTGCCCAG
LysGlyProAloLysLeuLeuTrpLysGlyGluGlyAloValValIleGlnAspAsnSerAspIleLysValValProAr
 800   810   820

GAGGAAGGCCAAGATCATCAGGGACTATGGCAAGCAGATGGCTGGGGATGACTGTGTGGCCTCCAGGCAGGATGAGGACT
gArgLysAloLysIleIleArgAspTyrGlyLysGlnMetAloGlyAspAspCysValAloSerArgGlnAspGluAspx
   830   840   850

AAAGCCCGGGCAGATCT (SEQ ID NO: 3)
Xx   BglII

FIG.2C

GATCACCATGGATGCAATGAAGAGAGGCCTCTGCTGTGTGCTGCTGTGTGGAGCAGTCTTCGTTTCGC
MetAspAlaMetLysArgGlyLeuCysCysValLeuLeuLeuCysGlyAlaValPheValSerP
-25   -20   -10

CCAGCGAGATCTCCGCCCCATCTCCCCATTGAGACTGTGCCTGTGAAGCTGGCATGGATGGC   (within SEQ ID NO: 7)
RoSerGluIleSerProIleGluThrValProValLysLeuProGlyMetAspGly   (within SEQ ID NO: 8)
-1   2   10   20

FIG.3

FIG.4

FIG.5

FIG.6A

FIG.6B

FIG.6C

FIG.7A

FIG.7B

FIG.8

FIG.9

FIG.10

SEQUENCE LISTING

<110> Merck & Co., Inc.

<120> POLYNUCLEOTIDE VACCINES EXPRESSING CODON
      OPTIMIZED HIV-1 POL AND MODIFIED HIV-1 POL

<130> 20608Y PCT

<160> 30

<170> FastSEQ for Windows Version 4.0

<210> 1
<211> 2577
<212> DNA
<213> Human Immunodeficiency Virus-1

<220>
<221> CDS
<222> (10)...(2562)

<400> 1
agatctacc atg gcc ccc atc tcc ccc att gag act gtg cct gtg aag ctg   51
          Met Ala Pro Ile Ser Pro Ile Glu Thr Val Pro Val Lys Leu
           1   5   10

aag cct ggc atg gat ggc ccc aag gtg aag cag tgg ccc ctg act gag   99
Lys Pro Gly Met Asp Gly Pro Lys Val Lys Gln Trp Pro Leu Thr Glu
 15   20   25   30

gag aag atc aag gcc ctg gtg gaa atc tgc act gag atg gag aag gag   147
Glu Lys Ile Lys Ala Leu Val Glu Ile Cys Thr Glu Met Glu Lys Glu
              35   40   45

ggc aaa atc tcc aag att ggc ccc gag aac ccc tac aac acc cct gtg   195
Gly Lys Ile Ser Lys Ile Gly Pro Glu Asn Pro Tyr Asn Thr Pro Val
              50   55   60

ttt gcc atc aag aag aag gac tcc acc aag tgg agg aag ctg gtg gac   243
Phe Ala Ile Lys Lys Lys Asp Ser Thr Lys Trp Arg Lys Leu Val Asp
          65   70   75

ttc agg gag ctg aac aag agg acc cag gac ttc tgg gag gtg cag ctg   291
Phe Arg Glu Leu Asn Lys Arg Thr Gln Asp Phe Trp Glu Val Gln Leu
     80   85   90

ggc atc ccc cac ccc gct ggc ctg aag aag aag aag tct gtg act gtg   339
Gly Ile Pro His Pro Ala Gly Leu Lys Lys Lys Lys Ser Val Thr Val
 95   100   105   110

ctg gat gtg ggg gat gcc tac ttc tct gtg ccc ctg gat gag gac ttc   387
Leu Asp Val Gly Asp Ala Tyr Phe Ser Val Pro Leu Asp Glu Asp Phe
                115   120   125

agg aag tac act gcc ttc acc atc ccc tcc atc aac aat gag acc cct   435
Arg Lys Tyr Thr Ala Phe Thr Ile Pro Ser Ile Asn Asn Glu Thr Pro
                130   135   140

ggc atc agg tac cag tac aat gtg ctg ccc cag ggc tgg aag ggc tcc   483
Gly Ile Arg Tyr Gln Tyr Asn Val Leu Pro Gln Gly Trp Lys Gly Ser
        145   150   155

cct gcc atc ttc cag tcc tcc atg acc aag atc ctg gag ccc ttc agg   531
Pro Ala Ile Phe Gln Ser Ser Met Thr Lys Ile Leu Glu Pro Phe Arg
    160   165   170

aag cag aac cct gac att gtg atc tac cag tac atg gat gac ctg tat   579
Lys Gln Asn Pro Asp Ile Val Ile Tyr Gln Tyr Met Asp Asp Leu Tyr
175   180   185   190

gtg ggc tct gac ctg gag att ggg cag cac agg acc aag att gag gag   627
Val Gly Ser Asp Leu Glu Ile Gly Gln His Arg Thr Lys Ile Glu Glu
            195   200   205

ctg agg cag cac ctg ctg agg tgg ggc ctg acc acc cct gac aag aag   675
Leu Arg Gln His Leu Leu Arg Trp Gly Leu Thr Thr Pro Asp Lys Lys
        210   215   220

cac cag aag gag ccc ccc ttc ctg tgg atg ggc tat gag ctg cac ccc   723
His Gln Lys Glu Pro Pro Phe Leu Trp Met Gly Tyr Glu Leu His Pro
        225   230   235

gac aag tgg act gtg cag ccc att gtg ctg cct gag aag gac tcc tgg   771
Asp Lys Trp Thr Val Gln Pro Ile Val Leu Pro Glu Lys Asp Ser Trp
    240   245   250

act gtg aat gac atc cag aag ctg gtg ggc aag ctg aac tgg gcc tcc   819
Thr Val Asn Asp Ile Gln Lys Leu Val Gly Lys Leu Asn Trp Ala Ser
255   260   265   270

caa atc tac cct ggc atc aag gtg agg cag ctg tgc aag ctg ctg agg   867
Gln Ile Tyr Pro Gly Ile Lys Val Arg Gln Leu Cys Lys Leu Leu Arg
                275   280   285

ggc acc aag gcc ctg act gag gtg atc ccc ctg act gag gag gct gag   915
Gly Thr Lys Ala Leu Thr Glu Val Ile Pro Leu Thr Glu Glu Ala Glu
            290   295   300

ctg gag ctg gct gag aac agg gag atc ctg aag gag cct gtg cat ggg   963
Leu Glu Leu Ala Glu Asn Arg Glu Ile Leu Lys Glu Pro Val His Gly
        305   310   315

gtg tac tat gac ccc tcc aag gac ctg att gct gag atc cag aag cag   1011
Val Tyr Tyr Asp Pro Ser Lys Asp Leu Ile Ala Glu Ile Gln Lys Gln
    320   325   330

ggc cag ggc cag tgg acc tac caa atc tac cag gag ccc ttc aag aac   1059
Gly Gln Gly Gln Trp Thr Tyr Gln Ile Tyr Gln Glu Pro Phe Lys Asn
335   340   345   350

ctg aag act ggc aag tat gcc agg atg agg ggg gcc cac acc aat gat   1107
Leu Lys Thr Gly Lys Tyr Ala Arg Met Arg Gly Ala His Thr Asn Asp
                355   360   365

gtg aag cag ctg act gag gct gtg cag aag atc acc act gag tcc att   1155
Val Lys Gln Leu Thr Glu Ala Val Gln Lys Ile Thr Thr Glu Ser Ile
            370   375   380

```
gtg atc tgg ggc aag acc ccc aag ttc aag ctg ccc atc cag aag gag      1203
Val Ile Trp Gly Lys Thr Pro Lys Phe Lys Leu Pro Ile Gln Lys Glu
        385                 390                 395

acc tgg gag acc tgg tgg act gag tac tgg cag gcc acc tgg atc cct      1251
Thr Trp Glu Thr Trp Trp Thr Glu Tyr Trp Gln Ala Thr Trp Ile Pro
        400                 405                 410

gag tgg gag ttt gtg aac acc ccc ccc ctg gtg aag ctg tgg tac cag      1299
Glu Trp Glu Phe Val Asn Thr Pro Pro Leu Val Lys Leu Trp Tyr Gln
415                 420                 425                 430

ctg gag aag gag ccc att gtg ggg gct gag acc ttc tat gtg gat ggg      1347
Leu Glu Lys Glu Pro Ile Val Gly Ala Glu Thr Phe Tyr Val Asp Gly
                435                 440                 445

gct gcc aac agg gag acc aag ctg ggc aag gct ggc tat gtg acc aac      1395
Ala Ala Asn Arg Glu Thr Lys Leu Gly Lys Ala Gly Tyr Val Thr Asn
                450                 455                 460

agg ggc agg cag aag gtg gtg acc ctg act gac acc acc aac cag aag      1443
Arg Gly Arg Gln Lys Val Val Thr Leu Thr Asp Thr Thr Asn Gln Lys
                465                 470                 475

act gag ctc cag gcc atc tac ctg gcc ctc cag gac tct ggc ctg gag      1491
Thr Glu Leu Gln Ala Ile Tyr Leu Ala Leu Gln Asp Ser Gly Leu Glu
        480                 485                 490

gtg aac att gtg act gac tcc cag tat gcc ctg ggc atc atc cag gcc      1539
Val Asn Ile Val Thr Asp Ser Gln Tyr Ala Leu Gly Ile Ile Gln Ala
495                 500                 505                 510

cag cct gat cag tct gag tct gag ctg gtg aac cag atc att gag cag      1587
Gln Pro Asp Gln Ser Glu Ser Glu Leu Val Asn Gln Ile Ile Glu Gln
                515                 520                 525

ctg atc aag aag gag aag gtg tac ctg gcc tgg gtg cct gcc cac aag      1635
Leu Ile Lys Lys Glu Lys Val Tyr Leu Ala Trp Val Pro Ala His Lys
                530                 535                 540

ggc att ggg ggc aat gag cag gtg gac aag ctg gtg tct gct ggc atc      1683
Gly Ile Gly Gly Asn Glu Gln Val Asp Lys Leu Val Ser Ala Gly Ile
                545                 550                 555

agg aag gtg ctg ttc ctg gat ggc att gac aag gcc cag gat gag cat      1731
Arg Lys Val Leu Phe Leu Asp Gly Ile Asp Lys Ala Gln Asp Glu His
        560                 565                 570

gag aag tac cac tcc aac tgg agg gct atg gcc tct gac ttc aac ctg      1779
Glu Lys Tyr His Ser Asn Trp Arg Ala Met Ala Ser Asp Phe Asn Leu
575                 580                 585                 590

ccc cct gtg gtg gct aag gag att gtg gcc tcc tgt gac aag tgc cag      1827
Pro Pro Val Val Ala Lys Glu Ile Val Ala Ser Cys Asp Lys Cys Gln
                595                 600                 605

ctg aag ggg gag gcc atg cat ggg cag gtg gac tgc tcc cct ggc atc      1875
Leu Lys Gly Glu Ala Met His Gly Gln Val Asp Cys Ser Pro Gly Ile
                610                 615                 620
```

```
tgg cag ctg gac tgc acc cac ctg gag ggc aag gtg atc ctg gtg gct     1923
Trp Gln Leu Asp Cys Thr His Leu Glu Gly Lys Val Ile Leu Val Ala
        625             630                 635

gtg cat gtg gcc tcc ggc tac att gag gct gag gtg atc cct gct gag     1971
Val His Val Ala Ser Gly Tyr Ile Glu Ala Glu Val Ile Pro Ala Glu
    640             645                 650

aca ggc cag gag act gcc tac ttc ctg ctg aag ctg gct ggc agg tgg     2019
Thr Gly Gln Glu Thr Ala Tyr Phe Leu Leu Lys Leu Ala Gly Arg Trp
655             660                 665                 670

cct gtg aag acc atc cac act gac aat ggc tcc aac ttc act ggg gcc     2067
Pro Val Lys Thr Ile His Thr Asp Asn Gly Ser Asn Phe Thr Gly Ala
                675                 680                 685

aca gtg agg gct gcc tgc tgg tgg gct ggc atc aag cag gag ttt ggc     2115
Thr Val Arg Ala Ala Cys Trp Trp Ala Gly Ile Lys Gln Glu Phe Gly
            690                 695                 700

atc ccc tac aac ccc cag tcc cag ggg gtg gtg gag tcc atg aac aag     2163
Ile Pro Tyr Asn Pro Gln Ser Gln Gly Val Val Glu Ser Met Asn Lys
        705                 710                 715

gag ctg aag aag atc att ggg cag gtg agg gac cag gct gag cac ctg     2211
Glu Leu Lys Lys Ile Ile Gly Gln Val Arg Asp Gln Ala Glu His Leu
    720                 725                 730

aag aca gct gtg cag atg gct gtg ttc atc cac aac ttc aag agg aag     2259
Lys Thr Ala Val Gln Met Ala Val Phe Ile His Asn Phe Lys Arg Lys
735                 740                 745                 750

ggg ggc atc ggg ggc tac tcc gct ggg gag agg att gtg gac atc att     2307
Gly Gly Ile Gly Gly Tyr Ser Ala Gly Glu Arg Ile Val Asp Ile Ile
                755                 760                 765

gcc aca gac atc cag acc aag gag ctc cag aag cag atc acc aag atc     2355
Ala Thr Asp Ile Gln Thr Lys Glu Leu Gln Lys Gln Ile Thr Lys Ile
                770                 775                 780

cag aac ttc agg gtg tac tac agg gac tcc agg aac ccc ctg tgg aag     2403
Gln Asn Phe Arg Val Tyr Tyr Arg Asp Ser Arg Asn Pro Leu Trp Lys
            785                 790                 795

ggc cct gcc aag ctg ctg tgg aag ggg gag ggg gct gtg gtg atc cag     2451
Gly Pro Ala Lys Leu Leu Trp Lys Gly Glu Gly Ala Val Val Ile Gln
        800                 805                 810

gac aac tct gac atc aag gtg gtg ccc agg agg aag gcc aag atc atc     2499
Asp Asn Ser Asp Ile Lys Val Val Pro Arg Arg Lys Ala Lys Ile Ile
815                 820                 825                 830

agg gac tat ggc aag cag atg gct ggg gat gac tgt gtg gcc tcc agg     2547
Arg Asp Tyr Gly Lys Gln Met Ala Gly Asp Asp Cys Val Ala Ser Arg
                835                 840                 845

cag gat gag gac taa agcccgggca gatct                                2577
Gln Asp Glu Asp *
                850
```

<210> 2

-4-

<211> 850
<212> PRT
<213> Human Immunodeficiency Virus-1

<400> 2
```
Met Ala Pro Ile Ser Pro Ile Glu Thr Val Pro Val Lys Leu Lys Pro
 1               5                  10                  15
Gly Met Asp Gly Pro Lys Val Lys Gln Trp Pro Leu Thr Glu Glu Lys
                20                  25                  30
Ile Lys Ala Leu Val Glu Ile Cys Thr Glu Met Glu Lys Glu Gly Lys
        35                  40                  45
Ile Ser Lys Ile Gly Pro Glu Asn Pro Tyr Asn Thr Pro Val Phe Ala
    50                  55                  60
Ile Lys Lys Lys Asp Ser Thr Lys Trp Arg Lys Leu Val Asp Phe Arg
65                  70                  75                  80
Glu Leu Asn Lys Arg Thr Gln Asp Phe Trp Glu Val Gln Leu Gly Ile
                85                  90                  95
Pro His Pro Ala Gly Leu Lys Lys Lys Ser Val Thr Val Leu Asp
            100                 105                 110
Val Gly Asp Ala Tyr Phe Ser Val Pro Leu Asp Glu Asp Phe Arg Lys
        115                 120                 125
Tyr Thr Ala Phe Thr Ile Pro Ser Ile Asn Asn Glu Thr Pro Gly Ile
    130                 135                 140
Arg Tyr Gln Tyr Asn Val Leu Pro Gln Gly Trp Lys Gly Ser Pro Ala
145                 150                 155                 160
Ile Phe Gln Ser Ser Met Thr Lys Ile Leu Glu Pro Phe Arg Lys Gln
                165                 170                 175
Asn Pro Asp Ile Val Ile Tyr Gln Tyr Met Asp Asp Leu Tyr Val Gly
                180                 185                 190
Ser Asp Leu Glu Ile Gly Gln His Arg Thr Lys Ile Glu Glu Leu Arg
        195                 200                 205
Gln His Leu Leu Arg Trp Gly Leu Thr Thr Pro Asp Lys Lys His Gln
    210                 215                 220
Lys Glu Pro Pro Phe Leu Trp Met Gly Tyr Glu Leu His Pro Asp Lys
225                 230                 235                 240
Trp Thr Val Gln Pro Ile Val Leu Pro Glu Lys Asp Ser Trp Thr Val
                245                 250                 255
Asn Asp Ile Gln Lys Leu Val Gly Lys Leu Asn Trp Ala Ser Gln Ile
                260                 265                 270
Tyr Pro Gly Ile Lys Val Arg Gln Leu Cys Lys Leu Leu Arg Gly Thr
        275                 280                 285
Lys Ala Leu Thr Glu Val Ile Pro Leu Thr Glu Glu Ala Glu Leu Glu
    290                 295                 300
Leu Ala Glu Asn Arg Glu Ile Leu Lys Glu Pro Val His Gly Val Tyr
305                 310                 315                 320
Tyr Asp Pro Ser Lys Asp Leu Ile Ala Glu Ile Gln Lys Gln Gly Gln
                325                 330                 335
Gly Gln Trp Thr Tyr Gln Ile Tyr Gln Glu Pro Phe Lys Asn Leu Lys
            340                 345                 350
Thr Gly Lys Tyr Ala Arg Met Arg Gly Ala His Thr Asn Asp Val Lys
        355                 360                 365
Gln Leu Thr Glu Ala Val Gln Lys Ile Thr Thr Glu Ser Ile Val Ile
    370                 375                 380
Trp Gly Lys Thr Pro Lys Phe Lys Leu Pro Ile Gln Lys Glu Thr Trp
385                 390                 395                 400
Glu Thr Trp Trp Thr Glu Tyr Trp Gln Ala Thr Trp Ile Pro Glu Trp
                405                 410                 415
Glu Phe Val Asn Thr Pro Pro Leu Val Lys Leu Trp Tyr Gln Leu Glu
                420                 425                 430
Lys Glu Pro Ile Val Gly Ala Glu Thr Phe Tyr Val Asp Gly Ala Ala
            435                 440                 445
```

```
Asn Arg Glu Thr Lys Leu Gly Lys Ala Gly Tyr Val Thr Asn Arg Gly
    450             455             460
Arg Gln Lys Val Val Thr Leu Thr Asp Thr Thr Asn Gln Lys Thr Glu
465             470             475             480
Leu Gln Ala Ile Tyr Leu Ala Leu Gln Asp Ser Gly Leu Glu Val Asn
            485             490             495
Ile Val Thr Asp Ser Gln Tyr Ala Leu Gly Ile Ile Gln Ala Gln Pro
            500             505             510
Asp Gln Ser Glu Ser Glu Leu Val Asn Gln Ile Ile Glu Gln Leu Ile
        515             520             525
Lys Lys Glu Lys Val Tyr Leu Ala Trp Val Pro Ala His Lys Gly Ile
    530             535             540
Gly Gly Asn Glu Gln Val Asp Lys Leu Val Ser Ala Gly Ile Arg Lys
545             550             555             560
Val Leu Phe Leu Asp Gly Ile Asp Lys Ala Gln Asp Glu His Glu Lys
            565             570             575
Tyr His Ser Asn Trp Arg Ala Met Ala Ser Asp Phe Asn Leu Pro Pro
            580             585             590
Val Val Ala Lys Glu Ile Val Ala Ser Cys Asp Lys Cys Gln Leu Lys
    595             600             605
Gly Glu Ala Met His Gly Gln Val Asp Cys Ser Pro Gly Ile Trp Gln
    610             615             620
Leu Asp Cys Thr His Leu Glu Gly Lys Val Ile Leu Val Ala Val His
625             630             635             640
Val Ala Ser Gly Tyr Ile Glu Ala Glu Val Ile Pro Ala Glu Thr Gly
            645             650             655
Gln Glu Thr Ala Tyr Phe Leu Leu Lys Leu Ala Gly Arg Trp Pro Val
        660             665             670
Lys Thr Ile His Thr Asp Asn Gly Ser Asn Phe Thr Gly Ala Thr Val
        675             680             685
Arg Ala Ala Cys Trp Trp Ala Gly Ile Lys Gln Glu Phe Gly Ile Pro
    690             695             700
Tyr Asn Pro Gln Ser Gln Gly Val Val Glu Ser Met Asn Lys Glu Leu
705             710             715             720
Lys Lys Ile Ile Gly Gln Val Arg Asp Gln Ala Glu His Leu Lys Thr
            725             730             735
Ala Val Gln Met Ala Val Phe Ile His Asn Phe Lys Arg Lys Gly Gly
            740             745             750
Ile Gly Gly Tyr Ser Ala Gly Glu Arg Ile Val Asp Ile Ile Ala Thr
        755             760             765
Asp Ile Gln Thr Lys Glu Leu Gln Lys Gln Ile Thr Lys Ile Gln Asn
770.             775             780
Phe Arg Val Tyr Tyr Arg Asp Ser Arg Asn Pro Leu Trp Lys Gly Pro
785             790             795             800
Ala Lys Leu Leu Trp Lys Gly Glu Gly Ala Val Val Ile Gln Asp Asn
            805             810             815
Ser Asp Ile Lys Val Val Pro Arg Arg Lys Ala Lys Ile Ile Arg Asp
            820             825             830
Tyr Gly Lys Gln Met Ala Gly Asp Asp Cys Val Ala Ser Arg Gln Asp
        835             840             845
Glu Asp
    850
```

<210> 3
<211> 2577
<212> DNA
<213> Human Immunodeficiency Virus-1

<220>
<221> CDS
<222> (10)...(2562)

```
<400> 3
agatctacc atg gcc ccc atc tcc ccc att gag act gtg cct gtg aag ctg        51
          Met Ala Pro Ile Ser Pro Ile Glu Thr Val Pro Val Lys Leu
           1           5                   10

aag cct ggc atg gat ggc ccc aag gtg aag cag tgg ccc ctg act gag        99
Lys Pro Gly Met Asp Gly Pro Lys Val Lys Gln Trp Pro Leu Thr Glu
15              20                  25                  30

gag aag atc aag gcc ctg gtg gaa atc tgc act gag atg gag aag gag       147
Glu Lys Ile Lys Ala Leu Val Glu Ile Cys Thr Glu Met Glu Lys Glu
                35                  40                  45

ggc aaa atc tcc aag att ggc ccc gag aac ccc tac aac acc cct gtg       195
Gly Lys Ile Ser Lys Ile Gly Pro Glu Asn Pro Tyr Asn Thr Pro Val
            50                  55                  60

ttt gcc atc aag aag aag gac tcc acc aag tgg agg aag ctg gtg gac       243
Phe Ala Ile Lys Lys Lys Asp Ser Thr Lys Trp Arg Lys Leu Val Asp
            65                  70                  75

ttc agg gag ctg aac aag agg acc cag gac ttc tgg gag gtg cag ctg       291
Phe Arg Glu Leu Asn Lys Arg Thr Gln Asp Phe Trp Glu Val Gln Leu
        80                  85                  90

ggc atc ccc cac ccc gct ggc ctg aag aag aag aag tct gtg act gtg       339
Gly Ile Pro His Pro Ala Gly Leu Lys Lys Lys Lys Ser Val Thr Val
95              100                 105                 110

ctg gct gtg ggg gat gcc tac ttc tct gtg ccc ctg gat gag gac ttc       387
Leu Ala Val Gly Asp Ala Tyr Phe Ser Val Pro Leu Asp Glu Asp Phe
                115                 120                 125

agg aag tac act gcc ttc acc atc ccc tcc atc aac aat gag acc cct       435
Arg Lys Tyr Thr Ala Phe Thr Ile Pro Ser Ile Asn Asn Glu Thr Pro
            130                 135                 140

ggc atc agg tac cag tac aat gtg ctg ccc cag ggc tgg aag ggc tcc       483
Gly Ile Arg Tyr Gln Tyr Asn Val Leu Pro Gln Gly Trp Lys Gly Ser
            145                 150                 155

cct gcc atc ttc cag tcc tcc atg acc aag atc ctg gag ccc ttc agg       531
Pro Ala Ile Phe Gln Ser Ser Met Thr Lys Ile Leu Glu Pro Phe Arg
160                 165                 170

aag cag aac cct gac att gtg atc tac cag tac atg gct gcc ctg tat       579
Lys Gln Asn Pro Asp Ile Val Ile Tyr Gln Tyr Met Ala Ala Leu Tyr
175                 180                 185                 190

gtg ggc tct gac ctg gag att ggg cag cac agg acc aag att gag gag       627
Val Gly Ser Asp Leu Glu Ile Gly Gln His Arg Thr Lys Ile Glu Glu
                195                 200                 205

ctg agg cag cac ctg ctg agg tgg ggc ctg acc acc cct gac aag aag       675
Leu Arg Gln His Leu Leu Arg Trp Gly Leu Thr Thr Pro Asp Lys Lys
            210                 215                 220

cac cag aag gag ccc ccc ttc ctg tgg atg ggc tat gag ctg cac ccc       723
His Gln Lys Glu Pro Pro Phe Leu Trp Met Gly Tyr Glu Leu His Pro
            225                 230                 235
```

```
gac aag tgg act gtg cag ccc att gtg ctg cct gag aag gac tcc tgg    771
Asp Lys Trp Thr Val Gln Pro Ile Val Leu Pro Glu Lys Asp Ser Trp
    240           245               250

act gtg aat gac atc cag aag ctg gtg ggc aag ctg aac tgg gcc tcc    819
Thr Val Asn Asp Ile Gln Lys Leu Val Gly Lys Leu Asn Trp Ala Ser
255               260               265               270

caa atc tac cct ggc atc aag gtg agg cag ctg tgc aag ctg ctg agg    867
Gln Ile Tyr Pro Gly Ile Lys Val Arg Gln Leu Cys Lys Leu Leu Arg
              275               280               285

ggc acc aag gcc ctg act gag gtg atc ccc ctg act gag gag gct gag    915
Gly Thr Lys Ala Leu Thr Glu Val Ile Pro Leu Thr Glu Glu Ala Glu
          290               295               300

ctg gag ctg gct gag aac agg gag atc ctg aag gag cct gtg cat ggg    963
Leu Glu Leu Ala Glu Asn Arg Glu Ile Leu Lys Glu Pro Val His Gly
          305               310               315

gtg tac tat gac ccc tcc aag gac ctg att gct gag atc cag aag cag    1011
Val Tyr Tyr Asp Pro Ser Lys Asp Leu Ile Ala Glu Ile Gln Lys Gln
    320               325               330

ggc cag ggc cag tgg acc tac caa atc tac cag gag ccc ttc aag aac    1059
Gly Gln Gly Gln Trp Thr Tyr Gln Ile Tyr Gln Glu Pro Phe Lys Asn
335               340               345               350

ctg aag act ggc aag tat gcc agg atg agg ggg gcc cac acc aat gat    1107
Leu Lys Thr Gly Lys Tyr Ala Arg Met Arg Gly Ala His Thr Asn Asp
              355               360               365

gtg aag cag ctg act gag gct gtg cag aag atc acc act gag tcc att    1155
Val Lys Gln Leu Thr Glu Ala Val Gln Lys Ile Thr Thr Glu Ser Ile
          370               375               380

gtg atc tgg ggc aag acc ccc aag ttc aag ctg ccc atc cag aag gag    1203
Val Ile Trp Gly Lys Thr Pro Lys Phe Lys Leu Pro Ile Gln Lys Glu
          385               390               395

acc tgg gag acc tgg tgg act gag tac tgg cag gcc acc tgg atc cct    1251
Thr Trp Glu Thr Trp Trp Thr Glu Tyr Trp Gln Ala Thr Trp Ile Pro
    400               405               410

gag tgg gag ttt gtg aac acc ccc ccc ctg gtg aag ctg tgg tac cag    1299
Glu Trp Glu Phe Val Asn Thr Pro Pro Leu Val Lys Leu Trp Tyr Gln
415               420               425               430

ctg gag aag gag ccc att gtg ggg gct gag acc ttc tat gtg gct ggg    1347
Leu Glu Lys Glu Pro Ile Val Gly Ala Glu Thr Phe Tyr Val Ala Gly
              435               440               445

gct gcc aac agg gag acc aag ctg ggc aag gct ggc tat gtg acc aac    1395
Ala Ala Asn Arg Glu Thr Lys Leu Gly Lys Ala Gly Tyr Val Thr Asn
              450               455               460

agg ggc agg cag aag gtg gtg acc ctg act gac acc acc aac cag aag    1443
Arg Gly Arg Gln Lys Val Val Thr Leu Thr Asp Thr Thr Asn Gln Lys
465               470               475
```

act gcc ctc cag gcc atc tac ctg gcc ctc cag gac tct ggc ctg gag   1491
Thr Ala Leu Gln Ala Ile Tyr Leu Ala Leu Gln Asp Ser Gly Leu Glu
    480   485   490

gtg aac att gtg act gcc tcc cag tat gcc ctg ggc atc atc cag gcc   1539
Val Asn Ile Val Thr Ala Ser Gln Tyr Ala Leu Gly Ile Ile Gln Ala
495   500   505   510

cag cct gat cag tct gag tct gag ctg gtg aac cag atc att gag cag   1587
Gln Pro Asp Gln Ser Glu Ser Glu Leu Val Asn Gln Ile Ile Glu Gln
                    515   520   525

ctg atc aag aag gag aag gtg tac ctg gcc tgg gtg cct gcc cac aag   1635
Leu Ile Lys Lys Glu Lys Val Tyr Leu Ala Trp Val Pro Ala His Lys
                530   535   540

ggc att ggg ggc aat gag cag gtg gac aag ctg gtg tct gct ggc atc   1683
Gly Ile Gly Gly Asn Glu Gln Val Asp Lys Leu Val Ser Ala Gly Ile
                545   550   555

agg aag gtg ctg ttc ctg gat ggc att gac aag gcc cag gat gag cat   1731
Arg Lys Val Leu Phe Leu Asp Gly Ile Asp Lys Ala Gln Asp Glu His
    560   565   570

gag aag tac cac tcc aac tgg agg gct atg gcc tct gac ttc aac ctg   1779
Glu Lys Tyr His Ser Asn Trp Arg Ala Met Ala Ser Asp Phe Asn Leu
575   580   585   590

ccc cct gtg gtg gct aag gag att gtg gcc tcc tgt gac aag tgc cag   1827
Pro Pro Val Val Ala Lys Glu Ile Val Ala Ser Cys Asp Lys Cys Gln
                595   600   605

ctg aag ggg gag gcc atg cat ggg cag gtg gac tgc tcc cct ggc atc   1875
Leu Lys Gly Glu Ala Met His Gly Gln Val Asp Cys Ser Pro Gly Ile
                610   615   620

tgg cag ctg gcc tgc acc cac ctg gag ggc aag gtg atc ctg gtg gct   1923
Trp Gln Leu Ala Cys Thr His Leu Glu Gly Lys Val Ile Leu Val Ala
                625   630   635

gtg cat gtg gcc tcc ggc tac att gag gct gag gtg atc cct gct gag   1971
Val His Val Ala Ser Gly Tyr Ile Glu Ala Glu Val Ile Pro Ala Glu
    640   645   650

aca ggc cag gag act gcc tac ttc ctg ctg aag ctg gct ggc agg tgg   2019
Thr Gly Gln Glu Thr Ala Tyr Phe Leu Leu Lys Leu Ala Gly Arg Trp
655   660   665   670

cct gtg aag acc atc cac act gcc aat ggc tcc aac ttc act ggg gcc   2067
Pro Val Lys Thr Ile His Thr Ala Asn Gly Ser Asn Phe Thr Gly Ala
                675   680   685

aca gtg agg gct gcc tgc tgg tgg gct ggc atc aag cag gag ttt ggc   2115
Thr Val Arg Ala Ala Cys Trp Trp Ala Gly Ile Lys Gln Glu Phe Gly
                690   695   700

atc ccc tac aac ccc cag tcc cag ggg gtg gtg gcc tcc atg aac aag   2163
Ile Pro Tyr Asn Pro Gln Ser Gln Gly Val Val Ala Ser Met Asn Lys
                705   710   715

```
gag ctg aag aag atc att ggg cag gtg agg gac cag gct gag cac ctg    2211
Glu Leu Lys Lys Ile Ile Gly Gln Val Arg Asp Gln Ala Glu His Leu
    720             .       725         .           730

aag aca gct gtg cag atg gct gtg ttc atc cac aac ttc aag agg aag    2259
Lys Thr Ala Val Gln Met Ala Val Phe Ile His Asn Phe Lys Arg Lys
735             740             745                 750

ggg ggc atc ggg ggc tac tcc gct ggg gag agg att gtg gac atc att    2307
Gly Gly Ile Gly Gly Tyr Ser Ala Gly Glu Arg Ile Val Asp Ile Ile
                755             760             765

gcc aca gac atc cag acc aag gag ctc cag aag cag atc acc aag atc    2355
Ala Thr Asp Ile Gln Thr Lys Glu Leu Gln Lys Gln Ile Thr Lys Ile
    .       770         .       .   775             780

cag aac ttc agg gtg tac tac agg gac tcc agg aac ccc ctg tgg aag    2403
Gln Asn Phe Arg Val Tyr Tyr Arg Asp Ser Arg Asn Pro Leu Trp Lys
        785             .   790             795

ggc cct gcc aag ctg ctg tgg aag ggg gag ggg gct gtg gtg atc cag    2451
Gly Pro Ala Lys Leu Leu Trp Lys Gly Glu Gly Ala Val Val Ile Gln
    800             .   805             810

gac aac tct gac atc aag gtg gtg ccc agg agg aag gcc aag atc atc    2499
Asp Asn Ser Asp Ile Lys Val Val Pro Arg Arg Lys Ala Lys Ile Ile
815             820             825             830

agg gac tat ggc aag cag atg gct ggg gat gac tgt gtg gcc tcc agg    2547
Arg Asp Tyr Gly Lys Gln Met Ala Gly Asp Asp Cys Val Ala Ser Arg
            835             840             845

cag gat gag gac taa agcccgggca gatct                              2577
Gln Asp Glu Asp *
            850
```

```
<210> 4
<211> 850
<212> PRT
<213> Human Immunodeficiency Virus-1

<400> 4
Met Ala Pro Ile Ser Pro Ile Glu Thr Val Pro Val Lys Leu Lys Pro
1               5               10              15
Gly Met Asp Gly Pro Lys Val Lys Gln Trp Pro Leu Thr Glu Glu Lys
            20              25              30
Ile Lys Ala Leu Val Glu Ile Cys Thr Glu Met Glu Lys Glu Gly Lys
        35              40              45
Ile Ser Lys Ile Gly Pro Glu Asn Pro Tyr Asn Thr Pro Val Phe Ala
    50              55              60
Ile Lys Lys Lys Asp Ser Thr Lys Trp Arg Lys Leu Val Asp Phe Arg
65              70              75              80
Glu Leu Asn Lys Arg Thr Gln Asp Phe Trp Glu Val Gln Leu Gly Ile
            85              90              95
Pro His Pro Ala Gly Leu Lys Lys Lys Lys Ser Val Thr Val Leu Ala
        100             105             110
Val Gly Asp Ala Tyr Phe Ser Val Pro Leu Asp Glu Asp Phe Arg Lys
    115             120             125
Tyr Thr Ala Phe Thr Ile Pro Ser Ile Asn Asn Glu Thr Pro Gly Ile
    130             135             140
```

```
Arg Tyr Gln Tyr Asn Val Leu Pro Gln Gly Trp Lys Gly Ser Pro Ala
145             150                 155                 160
Ile Phe Gln Ser Ser Met Thr Lys Ile Leu Glu Pro Phe Arg Lys Gln
            165                 170                 175
Asn Pro Asp Ile Val Ile Tyr Gln Tyr Met Ala Ala Leu Tyr Val Gly
            180                 185                 190
Ser Asp Leu Glu Ile Gly Gln His Arg Thr Lys Ile Glu Glu Leu Arg
        195                 200                 205
Gln His Leu Leu Arg Trp Gly Leu Thr Thr Pro Asp Lys Lys His Gln
210                 215                 220
Lys Glu Pro Pro Phe Leu Trp Met Gly Tyr Glu Leu His Pro Asp Lys
225                 230                 235                 240
Trp Thr Val Gln Pro Ile Val Leu Pro Glu Lys Asp Ser Trp Thr Val
            245                 250                 255
Asn Asp Ile Gln Lys Leu Val Gly Lys Leu Asn Trp Ala Ser Gln Ile
            260                 265                 270
Tyr Pro Gly Ile Lys Val Arg Gln Leu Cys Lys Leu Leu Arg Gly Thr
        275                 280                 285
Lys Ala Leu Thr Glu Val Ile Pro Leu Thr Glu Glu Ala Glu Leu Glu
290                 295                 300
Leu Ala Glu Asn Arg Glu Ile Leu Lys Glu Pro Val His Gly Val Tyr
305                 310                 315                 320
Tyr Asp Pro Ser Lys Asp Leu Ile Ala Glu Ile Gln Lys Gln Gly Gln
                325                 330                 335
Gly Gln Trp Thr Tyr Gln Ile Tyr Gln Glu Pro Phe Lys Asn Leu Lys
            340                 345                 350
Thr Gly Lys Tyr Ala Arg Met Arg Gly Ala His Thr Asn Asp Val Lys
            355                 360                 365
Gln Leu Thr Glu Ala Val Gln Lys Ile Thr Thr Glu Ser Ile Val Ile
    370                 375                 380
Trp Gly Lys Thr Pro Lys Phe Lys Leu Pro Ile Gln Lys Glu Thr Trp
385                 390                 395                 400
Glu Thr Trp Trp Thr Glu Tyr Trp Gln Ala Thr Trp Ile Pro Glu Trp
                405                 410                 415
Glu Phe Val Asn Thr Pro Pro Leu Val Lys Leu Trp Tyr Gln Leu Glu
            420                 425                 430
Lys Glu Pro Ile Val Gly Ala Glu Thr Phe Tyr Val Ala Gly Ala Ala
        435                 440                 445
Asn Arg Glu Thr Lys Leu Gly Lys Ala Gly Tyr Val Thr Asn Arg Gly
    450                 455                 460
Arg Gln Lys Val Val Thr Leu Thr Asp Thr Thr Asn Gln Lys Thr Ala
465                 470                 475                 480
Leu Gln Ala Ile Tyr Leu Ala Leu Gln Asp Ser Gly Leu Glu Val Asn
                485                 490                 495
Ile Val Thr Ala Ser Gln Tyr Ala Leu Gly Ile Ile Gln Ala Gln Pro
            500                 505                 510
Asp Gln Ser Glu Ser Glu Leu Val Asn Gln Ile Ile Glu Gln Leu Ile
        515                 520                 525
Lys Lys Glu Lys Val Tyr Leu Ala Trp Val Pro Ala His Lys Gly Ile
    530                 535                 540
Gly Gly Asn Glu Gln Val Asp Lys Leu Val Ser Ala Gly Ile Arg Lys
545                 550                 555                 560
Val Leu Phe Leu Asp Gly Ile Asp Lys Ala Gln Asp Glu His Glu Lys
                565                 570                 575
Tyr His Ser Asn Trp Arg Ala Met Ala Ser Asp Phe Asn Leu Pro Pro
            580                 585                 590
Val Val Ala Lys Glu Ile Val Ala Ser Cys Asp Lys Cys Gln Leu Lys
        595                 600                 605
Gly Glu Ala Met His Gly Gln Val Asp Cys Ser Pro Gly Ile Trp Gln
610                 615                 620
Leu Ala Cys Thr His Leu Glu Gly Lys Val Ile Leu Val Ala Val His
625                 630                 635                 640
```

```
Val Ala Ser Gly Tyr Ile Glu Ala Glu Val Ile Pro Ala Glu Thr Gly
              645                   650                   655
Gln Glu Thr Ala Tyr Phe Leu Leu Lys Leu Ala Gly Arg Trp Pro Val
              660                   665                   670
Lys Thr Ile His Thr Ala Asn Gly Ser Asn Phe Thr Gly Ala Thr Val
          675                   680                   685
Arg Ala Ala Cys Trp Trp Ala Gly Ile Lys Gln Glu Phe Gly Ile Pro
      690                   695                   700
Tyr Asn Pro Gln Ser Gln Gly Val Val Ala Ser Met Asn Lys Glu Leu
705                   710                   715                   720
Lys Lys Ile Ile Gly Gln Val Arg Asp Gln Ala Glu His Leu Lys Thr
                  725                   730                   735
Ala Val Gln Met Ala Val Phe Ile His Asn Phe Lys Arg Lys Gly Gly
              740                   745                   750
Ile Gly Gly Tyr Ser Ala Gly Glu Arg Ile Val Asp Ile Ile Ala Thr
          755                   760                   765
Asp Ile Gln Thr Lys Glu Leu Gln Lys Gln Ile Thr Lys Ile Gln Asn
      770                   775                   780
Phe Arg Val Tyr Tyr Arg Asp Ser Arg Asn Pro Leu Trp Lys Gly Pro
785                   790                   795                   800
Ala Lys Leu Leu Trp Lys Gly Glu Gly Ala Val Val Ile Gln Asp Asn
              805                   810                   815
Ser Asp Ile Lys Val Val Pro Arg Arg Lys Ala Lys Ile Ile Arg Asp
              820                   825                   830
Tyr Gly Lys Gln Met Ala Gly Asp Asp Cys Val Ala Ser Arg Gln Asp
          835                   840                   845
Glu Asp
    850
```

```
<210> 5
<211> 2650
<212> DNA
<213> Human Immunodeficiency Virus-1

<220>
<221> CDS
<222> (8)...(2635)

<400> 5
gatcacc atg gat gca atg aag aga ggg ctc tgc tgt gtg ctg ctg ctg        49
        Met Asp Ala Met Lys Arg Gly Leu Cys Cys Val Leu Leu Leu
        1               5                   10

tgt gga gca gtc ttc gtt tcg ccc agc gag atc tcc gcc ccc atc tcc        97
Cys Gly Ala Val Phe Val Ser Pro Ser Glu Ile Ser Ala Pro Ile Ser
15                   20                   25                   30

ccc att gag act gtg cct gtg aag ctg aag cct ggc atg gat ggc ccc       145
Pro Ile Glu Thr Val Pro Val Lys Leu Lys Pro Gly Met Asp Gly Pro
                35                   40                   45

aag gtg aag cag tgg ccc ctg act gag gag aag atc aag gcc ctg gtg       193
Lys Val Lys Gln Trp Pro Leu Thr Glu Glu Lys Ile Lys Ala Leu Val
            50                   55                   60

gaa atc tgc act gag atg gag aag gag ggc aaa atc tcc aag att ggc       241
Glu Ile Cys Thr Glu Met Glu Lys Glu Gly Lys Ile Ser Lys Ile Gly
            65                   70                   75

ccc gag aac ccc tac aac acc cct gtg ttt gcc atc aag aag aag gac       289
Pro Glu Asn Pro Tyr Asn Thr Pro Val Phe Ala Ile Lys Lys Lys Asp
        80                   85                   90
```

```
tcc acc aag tgg agg aag ctg gtg gac ttc agg gag ctg aac aag agg      337
Ser Thr Lys Trp Arg Lys Leu Val Asp Phe Arg Glu Leu Asn Lys Arg
 95             100              105              110

acc cag gac ttc tgg gag gtg cag ctg ggc atc ccc cac ccc gct ggc      385
Thr Gln Asp Phe Trp Glu Val Gln Leu Gly Ile Pro His Pro Ala Gly
               115              120              125

ctg aag aag aag aag tct gtg act gtg ctg gat gtg ggg gat gcc tac      433
Leu Lys Lys Lys Lys Ser Val Thr Val Leu Asp Val Gly Asp Ala Tyr
           130              135              140

ttc tct gtg ccc ctg gat gag gac ttc agg aag tac act gcc ttc acc      481
Phe Ser Val Pro Leu Asp Glu Asp Phe Arg Lys Tyr Thr Ala Phe Thr
           145              150              155

atc ccc tcc atc aac aat gag acc cct ggc atc agg tac cag tac aat      529
Ile Pro Ser Ile Asn Asn Glu Thr Pro Gly Ile Arg Tyr Gln Tyr Asn
       160              165              170

gtg ctg ccc cag ggc tgg aag ggc tcc cct gcc atc ttc cag tcc tcc      577
Val Leu Pro Gln Gly Trp Lys Gly Ser Pro Ala Ile Phe Gln Ser Ser
175              180              185              190

atg acc aag atc ctg gag ccc ttc agg aag cag aac cct gac att gtg      625
Met Thr Lys Ile Leu Glu Pro Phe Arg Lys Gln Asn Pro Asp Ile Val
               195              200              205

atc tac cag tac atg gat gac ctg tat gtg ggc tct gac ctg gag att      673
Ile Tyr Gln Tyr Met Asp Asp Leu Tyr Val Gly Ser Asp Leu Glu Ile
           210              215              220

ggg cag cac agg acc aag att gag gag ctg agg cag cac ctg ctg agg      721
Gly Gln His Arg Thr Lys Ile Glu Glu Leu Arg Gln His Leu Leu Arg
           225              230              235

tgg ggc ctg acc acc cct gac aag aag cac cag aag gag ccc ccc ttc      769
Trp Gly Leu Thr Thr Pro Asp Lys Lys His Gln Lys Glu Pro Pro Phe
           240              245              250

ctg tgg atg ggc tat gag ctg cac ccc gac aag tgg act gtg cag ccc      817
Leu Trp Met Gly Tyr Glu Leu His Pro Asp Lys Trp Thr Val Gln Pro
255              260              265              270

att gtg ctg cct gag aag gac tcc tgg act gtg aat gac atc cag aag      865
Ile Val Leu Pro Glu Lys Asp Ser Trp Thr Val Asn Asp Ile Gln Lys
               275              280              285

ctg gtg ggc aag ctg aac tgg gcc tcc caa atc tac cct ggc atc aag      913
Leu Val Gly Lys Leu Asn Trp Ala Ser Gln Ile Tyr Pro Gly Ile Lys
           290              295              300

gtg agg cag ctg tgc aag ctg ctg agg ggc acc aag gcc ctg act gag      961
Val Arg Gln Leu Cys Lys Leu Leu Arg Gly Thr Lys Ala Leu Thr Glu
           305              310              315

gtg atc ccc ctg act gag gag gct gag ctg gag ctg gct gag aac agg     1009
Val Ile Pro Leu Thr Glu Glu Ala Glu Leu Glu Leu Ala Glu Asn Arg
           320              325              330
```

```
gag atc ctg aag gag cct gtg cat ggg gtg tac tat gac ccc tcc aag          1057
Glu Ile Leu Lys Glu Pro Val His Gly Val Tyr Tyr Asp Pro Ser Lys
335                 340             345             350

gac ctg att gct gag atc cag aag cag ggc cag ggc cag tgg acc tac          1105
Asp Leu Ile Ala Glu Ile Gln Lys Gln Gly Gln Gly Gln Trp Thr Tyr
                355             360             365

caa atc tac cag gag ccc ttc aag aac ctg aag act ggc aag tat gcc          1153
Gln Ile Tyr Gln Glu Pro Phe Lys Asn Leu Lys Thr Gly Lys Tyr Ala
            370             375             380

agg atg agg ggg gcc cac acc aat gat gtg aag cag ctg act gag gct          1201
Arg Met Arg Gly Ala His Thr Asn Asp Val Lys Gln Leu Thr Glu Ala
        385             390             395

gtg cag aag atc acc act gag tcc att gtg atc tgg ggc aag acc ccc          1249
Val Gln Lys Ile Thr Thr Glu Ser Ile Val Ile Trp Gly Lys Thr Pro
        400             405             410

aag ttc aag ctg ccc atc cag aag gag acc tgg gag acc tgg tgg act          1297
Lys Phe Lys Leu Pro Ile Gln Lys Glu Thr Trp Glu Thr Trp Trp Thr
415             420             425             430

gag tac tgg cag gcc acc tgg atc cct gag tgg gag ttt gtg aac acc          1345
Glu Tyr Trp Gln Ala Thr Trp Ile Pro Glu Trp Glu Phe Val Asn Thr
                435             440             445

ccc ccc ctg gtg aag ctg tgg tac cag ctg gag aag gag ccc att gtg          1393
Pro Pro Leu Val Lys Leu Trp Tyr Gln Leu Glu Lys Glu Pro Ile Val
            450             455             460

ggg gct gag acc ttc tat gtg gat ggg gct gcc aac agg gag acc aag          1441
Gly Ala Glu Thr Phe Tyr Val Asp Gly Ala Ala Asn Arg Glu Thr Lys
            465             470             475

ctg ggc aag gct ggc tat gtg acc aac agg ggc agg cag aag gtg gtg          1489
Leu Gly Lys Ala Gly Tyr Val Thr Asn Arg Gly Arg Gln Lys Val Val
        480             485             490

acc ctg act gac acc acc aac cag aag act gag ctc cag gcc atc tac          1537
Thr Leu Thr Asp Thr Thr Asn Gln Lys Thr Glu Leu Gln Ala Ile Tyr
495             500             505             510

ctg gcc ctc cag gac tct ggc ctg gag gtg aac att gtg act gac tcc          1585
Leu Ala Leu Gln Asp Ser Gly Leu Glu Val Asn Ile Val Thr Asp Ser
            515             520             525

cag tat gcc ctg ggc atc atc cag gcc cag cct gat cag tct gag tct          1633
Gln Tyr Ala Leu Gly Ile Ile Gln Ala Gln Pro Asp Gln Ser Glu Ser
            530             535             540

gag ctg gtg aac cag atc att gag cag ctg atc aag aag gag aag gtg          1681
Glu Leu Val Asn Gln Ile Ile Glu Gln Leu Ile Lys Lys Glu Lys Val
        545             550             555

tac ctg gcc tgg gtg cct gcc cac aag ggc att ggg ggc aat gag cag          1729
Tyr Leu Ala Trp Val Pro Ala His Lys Gly Ile Gly Gly Asn Glu Gln
560             565             570
```

```
gtg gac aag ctg gtg tct gct ggc atc agg aag gtg ctg ttc ctg gat      1777
Val Asp Lys Leu Val Ser Ala Gly Ile Arg Lys Val Leu Phe Leu Asp
575             580                 585                 590

ggc att gac aag gcc cag gat gag cat gag aag tac cac tcc aac tgg      1825
Gly Ile Asp Lys Ala Gln Asp Glu His Glu Lys Tyr His Ser Asn Trp
                595                 600                 605

agg gct atg gcc tct gac ttc aac ctg ccc cct gtg gtg gct aag gag      1873
Arg Ala Met Ala Ser Asp Phe Asn Leu Pro Pro Val Val Ala Lys Glu
                610                 615                 620

att gtg gcc tcc tgt gac aag tgc cag ctg aag ggg gag gcc atg cat      1921
Ile Val Ala Ser Cys Asp Lys Cys Gln Leu Lys Gly Glu Ala Met His
            625                 630                 635

ggg cag gtg gac tgc tcc cct ggc atc tgg cag ctg gac tgc acc cac      1969
Gly Gln Val Asp Cys Ser Pro Gly Ile Trp Gln Leu Asp Cys Thr His
    640                 645                 650

ctg gag ggc aag gtg atc ctg gtg gct gtg cat gtg gcc tcc ggc tac      2017
Leu Glu Gly Lys Val Ile Leu Val Ala Val His Val Ala Ser Gly Tyr
655                 660                 665                 670

att gag gct gag gtg atc cct gct gag aca ggc cag gag act gcc tac      2065
Ile Glu Ala Glu Val Ile Pro Ala Glu Thr Gly Gln Glu Thr Ala Tyr
                675                 680                 685

ttc ctg ctg aag ctg gct ggc agg tgg cct gtg aag acc atc cac act      2113
Phe Leu Leu Lys Leu Ala Gly Arg Trp Pro Val Lys Thr Ile His Thr
            690                 695                 700

gac aat ggc tcc aac ttc act ggg gcc aca gtg agg gct gcc tgc tgg      2161
Asp Asn Gly Ser Asn Phe Thr Gly Ala Thr Val Arg Ala Ala Cys Trp
            705                 710                 715

tgg gct ggc atc aag cag gag ttt ggc atc ccc tac aac ccc cag tcc      2209
Trp Ala Gly Ile Lys Gln Glu Phe Gly Ile Pro Tyr Asn Pro Gln Ser
    720                 725                 730

cag ggg gtg gtg gag tcc atg aac aag gag ctg aag aag atc att ggg      2257
Gln Gly Val Val Glu Ser Met Asn Lys Glu Leu Lys Lys Ile Ile Gly
735                 740                 745                 750

cag gtg agg gac cag gct gag cac ctg aag aca gct gtg cag atg gct      2305
Gln Val Arg Asp Gln Ala Glu His Leu Lys Thr Ala Val Gln Met Ala
                755                 760                 765

gtg ttc atc cac aac ttc aag agg aag ggg ggc atc ggg ggc tac tcc      2353
Val Phe Ile His Asn Phe Lys Arg Lys Gly Gly Ile Gly Gly Tyr Ser
                770                 775                 780

gct ggg gag agg att gtg gac atc att gcc aca gac atc cag acc aag      2401
Ala Gly Glu Arg Ile Val Asp Ile Ile Ala Thr Asp Ile Gln Thr Lys
            785                 790                 795

gag ctc cag aag cag atc acc aag atc cag aac ttc agg gtg tac tac      2449
Glu Leu Gln Lys Gln Ile Thr Lys Ile Gln Asn Phe Arg Val Tyr Tyr
800                 805                 810
```

- 15 -

```
agg gac tcc agg aac ccc ctg tgg aag ggc cct gcc aag ctg ctg tgg    2497
Arg Asp Ser Arg Asn Pro Leu Trp Lys Gly Pro Ala Lys Leu Leu Trp
815             820             825             830

aag ggg gag ggg gct gtg gtg atc cag gac aac tct gac atc aag gtg    2545
Lys Gly Glu Gly Ala Val Val Ile Gln Asp Asn Ser Asp Ile Lys Val
            835             840             845

gtg ccc agg agg aag gcc aag atc atc agg gac tat ggc aag cag atg    2593
Val Pro Arg Arg Lys Ala Lys Ile Ile Arg Asp Tyr Gly Lys Gln Met
            850             855             860

gct ggg gat gac tgt gtg gcc tcc agg cag gat gag gac taa           2635
Ala Gly Asp Asp Cys Val Ala Ser Arg Gln Asp Glu Asp *
865                 870             875

agcccgggca gatct                                                   2650
```

```
<210> 6
<211> 875
<212> PRT
<213> Human Immunodeficiency Virus-1

<400> 6
Met Asp Ala Met Lys Arg Gly Leu Cys Cys Val Leu Leu Leu Cys Gly
1               5                   10                  15
Ala Val Phe Val Ser Pro Ser Glu Ile Ser Ala Pro Ile Ser Pro Ile
            20                  25                  30
Glu Thr Val Pro Val Lys Leu Lys Pro Gly Met Asp Gly Pro Lys Val
        35                  40                  45
Lys Gln Trp Pro Leu Thr Glu Glu Lys Ile Lys Ala Leu Val Glu Ile
    50                  55                  60
Cys Thr Glu Met Glu Lys Glu Gly Lys Ile Ser Lys Ile Gly Pro Glu
65                  70                  75                  80
Asn Pro Tyr Asn Thr Pro Val Phe Ala Ile Lys Lys Lys Asp Ser Thr
                85                  90                  95
Lys Trp Arg Lys Leu Val Asp Phe Arg Glu Leu Asn Lys Arg Thr Gln
            100                 105                 110
Asp Phe Trp Glu Val Gln Leu Gly Ile Pro His Pro Ala Gly Leu Lys
        115                 120                 125
Lys Lys Lys Ser Val Thr Val Leu Asp Val Gly Asp Ala Tyr Phe Ser
    130                 135                 140
Val Pro Leu Asp Glu Asp Phe Arg Lys Tyr Thr Ala Phe Thr Ile Pro
145                 150                 155                 160
Ser Ile Asn Asn Glu Thr Pro Gly Ile Arg Tyr Gln Tyr Asn Val Leu
                165                 170                 175
Pro Gln Gly Trp Lys Gly Ser Pro Ala Ile Phe Gln Ser Ser Met Thr
            180                 185                 190
Lys Ile Leu Glu Pro Phe Arg Lys Gln Asn Pro Asp Ile Val Ile Tyr
        195                 200                 205
Gln Tyr Met Asp Asp Leu Tyr Val Gly Ser Asp Leu Glu Ile Gly Gln
    210                 215                 220
His Arg Thr Lys Ile Glu Glu Leu Arg Gln His Leu Leu Arg Trp Gly
225                 230                 235                 240
Leu Thr Thr Pro Asp Lys Lys His Gln Lys Glu Pro Pro Phe Leu Trp
                245                 250                 255
Met Gly Tyr Glu Leu His Pro Asp Lys Trp Thr Val Gln Pro Ile Val
            260                 265                 270
Leu Pro Glu Lys Asp Ser Trp Thr Val Asn Asp Ile Gln Lys Leu Val
        275                 280                 285
Gly Lys Leu Asn Trp Ala Ser Gln Ile Tyr Pro Gly Ile Lys Val Arg
    290                 295                 300
```

```
Gln Leu Cys Lys Leu Leu Arg Gly Thr Lys Ala Leu Thr Glu Val Ile
305             310                 315                 320
Pro Leu Thr Glu Glu Ala Glu Leu Glu Leu Ala Glu Asn Arg Glu Ile
            325                 330                 335
Leu Lys Glu Pro Val His Gly Val Tyr Tyr Asp Pro Ser Lys Asp Leu
            340                 345                 350
Ile Ala Glu Ile Gln Lys Gln Gly Gln Gly Gln Trp Thr Tyr Gln Ile
        355                 360                 365
Tyr Gln Glu Pro Phe Lys Asn Leu Lys Thr Gly Lys Tyr Ala Arg Met
    370                 375                 380
Arg Gly Ala His Thr Asn Asp Val Lys Gln Leu Thr Glu Ala Val Gln
385             390                 395                 400
Lys Ile Thr Thr Glu Ser Ile Val Ile Trp Gly Lys Thr Pro Lys Phe
                405                 410                 415
Lys Leu Pro Ile Gln Lys Glu Thr Trp Glu Thr Trp Trp Thr Glu Tyr
            420                 425                 430
Trp Gln Ala Thr Trp Ile Pro Glu Trp Glu Phe Val Asn Thr Pro Pro
        435                 440                 445
Leu Val Lys Leu Trp Tyr Gln Leu Glu Lys Glu Pro Ile Val Gly Ala
    450                 455                 460
Glu Thr Phe Tyr Val Asp Gly Ala Ala Asn Arg Glu Thr Lys Leu Gly
465                 470                 475                 480
Lys Ala Gly Tyr Val Thr Asn Arg Gly Arg Gln Lys Val Val Thr Leu
                485                 490                 495
Thr Asp Thr Thr Asn Gln Lys Thr Glu Leu Gln Ala Ile Tyr Leu Ala
            500                 505                 510
Leu Gln Asp Ser Gly Leu Glu Val Asn Ile Val Thr Asp Ser Gln Tyr
        515                 520                 525
Ala Leu Gly Ile Ile Gln Ala Gln Pro Asp Gln Ser Glu Ser Glu Leu
    530                 535                 540
Val Asn Gln Ile Ile Glu Gln Leu Ile Lys Lys Glu Lys Val Tyr Leu
545                 550                 555                 560
Ala Trp Val Pro Ala His Lys Gly Ile Gly Gly Asn Glu Gln Val Asp
                565                 570                 575
Lys Leu Val Ser Ala Gly Ile Arg Lys Val Leu Phe Leu Asp Gly Ile
            580                 585                 590
Asp Lys Ala Gln Asp Glu His Glu Lys Tyr His Ser Asn Trp Arg Ala
        595                 600                 605
Met Ala Ser Asp Phe Asn Leu Pro Pro Val Val Ala Lys Glu Ile Val
    610                 615                 620
Ala Ser Cys Asp Lys Cys Gln Leu Lys Gly Glu Ala Met His Gly Gln
625                 630                 635                 640
Val Asp Cys Ser Pro Gly Ile Trp Gln Leu Asp Cys Thr His Leu Glu
                645                 650                 655
Gly Lys Val Ile Leu Val Ala Val His Val Ala Ser Gly Tyr Ile Glu
            660                 665                 670
Ala Glu Val Ile Pro Ala Glu Thr Gly Gln Glu Thr Ala Tyr Phe Leu
        675                 680                 685
Leu Lys Leu Ala Gly Arg Trp Pro Val Lys Thr Ile His Thr Asp Asn
    690                 695                 700
Gly Ser Asn Phe Thr Gly Ala Thr Val Arg Ala Ala Cys Trp Trp Ala
705                 710                 715                 720
Gly Ile Lys Gln Glu Phe Gly Ile Pro Tyr Asn Pro Gln Ser Gln Gly
                725                 730                 735
Val Val Glu Ser Met Asn Lys Glu Leu Lys Lys Ile Ile Gly Gln Val
            740                 745                 750
Arg Asp Gln Ala Glu His Leu Lys Thr Ala Val Gln Met Ala Val Phe
        755                 760                 765
Ile His Asn Phe Lys Arg Lys Gly Gly Ile Gly Gly Tyr Ser Ala Gly
    770                 775                 780
Glu Arg Ile Val Asp Ile Ile Ala Thr Asp Ile Gln Thr Lys Glu Leu
785                 790                 795                 800
```

```
Gln Lys Gln Ile Thr Lys Ile Gln Asn Phe Arg Val Tyr Tyr Arg Asp
              805             810                 815
Ser Arg Asn Pro Leu Trp Lys Gly Pro Ala Lys Leu Leu Trp Lys Gly
              820             825                 830
Glu Gly Ala Val Val Ile Gln Asp Asn Ser Asp Ile Lys Val Val Pro
          835                 840                 845
Arg Arg Lys Ala Lys Ile Ile Arg Asp Tyr Gly Lys Gln Met Ala Gly
      850                 855                 860
Asp Asp Cys Val Ala Ser Arg Gln Asp Glu Asp
865             870             875
```

<210> 7
<211> 2650
<212> DNA
<213> Human Immunodeficiency Virus-1

<220>
<221> CDS
<222> (8)...(2635)

<400> 7

```
gatcacc atg gat gca atg aag aga ggg ctc tgc tgt gtg ctg ctg ctg        49
        Met Asp Ala Met Lys Arg Gly Leu Cys Cys Val Leu Leu Leu
        1             5                 10

tgt gga gca gtc ttc gtt tcg ccc agc gag atc tcc gcc ccc atc tcc        97
Cys Gly Ala Val Phe Val Ser Pro Ser Glu Ile Ser Ala Pro Ile Ser
15                  20                  25                  30

ccc att gag act gtg cct gtg aag ctg aag cct ggc atg gat ggc ccc       145
Pro Ile Glu Thr Val Pro Val Lys Leu Lys Pro Gly Met Asp Gly Pro
                35                  40                  45

aag gtg aag cag tgg ccc ctg act gag gag aag atc aag gcc ctg gtg       193
Lys Val Lys Gln Trp Pro Leu Thr Glu Glu Lys Ile Lys Ala Leu Val
            50                  55                  60

gaa atc tgc act gag atg gag aag gag ggc aaa atc tcc aag att ggc       241
Glu Ile Cys Thr Glu Met Glu Lys Glu Gly Lys Ile Ser Lys Ile Gly
            65                  70                  75

ccc gag aac ccc tac aac acc cct gtg ttt gcc atc aag aag aag gac       289
Pro Glu Asn Pro Tyr Asn Thr Pro Val Phe Ala Ile Lys Lys Lys Asp
        80                  85                  90

tcc acc aag tgg agg aag ctg gtg gac ttc agg gag ctg aac aag agg       337
Ser Thr Lys Trp Arg Lys Leu Val Asp Phe Arg Glu Leu Asn Lys Arg
95                  100                 105                 110

acc cag gac ttc tgg gag gtg cag ctg ggc atc ccc cac ccc gct ggc       385
Thr Gln Asp Phe Trp Glu Val Gln Leu Gly Ile Pro His Pro Ala Gly
                115                 120                 125

ctg aag aag aag aag tct gtg act gtg ctg gct gtg ggg gat gcc tac       433
Leu Lys Lys Lys Lys Ser Val Thr Val Leu Ala Val Gly Asp Ala Tyr
            130                 135                 140

ttc tct gtg ccc ctg gat gag gac ttc agg aag tac act gcc ttc acc       481
Phe Ser Val Pro Leu Asp Glu Asp Phe Arg Lys Tyr Thr Ala Phe Thr
            145                 150                 155
```

```
atc ccc tcc atc aac aat gag acc cct ggc atc agg tac cag tac aat      529
Ile Pro Ser Ile Asn Asn Glu Thr Pro Gly Ile Arg Tyr Gln Tyr Asn
    160                 165             170

gtg ctg ccc cag ggc tgg aag ggc tcc cct gcc atc ttc cag tcc tcc      577
Val Leu Pro Gln Gly Trp Lys Gly Ser Pro Ala Ile Phe Gln Ser Ser
175                 180             185                 190

atg acc aag atc ctg gag ccc ttc agg aag cag aac cct gac att gtg      625
Met Thr Lys Ile Leu Glu Pro Phe Arg Lys Gln Asn Pro Asp Ile Val
                195             200             205

atc tac cag tac atg gct gcc ctg tat gtg ggc tct gac ctg gag att      673
Ile Tyr Gln Tyr Met Ala Ala Leu Tyr Val Gly Ser Asp Leu Glu Ile
            210             215             220

ggg cag cac agg acc aag att gag gag ctg agg cag cac ctg ctg agg      721
Gly Gln His Arg Thr Lys Ile Glu Glu Leu Arg Gln His Leu Leu Arg
        225             230             235

tgg ggc ctg acc acc cct gac aag aag cac cag aag gag ccc ccc ttc      769
Trp Gly Leu Thr Thr Pro Asp Lys Lys His Gln Lys Glu Pro Pro Phe
        240             245             250

ctg tgg atg ggc tat gag ctg cac ccc gac aag tgg act gtg cag ccc      817
Leu Trp Met Gly Tyr Glu Leu His Pro Asp Lys Trp Thr Val Gln Pro
255                 260             265                 270

att gtg ctg cct gag aag gac tcc tgg act gtg aat gac atc cag aag      865
Ile Val Leu Pro Glu Lys Asp Ser Trp Thr Val Asn Asp Ile Gln Lys
                275             280             285

ctg gtg ggc aag ctg aac tgg gcc tcc caa atc tac cct ggc atc aag      913
Leu Val Gly Lys Leu Asn Trp Ala Ser Gln Ile Tyr Pro Gly Ile Lys
            290             295             300

gtg agg cag ctg tgc aag ctg ctg agg ggc acc aag gcc ctg act gag      961
Val Arg Gln Leu Cys Lys Leu Leu Arg Gly Thr Lys Ala Leu Thr Glu
        305             310             315

gtg atc ccc ctg act gag gag gct gag ctg gag ctg gct gag aac agg     1009
Val Ile Pro Leu Thr Glu Glu Ala Glu Leu Glu Leu Ala Glu Asn Arg
        320             325             330

gag atc ctg aag gag cct gtg cat ggg gtg tac tat gac ccc tcc aag     1057
Glu Ile Leu Lys Glu Pro Val His Gly Val Tyr Tyr Asp Pro Ser Lys
335                 340             345                 350

gac ctg att gct gag atc cag aag cag ggc cag ggc cag tgg acc tac     1105
Asp Leu Ile Ala Glu Ile Gln Lys Gln Gly Gln Gly Gln Trp Thr Tyr
            355             360             365

caa atc tac cag gag ccc ttc aag aac ctg aag act ggc aag tat gcc     1153
Gln Ile Tyr Gln Glu Pro Phe Lys Asn Leu Lys Thr Gly Lys Tyr Ala
            370             375             380

agg atg agg ggg gcc cac acc aat gat gtg aag cag ctg act gag gct     1201
Arg Met Arg Gly Ala His Thr Asn Asp Val Lys Gln Leu Thr Glu Ala
        385             390             395
```

```
gtg cag aag atc acc act gag tcc att gtg atc tgg ggc aag acc ccc      1249
Val Gln Lys Ile Thr Thr Glu Ser Ile Val Ile Trp Gly Lys Thr Pro
    400             405              410

aag ttc aag ctg ccc atc cag aag gag acc tgg gag acc tgg tgg act      1297
Lys Phe Lys Leu Pro Ile Gln Lys Glu Thr Trp Glu Thr Trp Trp Thr
415             420              425              430

gag tac tgg cag gcc acc tgg atc cct gag tgg gag ttt gtg aac acc      1345
Glu Tyr Trp Gln Ala Thr Trp Ile Pro Glu Trp Glu Phe Val Asn Thr
            435              440              445

ccc ccc ctg gtg aag ctg tgg tac cag ctg gag aag gag ccc att gtg      1393
Pro Pro Leu Val Lys Leu Trp Tyr Gln Leu Glu Lys Glu Pro Ile Val
            450              455              460

ggg gct gag acc ttc tat gtg gct ggg gct gcc aac agg gag acc aag      1441
Gly Ala Glu Thr Phe Tyr Val Ala Gly Ala Ala Asn Arg Glu Thr Lys
            465              470              475

ctg ggc aag gct ggc tat gtg acc aac agg ggc agg cag aag gtg gtg      1489
Leu Gly Lys Ala Gly Tyr Val Thr Asn Arg Gly Arg Gln Lys Val Val
    480              485              490

acc ctg act gac acc acc aac cag aag act gcc ctc cag gcc atc tac      1537
Thr Leu Thr Asp Thr Thr Asn Gln Lys Thr Ala Leu Gln Ala Ile Tyr
495             500              505              510

ctg gcc ctc cag gac tct ggc ctg gag gtg aac att gtg act gcc tcc      1585
Leu Ala Leu Gln Asp Ser Gly Leu Glu Val Asn Ile Val Thr Ala Ser
                515              520              525

cag tat gcc ctg ggc atc atc cag gcc cag cct gat cag tct gag tct      1633
Gln Tyr Ala Leu Gly Ile Ile Gln Ala Gln Pro Asp Gln Ser Glu Ser
            530              535              540

gag ctg gtg aac cag atc att gag cag ctg atc aag aag gag aag gtg      1681
Glu Leu Val Asn Gln Ile Ile Glu Gln Leu Ile Lys Lys Glu Lys Val
            545              550              555

tac ctg gcc tgg gtg cct gcc cac aag ggc att ggg ggc aat gag cag      1729
Tyr Leu Ala Trp Val Pro Ala His Lys Gly Ile Gly Gly Asn Glu Gln
    560              565              570

gtg gac aag ctg gtg tct gct ggc atc agg aag gtg ctg ttc ctg gat      1777
Val Asp Lys Leu Val Ser Ala Gly Ile Arg Lys Val Leu Phe Leu Asp
575             580              585              590

ggc att gac aag gcc cag gat gag cat gag aag tac cac tcc aac tgg      1825
Gly Ile Asp Lys Ala Gln Asp Glu His Glu Lys Tyr His Ser Asn Trp
            595              600              605

agg gct atg gcc tct gac ttc aac ctg ccc cct gtg gtg gct aag gag      1873
Arg Ala Met Ala Ser Asp Phe Asn Leu Pro Pro Val Val Ala Lys Glu
            610              615              620

att gtg gcc tcc tgt gac aag tgc cag ctg aag ggg gag gcc atg cat      1921
Ile Val Ala Ser Cys Asp Lys Cys Gln Leu Lys Gly Glu Ala Met His
            625              630              635
```

```
ggg cag gtg gac tgc tcc cct ggc atc tgg cag ctg gcc tgc acc cac      1969
Gly Gln Val Asp Cys Ser Pro Gly Ile Trp Gln Leu Ala Cys Thr His
    640               645               650

ctg gag ggc aag gtg atc ctg gtg gct gtg cat gtg gcc tcc ggc tac      2017
Leu Glu Gly Lys Val Ile Leu Val Ala Val His Val Ala Ser Gly Tyr
655               660               665               670

att gag gct gag gtg atc cct gct gag aca ggc cag gag act gcc tac      2065
Ile Glu Ala Glu Val Ile Pro Ala Glu Thr Gly Gln Glu Thr Ala Tyr
                  675               680               685

ttc ctg ctg aag ctg gct ggc agg tgg cct gtg aag acc atc cac act      2113
Phe Leu Leu Lys Leu Ala Gly Arg Trp Pro Val Lys Thr Ile His Thr
              690               695               700

gcc aat ggc tcc aac ttc act ggg gcc aca gtg agg gct gcc tgc tgg      2161
Ala Asn Gly Ser Asn Phe Thr Gly Ala Thr Val Arg Ala Ala Cys Trp
          705               710               715

tgg gct ggc atc aag cag gag ttt ggc atc ccc tac aac ccc cag tcc      2209
Trp Ala Gly Ile Lys Gln Glu Phe Gly Ile Pro Tyr Asn Pro Gln Ser
    720               725               730

cag ggg gtg gtg gcc tcc atg aac aag gag ctg aag aag atc att ggg      2257
Gln Gly Val Val Ala Ser Met Asn Lys Glu Leu Lys Lys Ile Ile Gly
735               740               745               750

cag gtg agg gac cag gct gag cac ctg aag aca gct gtg cag atg gct      2305
Gln Val Arg Asp Gln Ala Glu His Leu Lys Thr Ala Val Gln Met Ala
              755               760               765

gtg ttc atc cac aac ttc aag agg aag ggg ggc atc ggg ggc tac tcc      2353
Val Phe Ile His Asn Phe Lys Arg Lys Gly Gly Ile Gly Gly Tyr Ser
              770               775               780

gct ggg gag agg att gtg gac atc att gcc aca gac atc cag acc aag      2401
Ala Gly Glu Arg Ile Val Asp Ile Ile Ala Thr Asp Ile Gln Thr Lys
          785               790               795

gag ctc cag aag cag atc acc aag atc cag aac ttc agg gtg tac tac      2449
Glu Leu Gln Lys Gln Ile Thr Lys Ile Gln Asn Phe Arg Val Tyr Tyr
    800               805               810

agg gac tcc agg aac ccc ctg tgg aag ggc cct gcc aag ctg ctg tgg      2497
Arg Asp Ser Arg Asn Pro Leu Trp Lys Gly Pro Ala Lys Leu Leu Trp
815               820               825               830

aag ggg gag ggg gct gtg gtg atc cag gac aac tct gac atc aag gtg      2545
Lys Gly Glu Gly Ala Val Val Ile Gln Asp Asn Ser Asp Ile Lys Val
              835               840               845

gtg ccc agg agg aag gcc aag atc atc agg gac tat ggc aag cag atg      2593
Val Pro Arg Arg Lys Ala Lys Ile Ile Arg Asp Tyr Gly Lys Gln Met
          850               855               860

gct ggg gat gac tgt gtg gcc tcc agg cag gat gag gac taa           2635
Ala Gly Asp Asp Cys Val Ala Ser Arg Gln Asp Glu Asp  *
    865               870               875

agcccgggca gatct                                                      2650
```

```
<210> 8
<211> 875
<212> PRT
<213> Human Immunodeficiency Virus-1

<400> 8
Met Asp Ala Met Lys Arg Gly Leu Cys Cys Val Leu Leu Leu Cys Gly
1               5                   10                  15
Ala Val Phe Val Ser Pro Ser Glu Ile Ser Ala Pro Ile Ser Pro Ile
            20                  25                  30
Glu Thr Val Pro Val Lys Leu Lys Pro Gly Met Asp Gly Pro Lys Val
        35                  40                  45
Lys Gln Trp Pro Leu Thr Glu Glu Lys Ile Lys Ala Leu Val Glu Ile
    50                  55                  60
Cys Thr Glu Met Glu Lys Glu Gly Lys Ile Ser Lys Ile Gly Pro Glu
65                  70                  75                  80
Asn Pro Tyr Asn Thr Pro Val Phe Ala Ile Lys Lys Lys Asp Ser Thr
                85                  90                  95
Lys Trp Arg Lys Leu Val Asp Phe Arg Glu Leu Asn Lys Arg Thr Gln
            100                 105                 110
Asp Phe Trp Glu Val Gln Leu Gly Ile Pro His Pro Ala Gly Leu Lys
        115                 120                 125
Lys Lys Lys Ser Val Thr Val Leu Ala Val Gly Asp Ala Tyr Phe Ser
    130                 135                 140
Val Pro Leu Asp Glu Asp Phe Arg Lys Tyr Thr Ala Phe Thr Ile Pro
145                 150                 155                 160
Ser Ile Asn Asn Glu Thr Pro Gly Ile Arg Tyr Gln Tyr Asn Val Leu
                165                 170                 175
Pro Gln Gly Trp Lys Gly Ser Pro Ala Ile Phe Gln Ser Ser Met Thr
            180                 185                 190
Lys Ile Leu Glu Pro Phe Arg Lys Gln Asn Pro Asp Ile Val Ile Tyr
        195                 200                 205
Gln Tyr Met Ala Ala Leu Tyr Val Gly Ser Asp Leu Glu Ile Gly Gln
    210                 215                 220
His Arg Thr Lys Ile Glu Glu Leu Arg Gln His Leu Leu Arg Trp Gly
225                 230                 235                 240
Leu Thr Thr Pro Asp Lys Lys His Gln Lys Glu Pro Pro Phe Leu Trp
                245                 250                 255
Met Gly Tyr Glu Leu His Pro Asp Lys Trp Thr Val Gln Pro Ile Val
            260                 265                 270
Leu Pro Glu Lys Asp Ser Trp Thr Val Asn Asp Ile Gln Lys Leu Val
        275                 280                 285
Gly Lys Leu Asn Trp Ala Ser Gln Ile Tyr Pro Gly Ile Lys Val Arg
    290                 295                 300
Gln Leu Cys Lys Leu Leu Arg Gly Thr Lys Ala Leu Thr Glu Val Ile
305                 310                 315                 320
Pro Leu Thr Glu Glu Ala Glu Leu Glu Leu Ala Glu Asn Arg Glu Ile
                325                 330                 335
Leu Lys Glu Pro Val His Gly Val Tyr Tyr Asp Pro Ser Lys Asp Leu
            340                 345                 350
Ile Ala Glu Ile Gln Lys Gln Gly Gln Gly Gln Trp Thr Tyr Gln Ile
        355                 360                 365
Tyr Gln Glu Pro Phe Lys Asn Leu Lys Thr Gly Lys Tyr Ala Arg Met
    370                 375                 380
Arg Gly Ala His Thr Asn Asp Val Lys Gln Leu Thr Glu Ala Val Gln
385                 390                 395                 400
Lys Ile Thr Thr Glu Ser Ile Val Ile Trp Gly Lys Thr Pro Lys Phe
                405                 410                 415
Lys Leu Pro Ile Gln Lys Glu Thr Trp Glu Thr Trp Trp Thr Glu Tyr
            420                 425                 430
Trp Gln Ala Thr Trp Ile Pro Glu Trp Glu Phe Val Asn Thr Pro Pro
        435                 440                 445
```

- 22 -

```
Leu Val Lys Leu Trp Tyr Gln Leu Glu Lys Glu Pro Ile Val Gly Ala
    450                     455                 460
Glu Thr Phe Tyr Val Ala Gly Ala Ala Asn Arg Glu Thr Lys Leu Gly
465                     470                 475                 480
Lys Ala Gly Tyr Val Thr Asn Arg Gly Arg Gln Lys Val Val Thr Leu
                485                 490                 495
Thr Asp Thr Thr Asn Gln Lys Thr Ala Leu Gln Ala Ile Tyr Leu Ala
            500                 505                 510
Leu Gln Asp Ser Gly Leu Glu Val Asn Ile Val Thr Ala Ser Gln Tyr
    515                     520                 525
Ala Leu Gly Ile Ile Gln Ala Gln Pro Asp Gln Ser Glu Ser Glu Leu
    530                     535                 540
Val Asn Gln Ile Ile Glu Gln Leu Ile Lys Lys Glu Lys Val Tyr Leu
545                     550                 555                 560
Ala Trp Val Pro Ala His Lys Gly Ile Gly Gly Asn Glu Gln Val Asp
                565                 570                 575
Lys Leu Val Ser Ala Gly Ile Arg Lys Val Leu Phe Leu Asp Gly Ile
            580                 585                 590
Asp Lys Ala Gln Asp Glu His Glu Lys Tyr His Ser Asn Trp Arg Ala
    595                     600                 605
Met Ala Ser Asp Phe Asn Leu Pro Pro Val Val Ala Lys Glu Ile Val
    610                     615                 620
Ala Ser Cys Asp Lys Cys Gln Leu Lys Gly Glu Ala Met His Gly Gln
625                     630                 635                 640
Val Asp Cys Ser Pro Gly Ile Trp Gln Leu Ala Cys Thr His Leu Glu
                645                 650                 655
Gly Lys Val Ile Leu Val Ala Val His Val Ala Ser Gly Tyr Ile Glu
            660                 665                 670
Ala Glu Val Ile Pro Ala Glu Thr Gly Gln Glu Thr Ala Tyr Phe Leu
    675                     680                 685
Leu Lys Leu Ala Gly Arg Trp Pro Val Lys Thr Ile His Thr Ala Asn
    690                     695                 700
Gly Ser Asn Phe Thr Gly Ala Thr Val Arg Ala Ala Cys Trp Trp Ala
705                     710                 715                 720
Gly Ile Lys Gln Glu Phe Gly Ile Pro Tyr Asn Pro Gln Ser Gln Gly
                725                 730                 735
Val Val Ala Ser Met Asn Lys Glu Leu Lys Lys Ile Ile Gly Gln Val
            740                 745                 750
Arg Asp Gln Ala Glu His Leu Lys Thr Ala Val Gln Met Ala Val Phe
    755                     760                 765
Ile His Asn Phe Lys Arg Lys Gly Gly Ile Gly Gly Tyr Ser Ala Gly
    770                     775                 780
Glu Arg Ile Val Asp Ile Ile Ala Thr Asp Ile Gln Thr Lys Glu Leu
785                     790                 795                 800
Gln Lys Gln Ile Thr Lys Ile Gln Asn Phe Arg Val Tyr Tyr Arg Asp
                805                 810                 815
Ser Arg Asn Pro Leu Trp Lys Gly Pro Ala Lys Leu Leu Trp Lys Gly
            820                 825                 830
Glu Gly Ala Val Val Ile Gln Asp Asn Ser Asp Ile Lys Val Val Pro
    835                     840                 845
Arg Arg Lys Ala Lys Ile Ile Arg Asp Tyr Gly Lys Gln Met Ala Gly
    850                     855                 860
Asp Asp Cys Val Ala Ser Arg Gln Asp Glu Asp
865                     870                 875
```

```
<210> 9
<211> 4945
<212> DNA
<213> E. coli (V1Jns-tpa)

<400> 9
tcgcgcgttt cggtgatgac ggtgaaaacc tctgacacat gcagctcccg gagacggtca        60
```

```
cagcttgtct gtaagcggat gccgggagca gacaagcccg tcagggcgcg tcagcgggtg      120
ttggcgggtg tcggggctgg cttaactatg cggcatcaga gcagggattgta ctgagagtgc     180
accatatgcg gtgtgaaata ccgcacagat gcgtaaggag aaaataccgc atcagattgg        240
ctattggcca ttgcatacgt tgtatccata tcataatatg tacatttata ttggctcatg        300
tccaacatta ccgccatgtt gacattgatt attgactagt tattaatagt aatcaattac        360
ggggtcatta gttcatagcc catatatgga gttccgcgtt acataactta cggtaaatgg        420
cccgcctggc tgaccgccca acgacccccg cccattgacg tcaataatga cgtatgttcc        480
catagtaacg ccaataggga ctttccattg acgtcaatgg gtggagtatt tacggtaaac        540
tgcccacttg gcagtacatc aagtgtatca tatgccaagt acgccccta ttgacgtcaa        600
tgacggtaaa tggcccgcct ggcattatgc ccagtacatg accttatggg actttcctac        660
ttggcagtac atctacgtat tagtcatcgc tattaccatg gtgatgcggt tttggcagta        720
catcaatggg cgtggatagc ggtttgactc acggggattt ccaagtctcc accccattga        780
cgtcaatggg agtttgtttt ggcaccaaaa tcaacgggac tttccaaaat gtcgtaacaa        840
ctccgcccca ttgacgcaaa tgggcggtag gcgtgtacgg tgggaggtct ataaagcag        900
agctcgttta gtgaaccgtc agatcgcctg gagacgccat ccacgctgtt ttgacctcca       960
tagaagacac cgggaccgat ccagcctccg cggccgggaa cggtgcattg gaacgcggat       1020
tcccccgtgcc aagagtgacg taagtaccgc ctatagactc tataggcaca cccctttggc      1080
tcttatgcat gctatactgt ttttggcttg gggcctatac accccgctt ccttatgcta       1140
taggtgatgg tatagcttag cctataggtg tgggttattg accattattg accactcccc      1200
tattggtgac gatactttcc attactaatc cataacatgg ctctttgcca caactatctc      1260
tattggctat atgccaatac tctgtccttc agagactgac acggactctg tatttttaca     1320
ggatggggtc ccatttatta tttacaaatt cacatataca acaacgccgt cccccgtgcc     1380
cgcagttttt attaaacata gcgtgggatc tccacgcgaa tctcgggtac gtgttccgga     1440
catgggctct tctccggtag cggcggagct tccacatccg agccctggtc ccatgcctcc     1500
agcggctcat ggtcgctcgg cagctccttg ctcctaacag tggaggccag acttaggcac     1560
agcacaatgc ccaccaccac cagtgtgccg cacaaggccg tggcggtagg gtatgtgtct     1620
gaaaatgagc gtgggagattg ggctcgcacg gctgacgcag atggaagact taaggcagcg     1680
gcagaagaag atgcaggcag ctgagttgtt gtattctgat aagagtcaga ggtaactccc      1740
gttgcggtgc tgttaacggt ggagggcagt gtagtctgag cagtactcgt tgctgccgcg     1800
cgcgccacca gacataatag ctgacagact aacagactgt tcctttccat gggtcttttc     1860
tgcagtcacc gtccttagat caccatggat gcaatgaaga gagggctctg ctgtgtgctg     1920
ctgctgtgtg gagcagtctt cgtttcgccc agcgagatct gctgtgcctt ctagttgcca     1980
gccatctgtt gtttgcccct cccccgtgcc ttccttgacc ctggaaggtg ccactcccac     2040
tgtcctttcc taataaaatg aggaaattgc atcgcattgt ctgagtaggt gtcattctat     2100
tctggggggt gggtggggc aggacagcaa ggggaggat tgggaagaca atagcaggca      2160
tgctggggat gcggtgggct ctatggccgc tgcggccagg tgctgaagaa ttgacccggt     2220
tcctcctggg ccagaaagaa gcaggcacat cccttctct gtgacacacc ctgtccacgc     2280
ccctggttct tagttccagc cccactcata ggacactcat agctcaggag ggctccgcct     2340
tcaatcccac ccgctaaagt acttggagcg gtctctcct ccctcatcag cccaccaaac      2400
caaacctagc ctccaagagt gggaagaaat taaagcaaga taggctatta agtgcagagg     2460
gagagaaaat gcctccaaca tgtgaggaag taatgagaga aatcatagaa tttcttccgc      2520
ttcctcgctc actgactcgc tgcgctcggt cgttcggctg cggcgagcgg tatcagctca     2580
ctcaaaggcg gtaatacggt tatccacaga atcagggggat aacgcaggaa agaacatgtg     2640
agcaaaaggc cagcaaaagg ccaggaaccg taaaaaggcc gcgttgctgg cgtttttcca     2700
taggctccgc cccctgacg agcatcacaa aaatcgacgc tcaagtcaga ggtggcgaaa      2760
cccgacagga ctataaagat accaggcgtt tccccctgga agctccctcg tgcgctctcc     2820
tgttccgacc ctgccgctta ccggatacct gtccgccttt ctcccttcgg gaagcgtggc     2880
gctttctcat agctcacgct gtaggtatct cagttcggtg taggtcgttc gctccaagct     2940
gggctgtgtg cacgaacccc ccgttcagcc cgaccgctgc gccttatccg gtaactatcg     3000
tcttgagtcc aacccggtaa gacacgactt atcgccactg gcagcagcca ctggtaacag     3060
gattagcaga gcgaggtatg taggcggtgc tacagagttc ttgaagtggt ggcctaacta     3120
cggctacact agaagaacag tatttggtat ctgcgctctg ctgaagccag ttaccttcgg     3180
aaaaagagtt ggtagctctt gatccggcaa acaaaccacc gctggtagcg gtggtttttt     3240
tgtttgcaag cagcagatta cgcgcagaaa aaaaggatct caagaagatc ctttgatctt     3300
ttctacgggg tctgacgctc agtggaacga aaactcacgt taagggattt ggtcatgag      3360
attatcaaaa aggatcttca cctagatcct tttaaattaa aaatgaagtt ttaaatcaat     3420
ctaaagtata tatgagtaaa cttggtctga cagttaccaa tgcttaatca gtgaggcacc     3480
tatctcagcg atctgtctat ttcgttcatc catagttgcc tgactcgggg ggggggggcg     3540
ctgaggtctg cctcgtgaag aaggtgttgc tgactcatac caggcctgaa tcgccccatc     3600
atccagccag aaagtgaggg agccacggtt gatgagagct ttgttgtagg tggaccagtt     3660
ggtgattttg aacttttgct ttgccacgga acggtctgcg ttgtcgggaa gatgcgtgat     3720
ctgatccttc aactcagcaa aagttcgatt tattcaacaa agccgccgtc ccgtcaagtc     3780
```

```
agcgtaatgc tctgccagtg ttacaaccaa ttaaccaatt ctgattagaa aaactcatcg   3840
agcatcaaat gaaactgcaa tttattcata tcaggattat caataccata tttttgaaaa   3900
agccgtttct gtaatgaagg agaaaactca ccgaggcagt tccataggat ggcaagatcc   3960
tggtatcggt ctgcgattcc gactcgtcca acatcaatac aacctattaa tttcccctcg   4020
tcaaaaataa ggttatcaag tgagaaatca ccatgagtga cgactgaatc cggtgagaat   4080
ggcaaaagct tatgcatttc tttccagact tgttcaacag gccagccatt acgctcgtca   4140
tcaaaatcac tcgcatcaac caaaccgtta ttcattcgtg attgcgcctg agcgagacga   4200
aatacgcgat cgctgttaaa aggacaatta caaacaggaa tcgaatgcaa ccggcgcagg   4260
aacactgcca gcgcatcaac aatattttca cctgaatcag gatattcttc taatacctgg   4320
aatgctgttt tcccggggat cgcagtggtg agtaaccatg catcatcagg agtacggata   4380
aaatgcttga tggtcggaag aggcataaat tccgtcagcc agtttagtct gaccatctca   4440
tctgtaacat cattggcaac gctacctttg ccatgtttca gaaacaactc tggcgcatcg   4500
ggcttcccat acaatcgata gattgtcgca cctgattgcc cgacattatc gcgagcccat   4560
ttatacccat ataaatcagc atccatgttg gaatttaatc gcggcctcga gcaagacgtt   4620
tcccgttgaa tatggctcat aacacccctt gtattactgt ttatgtaagc agacagtttt   4680
attgttcatg atgatatatt tttatcttgt gcaatgtaac atcagagatt ttgagacaca   4740
acgtggcttt cccccccccc ccattattga agcatttatc agggttattg tctcatgagc   4800
ggatacatat ttgaatgtat ttagaaaaat aaacaaatag gggttccgcg cacatttccc   4860
cgaaaagtgc cacctgacgt ctaagaaacc attattatca tgacattaac ctataaaaat   4920
aggcgtatca cgaggccctt tcgtc                                        4945
```

```
<210> 10
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 10
ctatataagc agagctcgtt tag                                              23

<210> 11
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 11
gtagcaaaga tctaaggacg gtgactgcag                                       30

<210> 12
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 12
gtatgtgtct gaaaatgagc gtggagattg ggctcgcac                             39

<210> 13
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide
```

<400> 13
gtgcgagccc aatctccacg ctcattttca gacacatac

39

<210> 14
<211> 4432
<212> DNA
<213> E. coli (V1J plasmid)

<400> 14
```
tcgcgcgttt cggtgatgac ggtgaaaacc tctgacacat gcagctccg  gagacggtca
cagcttgtct gtaagcggat gccgggagca gacaagcccg tcagggcgcg tcagcgggtg   60
ttggcgggtg tcggggctgg cttaactatg cggcatcaga gcagattgta ctgagagtgc  120
accatatgcg gtgtgaaata ccgcacagat gcgtaaggag aaaataccgc atcagattgg  180
ctattggcca ttgcatacgt tgtatccata tcataatatg tacatttata ttggctcatg  240
tccaacatta ccgccatgtt gacattgatt attgactagt tattaatagt aatcaattac  300
ggggtcatta gttcatagcc catatatgga gttccgcgtt acataactta cggtaaatgg  360
cccgcctggc tgaccgccca acgaccccg cccattgacg tcaataatga cgtatgttcc  420
catagtaacg ccaatagggg ctttccattg acgtcaatgg gtggagtatt tacggtaaac  480
tgcccacttg gcagtacatc aagtgtatca tatgccaagt acgccccta ttgacgtcaa  540
tgacggtaaa tggcccgcct ggcattatgc ccagtacatg accttatggg actttcctac  600
ttggcagtac atctacgtat tagtcatcgc tattaccatg gtgatgcggt tttggcagta  660
catcaatggg cgtggatagc ggtttgactc acggggattt ccaagtctcc accccattga  720
cgtcaatggg agtttgtttt ggcaccaaaa tcaacgggac tttccaaaat gtcgtaacaa  780
ctccgcccca ttgacgcaaa tgggcggtag gcgtgtacgg tgggaggtct atataagcag  840
agctcgttta gtgaaccgtc agatcgcctg gagacgccat ccacgctgtt ttgacctcca  900
tagaagacac cgggaccgat ccagcctccg cggccgggaa cggtgcattg gaacgcggat  960
tccccgtgcc aagagtgacg taagtaccgc ctatagagtc tataggccca cccccttggc 1020
ttcttatgca tgctatactg ttttttggctt ggggtctata caccccgct tcctcatgtt 1080
ataggtgatg gtatagctta gcctataggt gtgggttatt gaccattatt gaccactccc 1140
ctattggtga cgatactttc cattactaat ccataacatg gctctttgcc acaactctct 1200
ttattggcta tatgccaata cactgtcctt cagagactga cacggactct gtatttttac 1260
aggatggggt ctcatttatt atttacaaat tcacatatac aacaccaccg tccccagtgc 1320
ccgcagtttt tattaaacat aacgtgggat ctccacgcga atctcgggta cgtgttccgg 1380
acatgggctc ttctccggta gcggcggagc ttctacatcc gagccctgct cccatgcctc 1440
cagcgactca tggtcgctcg gcagctcctt gctcctaaca gtggaggcca gacttaggca 1500
cagcacgatg cccaccacca ccagtgtgcc gcacaaggcc gtggcggtag ggtatgtgtc 1560
tgaaaatgag ctcggggagc gggcttgcac cgctgacgca tttggaagac ttaaggcagc 1620
ggcagaagaa gatgcaggca gctgagttgt tgtgttctga taagagtcag aggtaactcc 1680
cgttgcggtg ctgttaacgg tggagggcag tgtagtctga gcagtactcg ttgctgccgc 1740
gcgcgccacc agacataata gctgacagac taacagactg ttccttttcca tgggtctttt 1800
ctgcagtcac cgtccttaga tctgctgtgc cttctagttg ccagccatct gttgtttgcc 1860
cctcccccgt gccttccttg accctggaag gtgccactcc cactgtcctt tcctaataaa 1920
atgaggaaat tgcatcgcat tgtctgagta ggtgtcattc tattctgggg ggtggggtgg 1980
ggcagcacag caagggggag gattgggaag acaatagcag gcatgctggg gatgcggtgg 2040
gctctatggg tacccaggtg ctgaagaatt gacccggttc ctcctgggcc agaaagaagc 2100
aggcacatcc ccttctctgt gacacaccct gtccacgccc ctggttctta gttccagccc 2160
ttggagcggt ctctccctcc ctcatcagcc ctcgccttc aatcccaccc gctaaagtac 2220
gaagaaatta aagcaagata ggctattaag tgcagaggga gagaaaatgc ctccaacatg 2280
tgaggaagta atgagagaaa tcatagaatt tcttccgctt cctcgctcac tgactcgctg 2340
cgctcggtcg ttcggctgcg gcgagcggta tcagctcact caaaggcggt aatacggtta 2400
tccacagaat caggggataa cgcaggaaag aacatgtgag caaaaggcca gcaaaaggcc 2460
aggaaccgta aaaaggccgc gttgctggcg tttttccata ggctccgccc cctgacgag 2520
catcacaaaa atcgacgctc aagtcagagg tggcgaaacc cgacaggact ataaagatac 2580
caggcgtttc ccctggaag ctccctcgtg cgctctcctg ttccgaccct gccgcttacc 2640
ggatacctgt ccgcctttct cccttcggga agcgtggcgc tttctcaatg ctcacgctgt 2700
aggtatctca gttcggtgta ggtcgttcgc tccaagctgg gctgtgtgca cgaacccccc 2760
gttcagcccg accgctgcgc cttatccggt aactatcgtc ttgagtccaa cccggtaaga 2820
cacgacttat cgccactggc agcagccact ggtaacagga ttagcagagc gaggtatgta 2880
ggcggtgcta cagagttctt gaagtggtgg cctaactacg gctacactag aaggacagta 2940
tttggtatct gcgctctgct gaagccagtt accttcggaa aaagagttgg tagctcttga 3000
tccggcaaac aaaccaccgc tggtagcggt ggtttttttg tttgcaagca gcagattacg 3060
```
                                                                     3120
                                                                     3180

- 26 -

```
cgcagaaaaa aaggatctca agaagatcct ttgatctttt ctacggggtc tgacgctcag    3240
tggaacgaaa actcacgtta agggattttg gtcatgagat tatcaaaaag gatcttcacc    3300
tagatccttt taaattaaaa atgaagtttt aaatcaatct aaagtatata tgagtaaact    3360
tggtctgaca gttaccaatg cttaatcagt gaggcaccta tctcagcgat ctgtctattt    3420
cgttcatcca tagttgcctg actccccgtc gtgtagataa ctacgatacg ggagggctta    3480
ccatctggcc ccagtgctgc aatgataccg cgagacccac gctcaccggc tccagattta    3540
tcagcaataa accagccagc cggaagggcc gagcgcagaa gtggtcctgc aactttatcc    3600
gcctccatcc agtctattaa ttgttgccgg gaagctagag taagtagttc gccagttaat    3660
agtttgcgca acgttgttgc cattgctaca ggcatcgtgg tgtcacgctc gtcgtttggt    3720
atggcttcat tcagctccgg ttcccaacga tcaaggcgag ttacatgatc ccccatgttg    3780
tgcaaaaaag cggttagctc cttcggtcct ccgatcgttg tcagaagtaa gttggccgca    3840
gtgttatcac tcatggttat ggcagcactg cataattctc ttactgtcat gccatccgta    3900
agatgctttt ctgtgactgg tgagtactca accaagtcat tctgagaata gtgtatgcgg    3960
cgaccgagtt gctcttgccc ggcgtcaata cgggataata ccgcgccaca tagcagaact    4020
ttaaaagtgc tcatcattgg aaaacgttct tcggggcgaa aactctcaag gatcttaccg    4080
ctgttgagat ccagttcgat gtaacccact cgtgcaccca actgatcttc agcatctttt    4140
actttcacca gcgtttctgg gtgagcaaaa acaggaaggc aaaatgccgc aaaaaaggga    4200
ataagggcga cacggaaatg ttgaatactc atactcttcc tttttcaata ttattgaagc    4260
atttatcagg gttattgtct catgagcgga tacatatttg aatgtattta gaaaaataaa    4320
caaatagggg ttccgcgcac atttccccga aaagtgccac ctgacgtcta agaaaccatt    4380
attatcatga cattaaccta taaaaatagg cgtatcacga ggccctttcg tc            4432
```

```
<210> 15
<211> 4864
<212> DNA
<213> E. coli (VlJneo plasmid)

<400> 15
tcgcgcgttt cggtgatgac ggtgaaaacc tctgacacat gcagctcccg gagacggtca     60
cagcttgtct gtaagcggat gccgggagca gacaagcccg tcagggcgcg tcagcgggtg    120
ttggcggggt gtcggggctgg cttaactatg cggcatcaga gcagattgta ctgagagtgc    180
accatatgcg gtgtgaaata ccgcacagat gcgtaaggag aaaataccgc atcagattgg    240
ctattggcca ttgcatacgt tgtatccata tcataatatg tacatttata ttggctcatg    300
tccaacatta ccgccatgtt gacattgatt attgactagt tattaatagt aatcaattac    360
ggggtcatta gttcatagcc catatatgga gttccgcgtt acataactta cggtaaatgg    420
cccgcctggc tgaccgccca acgacccccg cccattgacg tcaataatga cgtatgttcc    480
catagtaacg ccaatagggа ctttccattg acgtcaatgg gtggagtatt tacggtaaac    540
tgcccacttg gcagtacatc aagtgtatca tatgccaagt acgccccctа ttgacgtcaa    600
tgacggtaaa tggcccgcct ggcattatgc ccagtacatg accttcctac actttcctac    660
ttggcagtac atctacgtat tagtcatcgc tattaccatg gtgatgcggt tttggcagta    720
catcaatggg cgtggatagc ggtttgactc acggggattt ccaagtctcc accccattga    780
cgtcaatggg agtttgtttt ggcaccaaaa tcaacgggac tttccaaaat gtcgtaacaa    840
ctccgcccca ttgacgcaaa tgggcggtag gcgtgtacgg tgggaggtct atataagcag    900
agctcgttta gtgaaccgtc agatcgcctg gagacgccat ccacgctgtt ttgacctcca    960
tagaagacac cgggaccgat ccagcctccg cggccgggaa cggtgcattg gaacgcggat   1020
tccccgtgcc aagagtgacg taagtaccgc ctatagagtc tataggccca ccccccttggc   1080
ttcttatgca tgctatactg tttttggctt ggggtctata caccccgct tcctcatgtt   1140
ataggtgatg gtatagctta gcctataggt gtgggttatt gaccattatt gaccactccc   1200
ctattggtga cgatactttc cattactaat ccataacatg ctctttgcc acaactctct   1260
ttattggcta tatgccaata cactgtcctt cagagactga cacggactct gtattttac   1320
aggatggggt ctcatttatt atttacaaat tcacatatac aacaccaccg tccccagtgc   1380
ccgcagtttt tattaaacat aacgtgggat ctccacgcga atctcgggta cgtgttccgg   1440
acatgggctc ttctccggta gcggcgggagc ttctacatcc gagccctgct cccatgcctc   1500
cagcgactca tggtcgctcg gcagctcctt gctcctaaca gtggagccca gacttaggca   1560
cagcacgatg cccaccacca ccagtgtgcc gcacaaggcc gtggcggtag ggtatgtgtc   1620
tgaaaatgag ctcggggagc gggcttgcac cgctgacgca tttggaagac ttaaggcagc   1680
ggcagaagaa gatgcaggca gctgagttgt tgtgttctga taagagtcag aggtaactcc   1740
cgttgcggtg ctgttaacgg tggagggcag tgtagtctga gcagtactcg ttgctgccgc   1800
gcgcgccacc agacataata gctgacagac taacagactg ttccttttcca tgggtctttt   1860
ctgcagtcac cgtccttaga tctgctgtgc cttctagttg ccagccatct gttgtttgcc   1920
cctccccgt gccttccttg accctggaag gtgccactcc cactgtcctt tcctaataaa   1980
atgaggaaat tgcatcgcat tgtctgagta ggtgtcattc tattctgggg ggtggggtgg   2040
```

```
ggcagcacag caagggggag gattgggaag acaatagcag gcatgctggg gatgcggtgg    2100
gctctatggg tacccaggtg ctgaagaatt gacccggttc ctcctgggcc agaaagaagc    2160
aggcacatcc ccttctctgt gacacaccct gtccacgccc ctggttctta gttccagccc    2220
cactcatagg acactcatag ctcaggaggg ctccgccttc aatcccaccc gctaaagtac    2280
ttggagcggt ctctccctcc ctcatcagcc caccaaacca aacctagcct ccaagagtgg    2340
gaagaaatta aagcaagata ggctattaag tgcagaggga gagaaaatgc ctccaacatg    2400
tgaggaagta atgagagaaa tcatagaatt tcttccgctt cctcgctcac tgactcgctg    2460
cgctcggtcg ttcggctgcg gcgagcggta tcagctcact caaaggcggt aatacggtta    2520
tccacagaat caggggataa cgcaggaaag aacatgtgag caaaaggcca gcaaaaggcc    2580
aggaaccgta aaaaggccgc gttgctggcg ttttttccata ggctccgccc ccctgacgag    2640
catcacaaaa atcgacgctc aagtcagagg tggcgaaacc cgacaggact ataaagatac    2700
caggcgtttc ccctggaag ctccctcgtg cgctctcctg ttccgaccct gccgcttacc    2760
ggatacctgt ccgcctttct cccttcggga agcgtggcgc tttctcaatg ctcacgctgt    2820
gttcagcccg accgctgcgc cttatccggt aactatcgtc ttgagtccaa cccggtaaga    2880
cacgacttat cgccactggc agcagccact ggtaacagga ttagcagagc gaggtatgta    2940
ggcggtgcta cagagttctt gaagtggtgg cctaactacg gctacactag aaggacagta    3000
tttggtatct gcgctctgct gaagccagtt accttcggaa aaagagttgg tagctcttga    3060
tccggcaaac aaaccaccgc tggtagcggt ggtttttttg tttgcaagca gcagattacg    3120
cgcagaaaaa aaggatctca agaagatcct ttgatctttt ctacggggtc tgacgctcag    3240
tggaacgaaa actcacgtta agggattttg gtcatgagat tatcaaaaag gatcttcacc    3300
tagatccttt taaattaaaa atgaagtttt aaatcaatct aaagtatata tgagtaaact    3360
tggtctgaca gttaccaatg cttaatcagt gaggcaccta tctcagcgat ctgtctattt    3420
cgttcatcca tagttgcctg actccggggg gggggggcgc tgaggtctgc ctcgtgaaga    3480
aggtgttgct gactcatacc aggcctgaat cgccccatca tccagccaga aagtgaggga    3540
gccacggttg atgagagctt tgttgtaggt ggaccagttg gtgattttga acttttgctt    3600
tgccacggaa cggtctgcgt tgtcgggaag atgcgtgatc tgatccttca actcagcaaa    3660
agttcgattt attcaacaaa gccgccgtcc cgtcaagtca gcgtaatgct ctgccagtgt    3720
tacaaccaat taaccaattc tgattagaaa aactcatcga gcatcaaatg aaactgcaat    3780
ttattcatat caggattatc aataccatat ttttgaaaaa gccgtttctg taatgaagga    3840
gaaaactcac cgaggcagtt ccataggatg gcaagatcct ggtatcggtc tgcgattccg    3900
actcgtccaa catcaataca acctattaat ttcccctcgt caaaaataag gttatcaagt    3960
gagaaatcac catgagtgac gactgaatcc ggtgagaatg gcaaaagctt atgcatttct    4020
ttccagactt gttcaacagg ccagccatta cgctcgtcat caaaatcact cgcatcaacc    4080
aaaccgttat tcattcgtga ttgcgcctga gcgagacgaa atacgcgatc gctgttaaaa    4140
ggacaattac aaacaggaat cgaatgcaac cggcgcagga acactgccag cgcatcaaca    4200
atattttcac ctgaatcagg atattcttct aatacctgga atgctgtttt cccggggatc    4260
gcagtggtga gtaaccatgc atcatcagga gtacgataa aatgcttgat ggtcggaaga    4320
ggcataaatt ccgtcagcca gtttagtctg accatctcat ctgtaacatc attggcaacg    4380
ctaccttgc catgtttcag aaacaactct ggcgcatcgg gcttcccata caatcgatag    4440
attgtcgcac ctgattgccc gacattatcg cgagcccatt tatacccata taaatcagca    4500
tccatgttgg aatttaatcg cggcctcgag caagacgttt cccgttgaat atggctcata    4560
acacccttg tattactgtt tatgtaagca gacagtttta ttgttcatga tgatatattt    4620
ttatcttgtg caatgtaaca tcagagattt tgagacacaa cgtggctttc ccccccccc    4680
cattattgaa gcatttatca gggttattgt ctcatgagcg gatacatatt tgaatgtatt    4740
tagaaaaata aacaaatagg ggttccgcgc acatttcccc gaaaagtgcc acctgacgtc    4800
taagaaacca ttattatcat gacattaacc tataaaaata ggcgtatcac gaggcccttt    4860
cgtc                                                                4864
```

```
<210> 16
<211> 4867
<212> DNA
<213> E. coli (V1Jns plasmid)

<400> 16
```

```
tcgcgcgttt cggtgatgac ggtgaaaacc tctgacacat gcagctcccg gagacggtca     60
cagcttgtct gtaagcggat gccgggagca gacaagcccg tcagggcgcg tcagcgggtg    120
ttggcgggtg tcgggctgg cttaactatg cggcatcaga gcagattgta ctgagagtgc     180
accatatgcg gtgtgaaata ccgcacagat gcgtaaggag aaaataccgc atcagattgg    240
ctattggcca ttgcatacgt tgtatccata tcataatatg tacatttata ttggctcatg    300
tccaacatta ccgccatgtt gacattgatt attgactagt tattaatagt aatcaattac    360
ggggtcatta gttcatagcc catatatgga gttccgcgtt acataactta cggtaaatgg    420
```

```
cccgcctggc tgaccgccca acgacccccg cccattgacg tcaataatga cgtatgttcc   480
catagtaacg ccaatagggga ctttccattg acgtcaatgg gtggagtatt tacggtaaac   540
tgcccacttg gcagtacatc aagtgtatca tatgccaagt acgcccccta ttgacgtcaa   600
tgacggtaaa tggcccgcct ggcattatgc ccagtacatg accttatggg actttcctac   660
ttggcagtac atctacgtat tagtcatcgc tattaccatg gtgatgcggt tttggcagta   720
catcaatggg cgtggatagc ggtttgactc acggggattt ccaagtctcc accccattga   780
cgtcaatggg agtttgtttt ggcaccaaaa tcaacgggac tttccaaaat gtcgtaacaa   840
ctccgcccca ttgacgcaaa tgggcggtag gcgtgtacgg tgggaggtct atataagcag   900
agctcgttta gtgaaccgtc agatcgcctg gagacgccat ccacgctgtt ttgacctcca   960
tagaagacac cgggaccgat ccagcctccg cggccgggaa cggtgcattg gaacgcggat  1020
tccccgtgcc aagagtgacg taagtaccgc ctatagactc tataggcaca cccctttggc  1080
tcttatgcat gctatactgt ttttggcttg ggcctatac accccgctt ccttatgcta  1140
taggtgatgg tatagcttag cctataggtg tgggttattg accattattg accactcccc  1200
tattggtgac gatactttcc attactaatc cataacatgg ctctttgcca caactatctc  1260
tattggctat atgccaatac tctgtccttc agagactgac acggactctg tattttaca  1320
ggatggggtc ccatttatta tttacaaatt cacatataca acaacgccgt cccccgtgcc  1380
cgcagttttt attaaacata gcgtgggatc tccacgcgaa tctcgggtac gtgttccgga  1440
catgggctct tctccggtag cggcggagct tccacatccg agccctggtc ccatgcctcc  1500
agcggctcat ggtcgctcgg cagctccttg ctcctaacag tggaggccag acttaggcac  1560
agcacaatgc ccaccaccac cagtgtgccg cacaaggccg tggcggtagg gtatgtgtct  1620
gaaaatgagc gtggagattg ggctcgcacg gctgacgcag atggaagact taaggcagcg  1680
gcagaagaag atgcaggcag ctgagttgtt gtattctgat aagagtcaga ggtaactccc  1740
gttgcggtgc tgttaacggt ggagggcagt gtagtctgag cagtactcgt tgctgccgcg  1800
cgcgccacca gacataatag ctgacagact aacagactgt tcctttccat gggtcttttc  1860
tgcagtcacc gtccttagat ctgctgtgcc ttctagttgc cagccatctg ttgtttgccc  1920
ctccccgtg ccttccttga ccctggaagg tgccactccc actgtccttt cctaataaaa  1980
tgaggaaatt gcatcgcatt gtctgagtag gtgtcattct attctggggg gtggggtggg  2040
gcaggacagc aagggggagg attgggaaga caatagcagg catgctgggg atgcggtggg  2100
ctctatggcc gctgcggcca ggtgctgaag aattgacccg gttcctcctg ggccagaaag  2160
aagcaggcac atccccttct ctgtgacaca ccctgtccac gccctggtt cttagttcca  2220
gccccactca taggacactc atagctcagg agggctccgc cttcaatccc acccgctaaa  2280
gtacttggag cggtctctcc ctccctcatc agccaccaa accaaccta gcctccaaga  2340
gtgggaagaa attaaagcaa gatagggctat taagtgcaga gggagagaaa atgcctccaa  2400
catgtgagga agtaatgaga gaaatcatag aatttcttcc gcttcctcgc tcactgactc  2460
gctgcgctcg gtcgttcggc tgcggcgagc ggtatcagct cactcaaagg cggtaatacg  2520
gttatccaca gaatcagggg ataacgcagg aagaacatg tgagcaaaag gccagcaaaa  2580
ggccaggaac cgtaaaaagg ccgcgttgct ggcgttttc cataggctcc gcccccctga  2640
cgagcatcac aaaaatcgac gctcaagtca gaggtggcga aacccgacag gactataaag  2700
ataccaggcg tttccccctg gaagctccct cgtgcgctct cctgttccga ccctgccgct  2760
taccggatac ctgtccgcct ttctccgttc gggaagcgtg gcgctttctc atagctcacg  2820
ctgtaggtat ctcagttcgg tgtaggtcgt tcgctccaag ctgggctgtg tgcacgaacc  2880
ccccgttcag cccgaccgct gcgccttatc cggtaactat cgtcttgagt ccaacccggt  2940
aagacacgac ttatcgccac tggcagcagc cactggtaac aggattagca gagcgaggta  3000
tgtaggcggt gctacagagt tcttgaagtg gtggcctaac tacggctaca ctagaagaac  3060
agtatttggt atctgcgctc tgctgaagcc agttaccttc ggaaaaagag ttggtagctc  3120
ttgatccggc aaacaaacca ccgctggtag cggtggtttt tttgtttgca agcagcagat  3180
tacgcgcaga aaaaaaggat ctcaagaaga tcctttgatc ttttctacgg ggtctgacgc  3240
tcagtggaac gaaaactcac gttaagggat tttggtcatg agattatcaa aaaggatctt  3300
cacctagatc cttttaaatt aaaaatgaag ttttaaatca atctaaagta tatatgagta  3360
aacttggtct gacagttacc aatgcttaat cagtgaggca cctatctcag cgatctgtct  3420
atttcgttca tccatagttg cctgactcgg ggggggggg cgctgaggtc tgcctcgtga  3480
agaaggtgtt gctgactcat accaggcctg aatcgcccca tcatccagcc agaaagtgag  3540
ggagccacgg ttgatgagag ctttgttgta ggtggaccag ttggtgattt tgaacttttg  3600
ctttgccacg gaacggtctg cgttgtcggg aagatgcgtg atctgatcct tcaactcagc  3660
aaaagttcga tttattcaac aaagccacg tcccgtcaag tcagcgtaat gctctgccag  3720
tgttacaacc aattaaccaa ttctgattag aaaaactcat cgagcatcaa atgaaactgc  3780
aatttattca tatcaggatt atcaatacca tatttttgaa aaagccgttt ctgtaatgaa  3840
ggagaaaact caccgaggca gttccatagg atggcaagat cctggtatcg gtctgcgatt  3900
ccgactcgtc aacatcaat acaacctatt aatttcccct cgtcaaaaat aaggttatca  3960
agtgagaaat caccatgagt gacgactgaa tccggtgaga atggcaaaag cttatgcatt  4020
tctttccaga cttgttcaac aggccagcca ttacgctcgt catcaaaatc actcgcatca  4080
accaaaccgt tattcattcg tgattgcgcc tgagcgagac gaaatacgcg atcgctgtta  4140
```

                                    - 29 -

```
aaaggacaat tacaaacagg aatcgaatgc aaccggcgca ggaacactgc cagcgcatca    4200
acaatatttt cacctgaatc aggatattct tctaatacct ggaatgctgt tttcccgggg    4260
atcgcagtgg tgagtaacca tgcatcatca ggagtacgga taaaatgctt gatggtcgga    4320
agaggcataa attccgtcag ccagtttagt ctgaccatct catctgtaac atcattggca    4380
acgctacctt tgccatgttt cagaaacaac tctggcgcat cgggcttccc atacaatcga    4440
tagattgtcg cacctgattg cccgacatta tcgcgagccc atttataccc atataaatca    4500
gcatccatgt tggaatttaa tcgcggcctc gagcaagacg tttcccgttg aatatggctc    4560
ataacacccc ttgtattact gtttatgtaa gcagacagtt ttattgttca tgatgatata    4620
tttttatctt gtgcaatgta acatcagaga ttttgagaca caacgtggct ttcccccccc    4680
ccccattatt gaagcattta tcagggttat tgtctcatga gcggatacat atttgaatgt    4740
atttagaaaa ataaacaaat aggggttccg cgcacatttc cccgaaaagt gccacctgac    4800
gtctaagaaa ccattattat catgacatta acctataaaa ataggcgtat cacgaggccc    4860
tttcgtc                                                               4867
```

<210> 17
<211> 75
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 17
```
gatcaccatg gatgcaatga agagagggct ctgtgtgctg ctgctgtgtg gagcagtctt    60
cgtttcgccc agcga                                                       75
```

<210> 18
<211> 78
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 18
```
gatctcgctg ggcgaaacga agactgctcc acacagcagc agcacacagc agagccctct    60
cttcattgca tccatggt                                                    78
```

<210> 19
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 19
```
ggtacaaata ttggctattg gccattgcat acg                                   33
```

<210> 20
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 20
```
ccacatctcg aggaaccggg tcaattcttc agcacc                                36
```

<210> 21
<211> 38

```
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 21
ggtacagata tcggaaagcc acgttgtgtc tcaaaatc                              38

<210> 22
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 22
cacatggatc cgtaatgctc tgccagtgtt acaacc                               36

<210> 23
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 23
ggtacatgat cacgtagaaa agatcaaagg atcttcttg                            39

<210> 24
<211> 35
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 24
ccacatgtcg acccgtaaaa aggccgcgtt gctgg                                35

<210> 25
<211> 4864
<212> DNA
<213> E. coli (V1R plasmid)

<400> 25
tcgcgcgttt cggtgatgac ggtgaaaacc tctgacacat gcagctcccg gagacggtca     60
cagcttgtct gtaagcggat gccgggagca gacaagcccg tcagggcgcg tcagcgggtg    120
ttggcgggtg tcggggctgg cttaactatg cggcatcaga gcagattgta ctgagagtgc    180
accatatgcg gtgtgaaata ccgcacagat gcgtaaggag aaaataccgc atcagattgg    240
ctattggcca ttgcatacgt tgtatccata tcataatatg tacatttata ttggctcatg    300
tccaacatta ccgccatgtt gacattgatt attgactagt tattaatagt aatcaattac    360
ggggtcatta gttcatagcc catatatgga gttccgcgtt acataactta cggtaaatgg    420
cccgcctggc tgaccgccca acgacccccg cccattgacg tcaataatga cgtatgttcc    480
catagtaacg ccaatgggga ctttccattg acgtcaatgg gtggagtatt tacggtaaac    540
tgcccacttg gcagtacatc aagtgtatca tatgccaagt acgccccta ttgacgtcaa     600
tgacggtaaa tggcccgcct ggcattatgc ccagtacatg accttatggg actttcctac    660
ttggcagtac atctacgtat tagtcatcgc tattaccatg gtgatgcggt tttggcagta    720
catcaatggg cgtggatagc ggtttgactc acggggattt ccaagtctcc accccattga    780
cgtcaatggg agtttgtttt ggcaccaaaa tcaacgggac tttccaaaat gtcgtaacaa    840
```

```
ctccgcccca ttgacgcaaa tgggcggtag gcgtgtacgg tgggaggtct atataagcag    900
agctcgttta gtgaaccgtc agatcgcctg gagacgccat ccacgctgtt ttgacctcca    960
tagaagacac cgggaccgat ccagcctccg cggccgggaa cggtgcattg gaacgcggat   1020
tccccgtgcc aagagtgacg taagtaccgc ctatagagtc tataggccca cccccttggc   1080
ttcttatgca tgctatactg ttttttggctt ggggtctata cacccccgct tcctcatgtt   1140
ataggtgatg gtatagctta gcctataggt gtgggttatt gaccattatt gaccactccc   1200
ctattggtga cgatactttc cattactaat ccataacatg gctctttgcc acaactctct   1260
ttattggcta tatgccaata cactgtcctt cagagactga cacggactct gtatttttac   1320
aggatggggt ctcatttatt atttacaaat tcacatatac aacaccaccg tccccagtgc   1380
ccgcagtttt tattaaacat aacgtgggat ctccacgcga atctcgggta cgtgttccgg   1440
acatgggctc ttctccggta gcggcggagc ttctacatcc gagccctgct cccatgcctc   1500
cagcgactca tggtcgctcg gcagctcctt gctcctaaca gtggaggcca gacttaggca   1560
cagcacgatg cccaccacca ccagtgtgcc gcacaaggcc gtggcggtag ggtatgtgtc   1620
tgaaaatgag ctcggggagc gggcttgcac cgctgacgca tttggaagac ttaaggcagc   1680
ggcagaagaa gatgcaggca gctgagttgt tgtgttctga taagagtcag aggtaactcc   1740
cgttgcggtg ctgttaacgg tggagggcag tgtagtctga gcagtactcg ttgctgccgc   1800
gcgcgccacc agacataata gctgacagac taacagactg ttcctttcca tgggtctttt   1860
ctgcagtcac cgtccttaga tctgctgtgc cttctagttg ccagccatct gttgtttgcc   1920
cctcccccgt gccttccttg accctggaag gtgccactcc cactgtcctt tcctaataaa   1980
atgaggaaat tgcatcgcat tgtctgagta ggtgtcattc tattctgggg ggtggggtgg   2040
ggcagcacag caaggggggag gattgggaag acaatagcag gcatgctggg gatgcggtgg   2100
gctctatggg tacccaggtg ctgaagaatt gacccggttc ctcctgggcg agaaagaagc   2160
aggcacatcc ccttctctgt gacacaccct gtccacgccc ctggttctta gttccagccc   2220
cactcatagg acactcatag ctcaggaggg ctccgccttc aatcccaccc gctaaagtac   2280
ttggagcggt ctctccctcc ctcatcagcc caccaaacca aacctagcct ccaagagtgg   2340
gaagaaatta aagcaagata ggctattaag tgcagaggga gagaaatgc ctccaacatg    2400
tgaggaagta atgagagaaa tcataagaatt tcttccgctt cctcgctcac tgactcgctg   2460
cgctcggtcg ttcggctgcg gcgagcggta tcagctcact caaggcggt aatacggtta .  2520
tccacagaat caggggataa cgcaggaaag aacatgtgag caaaaggcca gcaaaaggcc   2580
aggaaccgta aaaaggccgc gttgctggcg tttttccata ggctccgccc cctgacgag    2640
catcacaaaa atcgacgctc aagtcagagg tggcgaaacc cgacaggact ataaagatac   2700
caggcgtttc ccctggaag ctccctcgtg cgctctcctg ttccgaccct gccgcttacc    2760
ggatacctgt ccgcctttct cccttcggga agcgtggcgc tttctcaatg ctcacgctgt   2820
aggtatctca gttcggtgta ggtcgttcgc tccaagctgg gctgtgtgca cgaacccccc   2880
gttcagcccg accgctgcgc cttatccggt aactatcgtc ttgagtccaa cccggtaaga   2940
cacgacttat cgccactggc agcagccact ggtaacagga ttagcagagc gaggtatgta   3000
ggcggtgcta cagagttctt gaagtggtgg cctaactacg gctacactag aaggacagta   3060
tttggtatct gcgctctgct gaagccagtt accttcggaa aaagagttgg tagctcttga   3120
tccggcaaac aaaccaccgc tggtagcggt ggtttttttg tttgcaagca gcagattacg   3180
cgcagaaaaa aaggatcctc aagaagatcct ttgatctttt ctacggggtc tgacgctcag   3240
tggaacgaaa actcacgtta agggattttg gtcatgagat tatcaaaaag gatcttcacc   3300
tagatccttt taaattaaaa atgaagtttt aaatcaatct aaagtatata tgagtaaact   3360
tggtctgaca gttaccaatg cttaatcagt gaggcaccta tctcagcgat ctgtctattt   3420
cgttcatcca tagttgcctg actccggggg gggggggcgc tgaggtctgc ctcgtgaaga   3480
aggtgttgct gactcatacc aggcctgaat cgccccatca tccagccaga aagtgaggga   3540
gccacggttg atgagagctt tgttgtaggt ggaccagttg gtgattttga acttttgctt   3600
tgccacggaa cggtctgcgt tgtcgggaag atgcgtgatc tgatccttca actcagcaaa   3660
agttcgattt attcaacaaa gccgccgtcc cgtcaagtca gcgtaatgct ctgccagtgt   3720
tacaaccaat taaccaattc tgattagaaa aactcatcga gcatcaaatg aaactgcaat   3780
ttattcatat caggattatc aataccatat ttttgaaaaa gccgtttctg taatgaagga   3840
gaaaactcac cgaggcagtt ccataggatg gcaagatcct ggtatcggtc tgcgattccg   3900
actcgtccaa catcaataca acctattaat ttcccctcgt caaaaataag gttatcaagt    3960
gagaaatcac catgagtgac gactgaatcc ggtgagaatg gcaaaagctt atgcatttct   4020
ttccagactt gttcaacagg ccagccatta cgctcgtcat caaaatcact cgcatcaacc   4080
aaaccgttat tcattcgtga ttgcgcctga gcgagacgaa atacgcgatc gctgttaaaa   4140
ggacaattac aaacaggaat cgaatgcaac cggcgcagga acactgccag cgcatcaaca   4200
atattttcac ctgaatcagg atattcttct aataccggaa atgctgtttt cccggggatc   4260
gcagtggtga gtaaccatgc atcatcagga gtacggataa aatgcttgat ggtcggaaga   4320
ggcataaatt ccgtcagcca gtttagtctg accatctcat ctgtaacatc attggcaacg   4380
ctacctttgc catgtttcag aaacaactct ggcgcatcgg gcttcccata caatcgatag   4440
attgtcgcac ctgattgccc gacattatcg cgagcccatt tatacccata taaatcagca   4500
tccatgttgg aatttaatcg cggcctcgag caagacgttt cccgttgaat atggctcata   4560
```

                                      - 32 -

```
acaccccttg tattactgtt tatgtaagca gacagtttta ttgttcatga tgatatattt          4620
ttatcttgtg caatgtaaca tcagagattt tgagacacaa cgtggctttc cccccccccc          4680
cattattgaa gcatttatca gggttattgt ctcatgagcg gatacatatt tgaatgtatt          4740
tagaaaaata aacaaatagg ggttccgcgc acatttcccc gaaaagtgcc acctgacgtc          4800
taagaaacca ttattatcat gacattaacc tataaaaata ggcgtatcac gaggcccttt          4860
cgtc                                                                        4864
```

<210> 26
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 26
ggtacaagat ctccgccccc atctccccca ttgaga   36

<210> 27
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 27
ccacatagat ctgcccgggc tttagtcctc atc   33

<210> 28
<211> 27
<212> PRT
<213> Homo sapien

<400> 28
Met Asp Ala Met Lys Arg Gly Leu Cys Cys Val Leu Leu Leu Cys Gly
1   5   10   15
Ala Val Phe Val Ser Pro Ser Glu Ile Ser Ser
            20   25

<210> 29
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 29
caggcgagat ctaccatggc ccccattagc cctattgaga ctgta   45

<210> 30
<211> 48
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 30
caggcgagat ctgcccgggc tttaatcctc atcctgtcta cttgccac   48

-33-

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/34724

A.	CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 48/00; C12Q 1/70.
US CL : 514/44; 435/5; 424/93.1.

According to International Patent Classification (IPC) or to both national classification and IPC

B.	FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
U.S. : 514/44; 435/5; 424/93.1.

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Medline, embase, scisearch, biosis, caplus and WEST

C.	DOCUMENTS CONSIDERED TO BE RELEVANT	
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y,P	US 6,099,848 A (FRANKEL et al) 08 August 2000 (08.08.2000), page 12 paragraph 6.	1-14, 17
Y	WO 97/31115 A2 (MERCK & CO. INC.), 28 August 1997, page 36.	4
X	WO 90/10230 A1 (UNIVERSITY OF OTTAWA) 07 September 1990, page 11.	17
Y	US 5,858,646 A (KANG) 12 January 1999 (12.01.1999), col. 2, lines 10-17	1-14, 17

☐ Further documents are listed in the continuation of Box C.   ☐ See patent family annex.

*	Special categories of cited documents:
"A"	document defining the general state of the art which is not considered to be of particular relevance
"E"	earlier application or patent published on or after the international filing date
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O"	document referring to an oral disclosure, use, exhibition or other means
"P"	document published prior to the international filing date but later than the priority date claimed

"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&"	document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
22 February 2001	09 MAR 2001

Name and mailing address of the ISA/US	Authorized officer
Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703)305-3230	Eleanor Sorbello TERRY J. DEY PARALEGAL SPECIALIST TECHNOLOGY CENTER 1600 Telephone No. 703-308-0196

Form PCT/ISA/210 (second sheet) (July 1998)

INTERNATIONAL SEARCH REPORT

Internat   application No.

PCT/US00/34724

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim Nos.:
   because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claim Nos.:
   because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☒ Claim Nos.: 15 & 16
   because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest ☐ The additional search fees were accompanied by the applicant's protest.

                    ☐ No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet(1)) (July 1998)